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ABSTRACT 
As the treatment of cancer evolves, complexity is increasing with the range of and number therapies now 
being offered to patients. Patients are living with or beyond cancer for longer periods of time. Cancer 
survivorship issues are therefore gaining greater importance, and long term toxicities from cancer 
therapies must be acknowledged and addressed. One such adverse effect is chemotherapy induced 
peripheral neuropathy (CIPN). Many widely used cytotoxic agents lead to peripheral neuropathy in a 
proportion of patients. For some, the neuropathy settles after completion of treatment but for a small, but 
not insignificant minority, the neuropathy persists.  The aims of this project were to systematically explore 
the clinical and molecular genetic risk factors, and effect on quality of life, of this potentially debilitating 
toxicity.  
Chapter 1 comprises an introduction to the topic including a narrative review of clinical risk factors. Choice 
of agent, duration of infusion and cumulative dose affect the development of CIPN. Patient-related factors 
are less clear, but body mass index and race appear to be of particular interest as possible determinants.  
Chapter 2 includes systematic reviews of the impact of diabetes and alcohol intake on risk of CIPN  which 
identified a number of studies but meta-analysis was not possible and no definitive conclusion on effect 
could be drawn as findings from the included studies were contradictory.  
Chapter 3 describes a comprehensive systematic review of pharmacogenetic studies related to the risk of 
developing CIPN. This identified 93 studies for inclusion with a median sample size of 118 patients.  GSTP 
Ile105Val was the most commonly investigated SNP, with SNPs in the excision repair genes, ABC 
transporter genes and CYP 3A4, 3A5 and 2C8 genes also frequently investigated. Meta-analysis was carried 
out where possible, the majority of which showed no significant association. CYP3A4*22 did show 
significant association but this data was based on two cohorts within the same study. Many studies 
however were not eligible for inclusion in meta-analysis due to lack of sufficient data presented. 
Pharmacogenetic studies in this field are fraught with methodological flaws. Accurate phenotypic definition 
and recognising potential clinical confounding factors in research populations is key to improving the 
quality of research.  
Chapter 4 presents a candidate gene study in both a taxane- and an oxaliplatin-treated cohort of patients 
187 taxane- treated patients were included for genotype analysis. Based on the systematic review, seven 
single nucleotide polymorphisms (SNPs) were identified for investigation.  However, no significant 
associations were identified for CYP2C8*3, CYP3A4*22, EPHA4, EPHA5, EPHA6, FGD4, and XKR4. For the 
oxaliplatin cohort of 120 patients, three SNPs, ACYP2 rs843748, FARS2 rs17140129 and TAC1 rs10486003, 
were investigated based on previous GWAS results. Again, no significant effects were seen in this 
population.  A strength of this pharmacogenetic study was use of both medical assessment of CIPN and 
patient reported outcome to support phenotypic definition.  
The quality of life study is presented in chapter 5 and confirmed a statistically significant correlation 
between patient reported neuropathy scores and both quality of life and functional measures. In the 
paclitaxel cohort, the sensory score was negatively correlated with a functional score at 6 months post-
chemotherapy. In the oxaliplatin cohort, at the end of the treatment time point for those who received >6 
cycles, there was a significant negative correlation between the sensory score and both functional and 
global QoL scores. More consistently over time, however, correlations with QoL and functional scores in 
those who scored more highly on the motor aspects of the CIPN20 module were seen. Persistent 
neuropathy leading to higher scores in the motor aspects of the CIPN20 showed a statistically significant 
difference in functional score (p=0.002) and global QoL score (p=0.026) at the 18 month time-point.   
Finally, chapter 6 comprises discussion of the work and concludes that future work needs to build a clinical 
and genetic model upon which to assess an individual’s risk for development of this toxicity which can 
impact quality of life and function many months and years after treatment. Improving assessment and 
standardising outcome measurements, potentially through the development of consortia to further the 
pharmacogenetic research aspect of cancer drug safety is key to improving the evidence base to build risk 
models which may start to improve individualisation of treatment and develop a more personalised 
assessment of risk of harm. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
  
 2 
Advances in oncology mean that patients are living longer with a cancer diagnosis 
following treatment. As a consequence, survivorship issues are becoming increasingly 
important and there is a growing need to consider the long term adverse effects of 
cancer treatment. Chemotherapy induced peripheral neuropathy (CIPN) is a common 
adverse effect during treatment, is a common reason for dose reduction or early 
cessation of therapy and, for a significant number of patients, it can persist for a long 
period of time following completion of treatment with significant impact on function. 
The mechanism of CIPN is poorly understood but there is emerging evidence that 
susceptibility to drug induced neurotoxicity can be predicted by an individual’s 
genotype.  
 
Agents associated with CIPN include the taxanes, platinums and vinca alkaloids. The 
taxanes, largely docetaxel and paclitaxel, are widely used in clinical practice in the 
treatment of breast cancer, gynaecological cancers and prostate cancer. Taxane 
induced peripheral neuropathy can affect approximately 50-60% of patients with up to 
33% of patients experiencing more severe neuropathy (NCI CTC grade 3-4) (2). A study 
investigating dose delivery of taxane chemotherapy in women with early breast cancer 
found that 37% of all dose delay/ dose reduction or early discontinuation events were 
due to CIPN (3).  
 
Of the platinum drugs, it is largely cisplatin and oxaliplatin which are associated with 
CIPN, with carboplatin having very little associated neuropathy. Myelosuppression 
instead is the main dose limiting toxicity of carboplatin.  Cisplatin is used in the 
treatment of many cancers, forming the basis of chemotherapy for lung cancer, germ 
cell tumours, head and neck and cervical cancers. Oxaliplatin on the other hand has 
been associated with two distinct forms of neurotoxic manifestations: acute, transient 
symptoms are due to peripheral sensory and motor neurone hypersensitivity and occur 
in up to 90% of patients (4); and cumulative more chronic peripheral neuropathy that 
interferes with function occurring in 15-20% of patients (5, 6).. Oxaliplatin is used in the 
treatment of colorectal, oesophageal and gastric cancers. 
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The vinca alkaloids have a major role in the treatment of haematological malignancies 
both in adults and children, as well as playing a role in sarcoma, breast and lung cancer 
therapy. Vincristine, in particular, is associated with neurotoxicity, one of its most 
important dose limiting effects.  
 
1.1 PRESENTATION, PHARMACOLOGY AND PATHOPHYSIOLOGY OF CIPN 
 
CIPN is peripheral nerve damage caused by cytotoxic systemic anti-cancer therapies. It 
most commonly affects large and small sensory nerves and results in loss of sensation, 
paraesthesia or neuropathic pain initially in the fingers and toes, but can progress to 
affect more of the distal limbs in a ‘glove and stocking’ pattern. Motor fibres can also be 
affected, but this is less common. Vincristine can also cause damage to autonomic 
nerves and can result in constipation or urinary retention (7). Sensory impairment can 
lead to difficulty in carrying out simple tasks such as doing up buttons or holding a pen 
and in more severe cases, can lead to dropping objects, difficulty walking and falls. 
Neuropathic pain may co-exist with other changes in sensation. Symptoms may be 
transient after doses of neurotoxic chemotherapy agents and settle completely after 
treatment, or they may also persist between cycles, accumulating to becoming chronic 
and lasting long after chemotherapy has finished. In the case of platinum 
chemotherapy, the toxicity may display ‘coasting’, where symptoms may become more 
apparent after completion of treatment (8). Often there is at least some reversal of 
symptoms within 12 months after treatment (9) but there are a significant minority of 
patients who have ongoing symptoms for much longer after therapy has finished (10-
12). 
 
1.1.1 Platinum agents 
 
The structures of the platinum agents are shown in figure 1.1.  The primary mechanism 
of platinum cytotoxicity is through covalent binding of reactive platinum species to DNA 
resulting in distortion, failure of replication and subsequent cell death (13). It is 
believed that cisplatin enters cells through a combination of passive diffusion and the 
copper transporter hCtr1 pathway (14).  
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Figure 1.1 Structure of the platinum drugs in common oncology use 
(http://pubs.rsc.org/EN/content/articlehtml/2014/cc/c4cc02254h?page=search) 
 
The main resistance mechanisms include failure of accumulation within the cell, 
increased detoxification (mainly by glutathione) and enhanced repair mechanisms (14). 
Platinum neurotoxicity occurs due to damage to the dorsal root ganglion (DRG). It has 
been shown that platinum drugs accumulate here (15, 16) and may cause apoptosis 
through DNA adduct formation in sensory neurones (17). There is in vitro  evidence of 
Ctr transporters in neuronal cells of the dorsal root ganglion in rats (18). In oxaliplatin 
induced acute neurotoxicity, there are also features of axonal hyperexcitability with 
evidence of alterations in voltage-gated calcium channel function (19) and sodium 
channels (20). Understanding of factors that may predispose to platinum accumulation, 
efflux and increased adduct formation are incomplete. A number of other transporters 
may play a role in accumulation and efflux of platinum agents in and out of various 
tissues including the ABC transporters, OCT1, OCT2 and MATE (21) . Repair of platinum- 
related DNA damage occurs predominantly through the nucleotide excision repair 
pathway with a smaller contribution from the base excision pathway. Various genetic 
variants in molecules such as excision repair cross- complementing group 1 (ERCC1), 
excision repair cross-complementing group 2 (ERCC2) and x-ray repair cross- 
complementing protein 1 (XRCC1) have been explored as possible resistance 
mechanisms to the platinum drugs but with largely contradictory results, and so no 
definite differential response or outcome with genetic variants is recognised (22). 
However, data for polymorphisms in XRCC1 in Asian populations is rather more 
suggestive of a clinically important effect (23). Other potential important molecular 
repair pathways are less well studied at present. 
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1.1.2 Taxanes 
 
The taxanes, largely paclitaxel and docetaxel, in widespread clinical use, are both 
metabolised in the liver. The structures of these two commonly used drugs are shown 
in figure 1.2. Both are substrates for CYP3A4 and CYP1B1 (24-26); paclitaxel is also 
metabolised by CYP2C8 (27) and docetaxel by CYP3A5 (28). They are transported by the 
ATP-binding cassette transporters ABCB1, ABCG2, ABCC1 and ABCC2, and in particular, 
OATP1B3 has been found to be a key molecule in transporting both taxane drugs into 
hepatocytes (26). Some studies have shown that variants in genes encoding for the 
above proteins have resulted in different taxane pharmacokinetics (29-31) whereas 
others have not shown evidence of change in paclitaxel clearance (32, 33). The taxanes 
have been hypothesized to cause neuropathy via several mechanisms. Their main 
mechanism of cytotoxicity is to affect microtubule dynamics by inhibiting tubulin 
depolymerisation. Microtubules are made up of    and  - tubulin heterodimers, and 
whilst most data suggest mutation of the tubulin-encoding TUBB gene is not a 
resistance mechanism, overexpression of tubulins may be (26). The process of altering 
microtubule dynamics is also thought to be a mechanism of neurotoxicity as 
interference with microtubules in the axons of nerves may disrupt axonal transport (34, 
35). It is also thought that taxanes may also cause damage at the DRG (36). A further 
theory is that taxanes induce damage in mitochondria leading to energy failure (37). 
Reactive oxygen species in sensory nerves have also been proposed as a mechanism for 
ongoing paclitaxel-induced painful neuropathy (38).   
Paclitaxel is hydrophobic and is solubilised in polyoxyethylated castor oil (Cremaphor 
EL) and ethanol. These vehicles are associated with some of the hypersensitivity 
reactions seen in a proportion of patients treated with paclitaxel. Nab- paclitaxel is 
albumin-bound paclitaxel and overcomes some of the problems of hypersensitivity and 
drug delivery.  
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Docetaxel     Paclitaxel 
         
Figure 1.2 Structures of docetaxel and paclitaxel  
(https://pubchem.ncbi.nlm.nih.gov/compound/) 
 
 
1.1.3 Vincristine 
 
Like the taxanes, vincristine is also primarily metabolised by the CYP3A system, being a 
substrate for both CYP3A4 and CYP3A5. Different variant alleles exist for expression of 
these enzymes and CYP3A5 production relies on the presence of at least one copy of 
the CYP3A5*1 allele. Absence of this allele results in no CYP3A5 production and reliance 
on the significantly less efficient CYP3A4 for metabolism of vincristine. Figure 1.3 shows 
the structure of vincristine. 
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Figure 1.3 Structure of vincristine 
(https://pubchem.ncbi.nlm.nih.gov/compound/5978#section=2D-Structure) 
 
There is a marked difference in expression of CYP3A5 between racial groups with 
African Americans being high expressors (approximately 75%), East Asians intermediate 
(approximately 47% of individuals are expressors) and Caucasians having low levels of 
expression (around 19% of Caucasians) (39). The CYP3A5*3 is the most common allele 
in Caucasians and results in a splice defect and ineffective enzyme production (40). 
Racial differences in the outcomes of vincristine-containing leukaemia therapy have led 
to speculation that CYP3A5 expression may play a clinically significant role in the 
pharmacokinetics of vincristine. This difference in CYP3A5 expression was 
retrospectively investigated when it was recognised that African American children had 
reduced survival rate in an acute lymphoblastic leukaemia (ALL) study. However, 
CYP3A5 expression was not significantly related to relapse rate (41). Renbarger et al 
also demonstrated a significantly lower neurotoxicity rate in vincristine-,treated African 
American children compared to  Caucasians (42). Membrane transporters including 
ABCB1, ABCC1, ABCC2 and ABCC3 (43-45) have roles in vincristine transport and 
elimination. Biliary excretion of vincristine is mediated by ABCB1 and ABCC2 and 
transport into the blood occurs through ABCC1 (46). As with other agents the 
mechanism of neurotoxicity is not fully understood, but similarly, neurone damage at 
the DRG (47) is recognised, as well as there being evidence that interference with both 
antegrade and retrograde transport in axoplasm due to its effects on microtubules is 
contributory (34, 48).  
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1.1.14 Epothilones 
 
The epothilones are non-taxane microtubule stabilising agents and produce mitotic 
arrest with a similar mechanism to the taxane drugs (49). They are not in widespread 
standard use in UK oncology practice but ixabepilone has been reported to have some 
activity in hormone refractory prostate cancer (50) and has been shown to have some 
efficacy in metastatic breast cancer (51). Like the taxanes, they can produce a primarily 
sensory peripheral neuropathy. It is thought that the predominant mechanism of 
neurotoxicity is through interference with axonal transport in effected neurons (52). As 
their current use is very limited at present, the epothilones, whilst mentioned in this 
thesis are not a topic of focus.  
 
1.2 INCIDENCE AND RISK FACTORS FOR DEVELOPMENT OF CIPN 
 
1.2.1 CIPN in different patient cohorts according to primary cancer 
 
Many studies include potentially neurotoxic drugs, both as single agent treatments and 
in different chemotherapy combinations, and will present data on toxicities including 
peripheral neuropathy. There are far too many studies to reference all so for the 
summary presented below, in general the papers quoted refer to the seminal studies 
which led to the standard inclusion of that drug in the treatment of the relevant cancer 
type. 
 
CIPN in patients treated for gynaecological cancer 
Paclitaxel is part of the standard treatment for ovarian cancer in patients whose fitness 
permits, alongside a platinum, usually carboplatin. It is used in doublet therapy in first 
line therapy, platinum-sensitive relapse and it is also utilised in a weekly regimen as a 
single agent in platinum-resistant disease.  Of the large-scale trials which have 
confirmed the use of paclitaxel in ovarian cancer, ICON 3 randomised 1421 patients to 
receive either single agent carboplatin or carboplatin with paclitaxel 175mg/m2 with the 
result that 19% of those receiving taxane experienced grade 2-3 sensory neuropathy 
while 6% experienced grade 2-3 motor neuropathy (in comparison with 1% and <1%, 
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respectively, on carboplatin alone) (53). Similarly, in a study conducted by the same 
group, paclitaxel was added to conventional platinum- based chemotherapy in the 
relapse setting. A similar increase in grade 2-4 neurological toxicity (1% with platinum 
alone compared to 20% with concurrent paclitaxel) was seen (54). The SCOTROC1 trial 
found a higher incidence with 30% of patients on the paclitaxel-carboplatin arm 
experiencing grade 2-4 sensory neuropathy with the same dose and schedule of 
paclitaxel. They found that 78% of patients experienced any grade of neurosensory 
toxicity. Many patients who experience neuropathy during treatment will have 
resolution of their symptoms. However, from clinical experience we know that a 
significant proportion of patients experience persistent symptoms after treatment. One 
study that looked at a group of 120 patients treated with carboplatin and paclitaxel 
found that of the 65 (54%) patients who developed at least grade 1 neuropathy during 
chemotherapy: 
• 9 patients (15% of the total treated) had residual neuropathy symptoms at 
assessment more than 6 months after completion of paclitaxel therapy (55); and  
• 14% of the treated population had residual neuropathy at one year and 11% at 
two years. 
Nab- paclitaxel is used far less commonly in gynaecological malignancies that paclitaxel. 
However, it does sometimes play a role as single agent therapy in platinum resistant or 
refractory disease. Sensory neuropathy has been reported in approximately 40% of 
patients with grade 3 neuropathy relatively infrequent in around 2% of patients (56). 
 
CIPN in patients treated for breast cancer 
Patients with early breast cancer who require neoadjuvant chemotherapy frequently 
receive a taxane-containing regimen, either docetaxel three-weekly or weekly 
paclitaxel. Those who require adjuvant chemotherapy after surgery may receive a 
taxane-containing regimen, particularly if they were found to have node positive 
disease. The TACT trial which investigated the addition of docetaxel to adjuvant 
chemotherapy in 4162 women with early breast cancer found a 5% rate of grade 3-4 
neuropathy (57). A study which was performed alongside a phase III trial in patients 
with early breast cancer receiving three cycles of three-weekly adjuvant docetaxel 
(100mg/m2 or 75mg/m2) identified 34% of patients experiencing grade 2-4 neuropathy, 
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although 5% of patients had pre-existing neuropathy (58). Eckhoff et al also investigated 
the persistence of neuropathy after adjuvant docetaxel treatment and reported a rate 
of 15% persistence 1-3 years after completion of therapy (59). Patients with advanced 
breast cancer are frequently treated with taxanes; in this population a phase III trial of 3 
weekly docetaxel versus doxorubicin showed a 42.8% and 5% rate of any and grade 3-4 
sensory neuropathy, respectively, in the docetaxel- treated patients (60). Nab-paclitaxel 
is sometimes used in patients with metastatic breast cancer, most commonly in those 
who experience hypersensitivity to paclitaxel. It’s use is associated with a 10% rate of 
grade 3 sensory peripheral neuropathy which has been reported to reduce to grade 1-2 
neuropathy with withholding of drug in a median of approximately 22 days (61). 
 
CIPN in patients treated for prostate cancer 
Docetaxel is frequently used in the management of castrate-resistant prostate cancer 
based on a seminal trial showing improved quality of life over mitoxantrone. A 30% 
incidence of any grade neuropathy was reported with the now standard three-weekly 
regimen of docetaxel 75mg/m2 (62). A further trial using the same standard regimen of 
docetaxel as the control arm (598 patients) with placebo similarly showed a rate of 26% 
for all grades of CIPN and a 3% incidence of grade 3-4 neuropathy (63). 
 
CIPN in patients treated for gastrointestinal cancer 
Oxaliplatin is integral to the management of both early stage operable and advanced 
colorectal adenocarcinoma (CRC). It has been shown to improve response rates and 
progression free survival in the advanced setting compared to a fluoropyrimidine alone 
but causes a significant degree of neurological toxicity. DeGramont et al reported that 
68% get any grade of paraesthesiae in their seminal phase III trial with oxaliplatin 
85mg/m2 delivered two-weekly with 5-fluorouracil (5FU), with 18.2% grade 3-4 sensory 
disturbance. Much of this was transient cold-related dysaethesia but they reported a 
16% rate of cumulative paraesthesiae interfering with function. There was an 
improvement from grade 3 neuropathy over a median of 13 weeks in three quarters of 
the patients (5). Goldberg et al also reported an 18% risk of grade 3 paraesthesiae in a 
key phase III trial of oxaliplatin use in advanced CRC (64). A further important phase III 
trial comparing different sequencing of combination regimens (FOLFIRI then FOLFOX or 
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vice versa) reported a higher rate of neuropathy with almost universal experience of 
some degree of neurotoxicity (>90%) during oxaliplatin therapy and an incidence of 
grade 3 neuropathy of 34% in those receiving FOLFOX6 (oxaliplatin at 100mg/m2 
administered two-weekly) as first line therapy. They state that 13% of these patients 
had resolution to <grade 3 neuropathy 1 month after completion of therapy, and 31% 
improved from grade 3 neuropathy within three months. This implies that 21 of 111 
patients had grade 3 neuropathy which lasted more than 3 months post treatment (65), 
a not insignificant statistic.  
 
The MOSAIC trial confirmed a role for oxaliplatin as adjuvant treatment for resected 
colon cancer with a significant improvement in disease-free survival. Oxaliplatin was 
delivered at a dose of 85mg/m2 two-weekly in combination with 5FU/LV. 92.1% 
experienced neuropathy of any grade, 12.4% developed grade 3 neuropathy during 
treatment and a further 12 patients developed grade 3 neuropathy after treatment. In 
total, 1.1% of patients had persistent grade 3 neuropathy at 1 year (66).  
 
A retrospective study of 188 patients treated with CAPOX outside of a trial setting 
demonstrated a rate of 16% grade 3-4 chronic neuropathy in individuals receiving 
adjuvant treatment, and 4% in palliatively-treated patients. At 12 months post 
treatment, 35% of 85 adjuvant-treatment patients were still experiencing neuropathy 
symptoms (67). 
 
For patients with gastric and oesophageal adenocarcinoma, CIPN has long been an 
adverse effect of treatment as it has generally involved platinum- based therapy. 
Treatment has evolved from cisplatin/5FU to ECF (epirubicin/cisplatin/5FU) to now 
many patients receiving EOX (epirubicin/ oxaliplatin/capecitabine) on the back of a 
large non-inferiority phase III trial by Cunningham et al (68). With the cisplatin 
combinations, peripheral neuropathy was found to affect 30-40% of patients with <2% 
experiencing grade 3-4 neurotoxicity. With the oxaliplatin triplets, this increased to 
around 80% of patients experiencing any grade neuropathy and 4.4% and 8.4% of 
patients experiencing grade 3-4 neuropathy receiving EOX or EOF, respectively. This 
figure is lower than in some of the CRC trials stated above. The differences are possibly 
 12 
due to a higher median number of cycles received by the CRC patients, the different 
regimens and different patient populations. 
 
CIPN in patients treated for testicular germ cell tumour 
Potentially neurotoxic drugs are used in the primary treatment of testicular germ cell 
tumours (GCTs) with cisplatin being a vital component of combination chemotherapy. 
Cisplatin, vinblastine and/or paclitaxel are frequently used in second line treatment 
where necessary. In a cross-sectional study of 1409 survivors of testicular cancer in 
Norway at a median of 10.7 years post orchidectomy (range 4-21), 29% of all men who 
had received chemotherapy reported paraesthesiae in hands or feet as a major 
symptom (69). Similarly in the UK, a study assessed 730 patients for evidence of 
ongoing neuropathy >3 years after treatment. On clinical assessment, evidence of 
neuropathy was found in 20.3% of men who had received chemotherapy and 11.8% of 
those completing a subjective assessment reported neuropathy as an ongoing 
significant issue (70). 
 
CIPN in patients treated for haematological cancer 
Vincristine is a key drug in the combination chemotherapy regimens used to treat acute 
lymphoblastic leukaemia (ALL). This is a common paediatric malignancy and cure rates 
of around 85% can be achieved. Maintaining dose intensity is important and this can be 
compromised by peripheral neuropathy which is the primary dose limiting toxicity of 
vincristine. Clinically important neuropathy occurs in around 25% of children 
undergoing ALL treatment protocols (71, 72).  
Vincristine is routinely dose-capped to 2mg per dose because of the occurrence of 
neurotoxicity but evidence suggests a large inter-individual variability in drug exposure 
(73). Vincristine is an integral part of the R-CHOP regimen which is commonly used for 
non-Hodgkin lymphoma (NHL). Peripheral neuropathy can occur in up to 44% of 
patients, but grade 3-4 neuropathy is not often seen (74) 
Vinblastine is used in the treatment of Hodgkins lymphoma but neuropathy is less of an 
issue here. Severe neurotoxicity is not usually encountered and dose reduction due to 
CIPN is far less frequent (75).  
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1.2.2 Age and chemotherapy induced peripheral neuropathy 
 
Taxanes 
Most of the literature shows no effect of age on the development of CIPN in both 
retrospective (76-79)  and prospective studies (80-82). Exceptions to this include one 
study which reported that patients younger than 50 years showed a significantly higher 
neurotoxicity rate than those older than 50. However, this was a very mixed group of 
patients with different primaries and different paclitaxel schedules (83). A further 
retrospective study suggested that CIPN related to adjuvant paclitaxel in breast cancer 
patients persisted for longer in patients over 60 years of age. However, the study 
design, involving case-note review only for grading and persistence of neuropathy, has 
to be taken into account (84). Weak evidence that older patients are at increased risk of 
sensory neuropathy was seen in a further paclitaxel study but this does not appear to 
be clinically significant (HR per year= 1.02, 95% CI 1.00-1.05, p =0.082) (85). A study 
presented in abstract form reported an increased incidence of paclitaxel-induced 
neuropathy with increasing age with a 12.9% increase in risk for every decade (86). 
However, this really stands out alone as the only study suggesting such a large impact of 
age. 
 
Oxaliplatin 
Similarly with oxaliplatin, much of the literature reports no significant difference both in 
prospective (5, 87-90) and retrospective studies (78, 91-95). In a prospective study of 
366 patients performed to assess the influence of baseline clinical characteristics in the 
risk of developing severe oxaliplatin induced chronic peripheral neurotoxicity (defined 
as grade 3 PN or grade 2 PN persisting for greater than 7 days), patients in the older age 
group (55 years or over) demonstrated an increased risk on univariate analysis, but this 
was not upheld in multivariate analysis (96). Vincenzi et al, in their retrospective cohort 
of 169 FOLFOX4-treated adjuvant colorectal cancer patients, showed no evidence of 
association between the development of CIPN and age, but did note a longer duration 
of symptoms in younger patients (<60 years) after adjustment for a group of other 
clinical parameters (97). 
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1.2.3 Gender and chemotherapy induced peripheral neuropathy 
 
The weight of evidence would suggest that there is no difference in the occurrence of 
CIPN based on gender for either taxanes (81), oxaliplatin (89-91, 94-96) or cisplatin (98).  
There is relatively little comparative evidence within taxane-based studies as many 
have been carried out in breast, ovarian or prostate cancer patient cohorts, which by 
their very nature are almost universally single-gender studies.  
 
A prospective study of 200 colorectal cancer patients undergoing oxaliplatin- based 
chemotherapy found that male patients were more likely to develop grade 3 or higher 
neuropathy than female patients. They excluded patients with pre-existing PN, 
diabetes, alcohol excess or any medications which may cause PN. This finding did not 
persist in multivariate analysis and the authors speculated that it may be related to the 
fact that men received higher cumulative doses (99). 
 
A retrospective analysis of prospectively collected data demonstrated that significantly 
more females than males developed any grade of neurotoxicity with taxane-based 
treatments in both exploratory and validation cohorts (67% of females vs 33% of males 
and 65% of females vs 29% of males in cohort sizes of 261 and 239 patients, 
respectively). Patients were being treated for any solid malignancy and there was no 
adjustment for schedule, which was weekly or 3 weekly, or differing dosages, and so 
there was a significant risk of confounding (100). 
 
 
1.2.3 Ethnicity and chemotherapy- induced peripheral neuropathy 
 
A retrospective review of 123 breast cancer patients who had received adjuvant or 
neoadjuvant taxanes showed that a greater proportion of African American patients 
(53%) had dose reductions due to CIPN than Caucasian or ‘other’ patients (22% 
combined) (101). A paclitaxel study in breast cancer patients noted a similar increased 
risk in African American patients (HR 2.1, p=4.5x 1011) (86).  A study designed to review 
participants recruited to a number of prospective treatment trials and compare 
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tolerability of cisplatin and doxorubicin in white and black women with endometrial 
cancer did not show a difference in neurological toxicity (102).  
 
The most notable discrepancy in different racial groups is that reported in vincristine- 
treated paediatric ALL patients. A relatively small, retrospective study reported a 34.8% 
risk of vincristine neuropathy in Caucasian children compared to a rate of 4.8% in 
African American patients, offering a hypothesis that this could be due to differential 
CYP3A5 expression (42) and some genetics studies support this theory (71).  The sheer 
magnitude of the differences seen in both taxanes and vincristine in racial difference 
would appear to warrant further investigation. 
 
1.2.4 Body mass index and chemotherapy induced peripheral neuropathy 
 
Body mass index has only been addressed as a potential risk factor for CIPN in a small 
number of studies but there is some evidence that raised BMI may be associated with 
increased risk of CIPN.   In taxane-treated patients, a case-control study with 150 
women treated with three-weekly docetaxel found that of the 75 women developing 
grade 2 or greater CIPN, 25% had a BMI of 30 or greater compared with 8% of those in 
the control group (p=0.008) (103).  Similarly, in a large cohort study of 6248 patients 
involved in one of four prospective randomised controlled trials, patients with a BMI in 
the overweight or obese range were found to have an increased risk of >grade 2 
neuropathy (104). A Danish trial cohort study however showed no evidence of 
association with BMI in a similar, although small, breast cancer population (105).  
 
In oxaliplatin-treated patients, a prospective study of 102 patients treated with 
adjuvant CAPOX demonstrated a HR 3.69 (1.2-11.27, p=0.01) of developing grade 2 or 
greater chronic peripheral neuropathy in patients with a BMI >25 (5 of 66 patients with 
BMI <25 compared with 9 of 36 patients with BMI > 25) (106). A further two studies 
have shown an association with increased neuropathy with oxaliplatin and increased 
body surface area. The first, a prospective study of 366 patients receiving treatment for 
colon cancer showed a difference in the risk of developing severe oxaliplatin induced 
chronic neuropathy associated with increased body surface area on univariate analysis, 
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although this was not observed with multivariate analysis (96). The second was a 
retrospective study investigating risk factors for developing CIPN with modified 
FOLFOX6.  This study demonstrated no effect of BMI on multivariate analysis but an 
increased risk of developing both acute and chronic oxaliplatin-induced neuropathy 
associated with body surface area (BSA) >2.0m2 (91). 
 
American Society of Clinical Oncology guidelines suggest that patient’s BSA should be 
calculated according to actual body weight due to evidence of worse outcome if dose 
capping or ideal body weight is utilised (107). If an increased risk of CIPN exists, as some 
studies suggest, there is a possibility that there could be issues with specific drugs, such 
as taxanes, leading to a hypothesis that perhaps BSA may not be the ideal way of 
calculating dose for those with high BMI. It also raises questions about the potential 
contribution of undiagnosed diabetes being possibly more prevalent in an obese 
population and the uncertain risk this may confer. 
 
1.2.5 Other comorbidities 
 
The role of other co-existent pathology is uncertain. A number of other pathologies can 
cause peripheral neuropathy separately from drug-induced peripheral neuropathy such 
as CIPN. Such conditions include diabetes mellitus, vitamin deficiencies, autoimmune 
diseases and alcohol excess. Both diabetes and alcohol excess have been explored and 
their influence on development of CIPN is not conclusive (76, 97, 101, 103, 108). These 
factors are evaluated in greater depth in chapter 2. 
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1.2.6 Differential neurotoxicity of different drugs 
 
Docetaxel and paclitaxel are clearly similar in their mechanism of action and have 
similar indications. Comparisons of the two drugs in trials in uniform populations have 
consistently demonstrated paclitaxel to be the more neurotoxic agent. Docetaxel/ 
carboplatin versus paclitaxel/ carboplatin as first line therapy for epithelial ovarian 
cancer or primary peritoneal cancer demonstrated grade 2 or greater sensory 
neuropathy in 11% versus 30% in the docetaxel and paclitaxel arms respectively (109). 
Other studies using similar schedules of the two drugs in comparable populations agree 
with these findings (110-112). 
 
Oxaliplatin has been found to be more neurotoxic than cisplatin (113) although the 
cumulative neurotoxicity with both drugs is similar and both can demonstrate coasting, 
a phenomenon where the neurotoxicity can actually worsen after the final dose of drug.  
Vincristine is the most neurotoxic of the vinca alkaloids with doses being capped due to 
increased prevalence of this toxicity >2mg (total dose per cycle). Of the neurotoxic 
cytotoxic agents, it is the most likely drug to cause autonomic neuropathy. 
 
 
1.2.7 Effect of cumulative dose on development of CIPN 
 
There certainly seems to be a dose-response with the development of CIPN with higher 
cumulative doses increasing the risk of its occurrence (80, 81, 91, 92, 114-116). 
However, it has also been shown that those individuals susceptible to CIPN can be liable 
to receiving lower total cumulative doses due to early cessation and dose reductions (3, 
103). The dose per cycle when given at the same frequency can affect occurrence, as 
reported in the case of paclitaxel with doses of 250mg/m2 given three-weekly 
associated with grade 3-4 neuropathy rates in the order of 20-35% whereas those with 
doses of <200mg/m2 are in the range of 5-12% (2). Similarly rates of grade 3-4 
neuropathy have been reported to be as high as 17% with docetaxel 100mg/m2 
compared to 2-4% with docetaxel 75mg/m2 (117). It is not clear that the same is true of 
cisplatin in terms of dose per cycle, but the effect of cumulative dose is accepted and 
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most patients receiving 300-450mg/m2 will develop at least some CIPN (118).  For 
vincristine it is accepted that neurotoxicity is the main dose limiting toxicity and doses 
per cycle are capped for this reason. 
 
1.2.8 Drug delivery and development of CIPN: Duration of infusion 
 
Paclitaxel 
Duration of infusion has mainly been studied in the administration of paclitaxel both for 
investigating differential effectiveness and tolerability. A Cochrane review published in 
2011 (119) showed that a 3- hour infusion was associated with more neurosensory 
changes compared to those receiving 24-hour infusions with a risk ratio of 1.26 (95% CI 
1.09-1.46). They used pooled data from three studies, two in breast cancer patients 
(120, 121) and one in ovarian cancer (122). However, in one of these studies whilst all 
patients commenced on 175mg/m2, the protocol allowed escalation of dose and this 
important clinical variable was therefore not uniform (120).  
 
Comparison of 3-hour versus 96-hour infusions, in one study reported increased 
neuropathy with the shorter infusion, but this was given at a significantly higher dose 
than the 96-hour infusion. Clearly such a prolonged infusion has significant practical 
disadvantages. In addition, an increased risk of myelosuppression was also found with 
such administration (123).   
 
24-hour versus 96-hour infusions have been investigated. One study showed no 
evidence of a difference in the occurrence in peripheral neuropathy in a randomised 
trial of 324 patients. However this was complicated by a slight difference in dose with a 
lower dose given with the longer infusion and concurrent treatment with cisplatin, 
albeit the cisplatin treatment was uniform (124). 
Shorter infusion durations have been investigated. One-hour versus three-hour 
infusions have been looked at in the context of weekly single agent paclitaxel for 
metastatic cancer. No difference was seen in the occurrence of CIPN as defined by 
change in the PNP score (81).  Overall, it would appear that paclitaxel infused over 24 
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hours rather than shorter durations, results in less neuropathy but this is at the expense 
of increased inconvenience and increased myelosuppression. 
 
Oxaliplatin 
 
For oxaliplatin, one identified study has compared administering oxaliplatin 85mg/m2 
over 6 hours compared with 2 hours in a randomised trial involving 64 patients. Other 
treatment factors were standardised. Reduction in neurotoxicity was assessed by the 
oxaliplatin-specific scale as the primary end point and the sample size was calculated 
accordingly. The longer infusion was associated with a reduced incidence of acute 
neurotoxicity (28.1% vs 59.3% grade > 2 neuropathy) (125).  
 
1.2.9 Scheduling of drug 
 
Different drug scheduling has been studied, especially in the case of the taxanes with 
lower more frequent doses being compared to higher, less frequent dosing. Largely 
these studies have looked for differential effect in terms of improved event-free 
survival, response rates or overall survival. Some have shown improved effectiveness 
with different dose scheduling, for example superior paclitaxel effect was seen in some 
studies comparing weekly scheduling with three weekly scheduling in both breast 
cancer (126) and ovarian cancer (127). These studies were not however conclusive and 
clear evidence of differential toxicity is uncertain. This is an area which is evaluated in 
depth in chapter 2. 
 
1.3 ASSESSMENT AND GRADING OF SEVERITY OF CIPN 
 
 
There is no standardised approach to the assessment of chemotherapy induced 
peripheral neuropathy. It is a subjective adverse effect and this makes assessment and 
grading particularly challenging. It is very difficult to compare CIPN outcomes between 
studies and treatment regimens due to the variability of assessment and grading tools 
used. One systematic review in non-small cell lung cancer patients identified 14 studies 
 20 
reporting CIPN and within these, 11 different tools were used to categorise severity 
(128). 
Objective measures of neuronal damage exist, and such neurophysiological measures 
include nerve conduction studies which give a quantification of sensory or motor nerve 
action potentials, respectively. The amplitude of these sensory action potentials may be 
reduced in CIPN reflecting axonal loss. Nerve conduction studies are a truly objective 
measure of nerve damage and can be considered a gold standard of measurement of 
neurotoxicity. However, they are not without their pitfalls. Firstly, they can be 
uncomfortable. Some studies have suggested that a reduction in sensory nerve action 
potentials in the sural nerve at mid-treatment may be predictive of more severe 
neuropathy (99, 129). By contrast, other studies have not shown sensory action 
potentials to be helpful in predicting outcome (130), and conversely it has been shown 
that they may not reflect nerve damage until late in the development of symptoms 
(131, 132). Results of testing also don’t necessarily correlate with severity of symptoms 
(133). NCS will give more of a picture of large fibre damage and may underestimate 
small fibre damage which may result in significant neuropathic pain without objective 
evidence of neurotoxicity (134). Additionally, Argyriou et al noted that whilst 
electrophysiological measurements improved following chemotherapy, there was no 
correlation with patient self-reports of persistent symptoms (135). NCS have a role in 
excluding other forms of neuropathy if there is a reason for diagnostic doubt as to the 
aetiology of neuropathy.  
Electromyography is not routinely helpful. It gives a non-quantitative assessment of 
harm to motor units where there is significant motor impairment, which is less useful in 
this predominantly sensory neuropathy and can be measured clinically without distress 
and discomfort to the patient (136).  Some groups have used quantitative sensory 
threshold testing (QST). This assesses the threshold for sensory stimuli, such as 
vibration or thermal sensation, and again may objectively measure sensory disturbance. 
However standardisation of the methods and instruments does not exist (136).  
Measures that involve neurological examination have shown to have advantages. There 
is some evidence that certain clinical neurological findings may correlate well with 
nerve conduction study findings (137). However whilst some studies suggest that inter- 
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and intra-observer reliability may be good (138), other studies suggest the contrary 
(133). 
Some scales incorporate a few of the above neurophysiological measures and 
neurological examination to result in a final score or grading but most use a descriptive 
scale alone with a score assigned of 0-3 or 0-4, based on severity as judged by the 
clinician along with assessment of impact on various functions or activities of daily 
living. The most widely used assessment measure is the National Cancer Institute 
Common Toxicity Criteria for Adverse Events (NCI CTCAE) toxicity grading scale (139).  
However, inter-observer variation has been reported to be high with just under 50% of 
agreement between different assessors (140). This improves with training. Table 1.1 
summarises this scale along with others in common use including the World Health 
Organisation (WHO) scale (141), Ajani scale, Eastern Cooperative Oncology Group 
(ECOG) scale (142), Oxaliplatin Specific Scale (143) and the Total Neuropathy Score 
(144). The Total neuropathy score (TNS) is a tool originally validated in diabetic 
peripheral neuropathy (145) but has been well studied in oncology populations. It is 
significantly correlated with the NCI CTC scale but is felt to have superior 
responsiveness to change over time as a score out of 40 is given rather than being 
limited to only four or five categories (146). It adds some objectivity in both sensory 
testing but also for motor neuropathy assessment where there is a suggestion that NCI 
CTC grading could in fact overestimate the severity of the effect as it fails to 
differentiate accurately between weakness due to motor nerve damage as opposed to 
cachexia or fatigue (147). 
The disadvantage of this composite tool is the in-depth nature of the evaluation 
requiring clinical examination and NCS to complete it along with additional time and 
equipment. Revised and modified versions of the total neuropathy score have been 
developed and shown to correlate with full TNS scores but easier to perform in routine 
clinical practice (146, 148). The various versions of the total neuropathy score also have 
practical pitfalls because neurological examination is required in all patients and there 
may also be problems with inter-examiner variability particularly when this may be 
performed by oncologists or research nurse practitioners, rather than neurologists as 
was the case in some of the studies (149). 
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Table 1.1. A summary of the different grading scales in use for CIPN 
 
Grading scale Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
NCI CTC (version 4)(139) Normal  loss of deep 
tendon 
reflexes or 
paraesthesia 
(including 
tingling) but 
not interfering 
with 
function 
objective sensory 
loss 
or paraesthesia 
(including 
tingling), 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
sensory loss or 
paraesthesia 
interfering 
with activities 
of daily 
living 
permanent 
sensory loss 
that interferes 
with 
function 
ECOG (142) None or no 
change  
Decreased deep 
tendon reflexes, 
mild paraesthesia  
Mild or moderate 
objective sensory 
loss; moderate 
paraesthesia 
Severe 
objective 
sensory loss 
that interferes 
with function 
- 
WHO(141) None Paraesthesia 
and/or decreased 
tendon reflexes 
Severe 
paraesthesia 
and/or mild 
weakness 
Intolerable 
paraesthesia 
and/or marked 
motor loss 
Paralysis 
Ajani scale (150) Normal  Paraesthesia, 
decreased deep 
tendon reflexes 
Mild objective 
abnormality, 
absence of deep 
tendon reflexes, 
mild to moderate 
functional 
abnormality 
Severe 
paraesthesia, 
moderate 
objective 
abnormalities, 
severe 
functional 
abnormalities 
Complete 
sensory loss, loss 
of function  
Total 
neuropathy 
score 
Sensory 
symptoms 
 
 
None 
 
 
 
Symptoms limited 
to fingers or toes 
 
Symptoms extend 
to the ankle or 
wrist 
 
Symptoms 
extend to knee 
or elbow 
Symptoms above 
knees or elbows 
or functionally 
disabling 
 
Motor symptoms None 
 
Slight difficulty 
 
Moderate 
difficulty 
 
Requires help/ 
assistance 
 
Paralysis 
 
Autonomic 
symptoms 
0 1 2 3 4 or 5 
Pin sensibility  
 
Normal Reduced in 
fingers/toes 
 
Reduced to 
wrist/ankle 
 
Reduced to 
elbow/knee 
 
Reduced to 
above 
knee/elbow 
 
Vibration 
sensibility 
 
Normal Reduced in 
fingers/toes 
 
Reduced to 
wrist/ankle 
 
Reduced to 
elbow/knee 
 
Reduced to 
above 
knee/elbow 
 
Strength Normal Mild Weakness 
 
Moderate 
Weakness 
 
Severe 
Weakness 
 
Paralysis 
 
Deep tendon 
reflexes 
 
Normal 
 
Ankle reflex 
reduced 
 
Ankle reflex 
absent 
 
Ankle reflex 
absent, others 
reduced 
 
All reflexes 
absent 
 
Sural amplitude Normal/red
uced by 
<5% LLN 
 
76-95% LLN 
 
51-75% LLN 
 
26-50% LLN 
 
0-25% LLN 
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Peroneal 
amplitude 
 
Normal/red
uced by 
<5% LLN 
 
76-95% LLN 
 
51-75% LLN 
 
26-50% LLN 
 
0-25% LLN 
 
Vibration 
sensation 
Normal- 
125% ULN 
126-150% ULN 151-200% ULN 201-300% ULN 
 
>300% ULN 
Oxaliplatin specific scale (136, 143) No 
paraesthe-
sia 
Paraesthesia of 
short duration (<7 
days) 
Paraesthesia 
lasting 8-14 days 
Paraesthesia 
persisting in the 
intercycle 
period 
Paraesthesia 
causing 
functional 
impairment 
 
 
Table 1.2. Different forms of the Total Neuropathy Score 
 
Variable TNS TNSr mTNS TNSc 
Pin prick Yes Yes Yes Yes 
Vibration threshold testing via tuning 
fork 
Yes Yes - Yes 
Vibration testing via QST Yes - Yes - 
Thermal threshold via QST Yes (in the 
original version) 
- - - 
NCS-sensory Yes Yes - - 
NCS- motor Yes Yes - - 
Deep tendon reflexes Yes Yes Yes Yes 
Strength Yes Yes Yes Yes 
Subjective report 
Sensory 
Motor 
Autonomic (fainting, impotence, 
constipation, loss of bladder and 
bowel control) 
 
Yes 
Yes 
Yes (in original) 
 
Yes 
- 
- 
 
Yes 
Yes 
- 
 
Yes 
- 
Yes 
 
Adapted from Lavoie Smith(149) 
 
All scales that have been used are relatively insensitive for mild neuropathy; for 
instance, if neuropathy isn’t interfering with any functions it may be scored at a very 
low level even though the sensory symptoms may cause discomfort and distress to 
patients. This then brings the argument for patient-reported aspects to assessment and 
modules for this purpose have been developed.  
 
Patient reported outcome tools and quality of life modules 
 
The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system 
comprises a large collection of health-related quality of life questionnaires tailored to a 
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variety of aspects of chronic illness (151). The system first started out with the FACT 
(Functional assessment of Cancer Therapy) questionnaires. Some are disease specific, 
whereas some are designed for specific symptoms or adverse drug effects.  The FACT-
taxane module is a taxane-specific subscale which has been validated and psychometric 
testing has supported its use for measuring the adverse effects of taxane therapy (152). 
Part of this module includes a neurotoxicity component (Ntx) which comprises 11 
questions related to symptoms such as tingling, discomfort, cramps and hearing 
problems as well as functional questions such as those related to trouble with 
buttoning shirts and walking. This was validated separately as the FACT/Gynecology 
Oncology Group (GOG)- NTx (153). A peripheral neuropathy questionnaire (PNQ) 
developed and tested in oncology practice consists of two sections, one for patients to 
assess the severity of sensory symptoms and one to assess severity of weakness with 
descriptors to guide patients to select the most appropriate level for their symptoms. It 
also includes a section for patients to report activities which may be affected by their 
symptoms. In testing it was found that this questionnaire had higher levels of sensitivity 
compared to the FACT- GOG- Ntx and NCI CTC and good responsiveness to change over 
time (154). The European Organisation for Research and Treatment of Cancer (EORTC) 
has also developed a chemotherapy-induced peripheral neuropathy module for use 
alongside its general EORTC QLQ C30 quality of life scale (155). This includes 20 
questions and has been validated and tested in several different languages and shows 
good levels of responsiveness to change over time (136, 156). Evidence suggests that 
the QLQ-CIPN20 may be better than the NCI CTC scale in detecting the effect of sensory 
symptoms (136). Neither the TNSc nor NCI-CTC scales have a perfect relationship with 
patients’ reports using the EORTC-C30 and CIPN20 modules. Most of the discrepancies 
lie in the intermediate grades of severity (157). This is to be expected as one would 
hope that patient reported data would bring out more important subjective detail 
compared to physician-directed tools.  
There is clearly no standard measure for chemotherapy induced peripheral neuropathy 
but consensus is that any physician-directed measure should ideally be combined with a 
patient reported outcome measure (136). 
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1.4 PROPHYLAXIS AND TREATMENT OF CIPN  
Calcium and magnesium infused around administration of oxaliplatin is one of the most 
commonly studied potential preventative measures. A meta-analysis performed in 2013 
included three retrospective studies and four prospective randomised controlled trials 
and suggested a reduction in > grade 2 chronic neuropathy (158-161), reduction in 
acute neurotoxicity (158, 159, 162) and higher delivered cumulative dose in the Ca/Mg 
infusion groups (158, 159, 163). However there was some concern of bias given the 
large proportion of patients from retrospective studies and the lack of benefit seen by 
some prospective studies (162, 164), albeit these may be underpowered due to early 
closure (158). The reason for this was that alarm was raised regarding a possible 
deleterious effect on anti-tumour efficacy with the Ca/Mg infusions alongside 
chemotherapy (165). However in a subsequent study, this was not been confirmed and 
in fact there has been no proven difference in response rate or survival outcomes (158). 
A large, adequately-powered phase III double blind, placebo controlled study published 
has now shown no benefit of Mg/Ca2+  infusions in oxaliplatin-treated patients (166). 
Vitamin E had been considered a potential preventative agent based on small studies 
(167); however a randomised, double- blind, placebo-controlled trial showed no 
evidence of benefit in platinum- or taxane- treated patients (168).  
Glutathione has been studied as a potential preventative agent as it is an anti-oxidant 
agent which can reduce accumulation of platinum within the dorsal root ganglion (169). 
Some studies have shown some benefit (170, 171); however a randomised placebo 
controlled trial in patients treated with taxane/ platinum chemotherapy showed no 
difference in CIPN symptoms (172) with glutathione. N-acetyl cysteine has been studied 
based on belief that it may increase glutathione production but only 14 patients with 
oxaliplatin were involved and whilst there was a reduction in neuropathy in the treated 
group, such a small study has major limitations (173).  Amifostine has been studied in 
several studies with some positive results (174, 175) but these have been inconsistent, 
of small magnitude when present and counterbalanced by adverse effects of its own 
(176). 
Other postulated preventative therapies have been explored in generally small studies. 
For some therapies there was no significant difference seen such as with alpha-lipoic 
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acid (177), carbamazepine (178), amitriptyline (179) and recombinant human leukaemia 
inhibitory factor (180). In some studies there has been suggestion of benefit, for 
example for venlafaxine (181), omega- 3- fatty acids (182) and oxcarbazepine (183), but 
further data is required in order to draw final conclusions. Others have shown the 
intervention to be worse; for example in the case of nimodipine (184) and possibly 
acetyl-L-carnitine (185).  With such protective strategies there is always some concern 
that there may be an impact on the anti-tumour effect of the drug. 
The studies that are available are generally too small and heterogenous to draw 
definitive conclusions and there is insufficient evidence to suggest any treatment for 
the prevention of CIPN (118, 176) 
 
Once peripheral neuropathy has developed it is difficult to treat. Neuropathic agents 
such as amitriptyline, gabapentin and pregabalin are frequently tried in clinical practice 
for symptom relief but trials of these agents have failed to show evidence of benefit 
(179, 186, 187). Lamotrigine has similarly been studied without benefit (188). Potential 
small benefits of nortriptyline have been noted but the study included only 51 patients 
(189). 
Acetyl-L-carnitine has been the subject of trials in CIPN due to evidence pointing to 
benefits in expression of nerve growth factor, tubulin strength and improvement in 
sensory nerve conduction (190). There has been evidence of benefit in the therapy 
setting but caution exists due to potential harmful effects in the preventative setting 
and more evidence is needed before this may be considered an option (176, 190).  
Topical treatments have also been studied.  A ketamine and amitriptyline preparation 
showed no benefit (191) and a trend, but no significant benefit, was seen for a 
baclofen, ketamine and amitriptyline cream in patients with neuropathy largely due to 
taxane or platinum chemotherapy (192). There is insufficient evidence to recommend 
one specific treatment over another, but the most promising evidence so far has come 
from a study of duloxetine. A randomised double-blind, placebo-controlled trial of 
duloxetine was conducted including 231 patients treated with neurotoxic 
chemotherapy with at least NCI CTC grade 1 CIPN and an average pain score of at least 
4 out of 10 using the Brief Pain Inventory-Short form. The results showed that there 
was a significant decrease in average pain score with 59% of those receiving the active 
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drug experiencing a decrease in pain compared with 38% of those receiving placebo. 
There was also an increased reduction in the reported numbness and tingling symptoms 
in those receiving duloxetine (193). Duloxetine is perhaps more effective in oxaliplatin-
induced peripheral neuropathy than taxane-related neuropathy as suggested by 
subgroup analysis (193). 
 
1.5 PHARMACOGENETICS AND ITS ROLE IN CLINICAL PRACTICE  
 
Routine testing for single nucleotide polymorphisms (SNPs) associated with drug 
related adverse events is far from widespread, but its potential value to alter 
experience for patients is recognised. Some examples where genetic variants may 
contribute to different dosing requirements or occurrence of toxicity include the case of 
warfarin where it has been shown that two genetic factors along with body mass index 
can account for a significant proportion of variance in warfarin dose requirement and 
therefore also impact on bleeding risk (194). Certain variant alleles in the thiopurine 
methyltransferase (TPMT) gene have been correlated with different dosing 
requirements for thiopurines, such as azathioprine, mercaptopurine and thioguanine, 
to reduce the risk of myelosuppression(195).  The presence of CYP2C19*2 has been 
associated with resistance to the therapeutic effects of clopidogrel after primary 
coronary intervention (PCI) (196). Point- of-care testing for the variant allele has been 
prospectively studied to guide personalised treatment after PCI (197). 
 
 
Many other examples exist, but very few pharmacogenetic variants are routinely tested 
for or mandated. The Food and Drug Administration (FDA) recommend HLA-B*-15:02 
testing prior to carbamazepine prescription due to an association between the variant 
allele and carbamazepine- induced Stevens-Johnson syndrome and toxic epidermal 
necrolysis, particularly in Asian patients, but uptake is variable (198). Some countries 
routinely carry out DYPD genotyping prior to fluorouracil based chemotherapy due to 
severe and potentially fatal toxicity (199, 200) that can ensue through administration to 
dihydropyrimidine dehydrogenase deficient individuals, but this is far from universal 
and is not carried in the UK.  
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The one example however where genotyping has become mandatory on a widespread 
basis is HLA-B*57:01 testing prior to the prescription of the HIV-1 reverse transcriptase 
inhibitor, abacavir. Prior to testing approximately 5-8% of individuals receiving the drug 
would experience a hypersensitivity reaction with dermatological, gastrointestinal and 
respiratory consequences which were sometimes fatal. The variant was identified 
alongside two others initially and validated in other study cohorts (201, 202). The 
PREDICT-1 study was a randomised controlled study of prospective, pre-prescription 
testing and identified a negative predictive value of 100% (none of the patients in the 
screening group experienced immunologically confirmed hypersensitivity reactions) and 
positive predictive value of 47.9% (203). Introduction of routine screening has been 
shown to reduce the incidence of abacavir hypersensitivity from 8% to <1% (204). 
Situations where such a strong correlation to a single alleleic variant is identified are 
likely to be in the minority with more complex, multifactorial susceptibility patterns 
more common. However, it is clear that genotyping for variant alleles has the potential 
to form part of pre-prescription algorithms to more fully assess an individuals’ 
sensitivity, likelihood of benefit and potential for significant adverse effects to lead to 
the ultimate aim of more personalised medicine. 
 
1.6 AIMS OF THE THESIS 
 
This introduction has outlined the problem of CIPN. It is a common adverse effect with 
the potential to be persistent after chemotherapy, impact on survivorship and there is 
no effective preventative measure or treatment. CIPN represents an adverse effect that 
warrants investigation to better define the most at risk groups. If one were able to 
better predict susceptible individuals it would aid more personalised counselling 
regarding the benefit/risk ratio of specific treatments. In some scenarios, where 
neurotoxic agents are utilised, for example oxaliplatin in adjuvant colorectal cancer 
therapy, or paclitaxel in addition to carboplatin in ovarian cancer, the absolute 
additional benefit conferred by the neurotoxic agent may be relatively small. In these 
situations, understanding the risks of long term toxicity and morbidity may have an 
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impact on the choice of treatment. A better understanding of the toxicity may also 
eventually lead to improved preventative or therapeutic strategies. 
 Three categories of risk factors will be explored in this work. Two are clinical risk 
factors: those related to features of the individual and those variables related to the 
treatment programme. The third is pharmacogenetic risk factors. These are related to 
single nucleotide polymorphisms (SNPs) in genes that may in some way affect the 
individual’s reactions to the drug. Increasingly this is a focus of research and this work 
aims to review this systematically and contribute to the body of evidence. Finally, this 
project includes a quality of life assessment to explore objective evidence of long term 
impact of return to ‘normal’ after completion of chemotherapy. This will also aim to 
complement physician graded neuropathy in view of the problems with assessment and 
grading as discussed above. 
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CHAPTER 2 
 
 
CLINICAL DETERMINANTS OF CHEMOTHERAPY 
INDUCED PERIPHERAL NEUROPATHY 
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2.1 INTRODUCTION 
 
It is known that chemotherapy induced peripheral neuropathy affects a significant 
number of people who are treated with platinum agents, taxanes and vinca alkaloids. 
We have estimates of the proportion of patients affected from phase III clinical trials 
involving these agents. This chapter aims to evaluate the clinical factors that may 
influence risk of this adverse effect. Some of these factors were described in chapter 1 
based on a narrative assessment of the literature. Such patient-related factors have 
been postulated to include age, gender, primary cancer, body mass index (BMI), 
ethnicity, alcohol consumption, diabetes and pre-existing neuropathy. Treatment-
related factors include cumulative dose, schedule of drug delivery and duration of drug 
infusion. Many review articles cite these as potential factors affecting risk but there is 
little evaluation of the objective evidence for their influence on the development of 
CIPN. For a number of these factors, systematic review may be useful, but the feasibility 
of performing such review is challenging. Consideration of many of these clinical risk 
factors is frequently hidden in one or two sentences within large scale trials focusing on 
drug efficacy. Therefore, a broad-ranging systematic review of clinical risk factors was 
not considered feasible. The search terms that would have been necessary to identify 
all relevant studies were difficult to define and would have either risked missing many 
relevant articles or been so broad that screening the number of returned results would 
not have been achievable; age and gender are such examples.  
 
Therefore, three factors were chosen for thorough systematic review to examine the 
evidence for a relationship with the development of CIPN and, where possible, meta-
analysis was planned. 
The three postulated risk factors were selected due to their clinical relevance and 
suitability for comparative studies, but also because it was possible to devise a specific 
search strategy and have confidence in the completeness of the review. The factors 
selected were  
• the risk conferred by co-existing diabetes,  
• the risk conferred by alcohol excess and  
• the impact of drug scheduling on the development of CIPN. 
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Diabetes is associated with a risk of peripheral neuropathy with an estimated 13-23% of 
patients with type I diabetes and 24-33% of patients with type II diabetes developing 
the condition respectively (205, 206). It has therefore been considered that treating 
these patients with potentially neurotoxic drugs could interplay with their already, 
increased risk of developing peripheral neuropathy, albeit through different 
mechanisms.  Excess alcohol is known to be associated with development of peripheral 
neuropathy likely through an interplay of direct toxic effects and nutritional 
complications (207, 208). It is therefore reasonable to speculate that it may have an 
effect on the susceptibility to CIPN.  Scheduling of neurotoxic drugs, either in more or 
less dose- dense regimens has been postulated to affect toxicity, but evidence has been 
controversial.  This chapter aims to provide a comprehensive overview of these factors 
and examine the evidence available. 
 
2.2 METHODS 
 
Systematic review methodology was used to explore the selected risk factors felt to be 
amenable to application of a search strategy which could be a) specific enough to 
identify a number of studies which would be able to be reviewed by a single 
investigator, but b) sensitive enough to identify relevant studies.  Within each 
systematic review, where more than one comparable study existed for the same drug, 
using similar outcome definitions and appropriate methodology, meta-analysis was 
carried out to explore pooled effects in combined study samples. For each meta-
analysis, inclusion criteria were set for each review and data were analysed. Forest plots 
were prepared using RevMan V5.0 (209) using the Mantel-Haenszel method, assuming 
a random effects model to allow for heterogeneity.  The extent of heterogeneity 
between studies was estimated using the I2 statistic and reasons examined where 
applicable. 
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2.2.1 Diabetes and association with development of CIPN 
 
Systematic reviews were carried out using SCOPUS, Medline and Cinahl databases to 
investigate the potential effect of this factor on the risk of CIPN using the search 
strategy outlined below (table 2.1, 2.2 and 2.3).  Full texts published studies in English 
were considered eligible if they investigated the risk of developing CIPN with potentially 
neurotoxic drugs in patients with a diagnosis of diabetes compared to the risk of 
developing CIPN in patients without a diagnosis of diabetes. The review was limited to 
the effects of neurotoxic cytotoxic chemotherapy drugs and did not include potentially 
neurotoxic novel targeted and biological agents. Both prospective and retrospective 
studies were included but in retrospective studies there needed to be evidence that the 
reported neuropathy occurred as a result of chemotherapy (for example, temporal 
evidence or case-note review of assessments during chemotherapy). 
 
A standard data extraction form was utilised to collect information relating to patient 
demographics, treatment, primary cancer, measures of assessment and outcomes.  
Other confounding factors and methodological considerations were also considered 
along with the results of the studies.  
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Table 2.1. Search strategy for systematic review of diabetes and risk of CIPN  
1. Oxaliplatin 
2. Cisplatin 
3. Platinum 
4. Paclitaxel 
5. Docetaxel 
6. Taxane*  
7. Vincristine 
8. Vinca alkaloid 
9. Chemotherapy 
10. *sensory impairment* 
11. Neuropath* 
12. Neurotox* 
13. Diabet* 
14. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 
15. 10 OR 11 OR 12  
16. 13 AND 14 AND 15 
 
 
2.2.2 Alcohol and an association with CIPN 
 
A search strategy was designed (table 2.2) to identify studies in the English language 
which compared the risk of developing peripheral neuropathy in patients who 
consumed alcohol or consumed alcohol to excess and those who did not. Studies 
focusing on biological or targeted agents rather than cytotoxic chemotherapy drugs 
were excluded. Both prospective and retrospective studies were included but in 
retrospective studies there needed to be evidence that the reported neuropathy 
occurred as a result of chemotherapy, for example, temporal evidence or case-note 
review of assessments during chemotherapy).  The search strategy was applied to 
Medline, SCOPUS and Cinahl databases. 
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Table 2.2. Search strategy for systematic review of alcohol consumption and risk of CIPN 
1. Oxaliplatin 
2. Cisplatin 
3. Platinum 
4. Paclitaxel 
5. Docetaxel 
6. Taxane*  
7. Vincristine 
8. Vinca alkaloid 
9. Chemotherapy 
10. *sensory impairment* 
11. Neuropath* 
12. Neurotox* 
13. Alcohol* 
14. Ethanol 
15. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 
16. 10 OR 11 OR 12  
17. 13 OR 14 
18. 15 OR 16 OR 17 
 
2.2.3 Scheduling of neurotoxic chemotherapy drug and association with CIPN 
 
Finally, the search strategy for different schedules of drugs is detailed in table 2.3. The 
search was designed to explore neurotoxic drugs which are in common oncological 
practice. Ixabepilone and nab-paclitaxel were not specifically included in the search 
strategy as at the time of the search neither were in common use routinely in the UK. 
Some studies involving these drugs were identified so were mentioned in the results 
section.  
Inclusion criteria were randomised controlled trials or other prospective comparative 
designs that reported differential rates of CIPN in groups receiving different schedules 
of the same potentially neurotoxic cytotoxic agent. Retrospective cohort studies were 
included provided there was evidence of prospective toxicity recording. Data extraction 
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was performed to allow collection of the key information regarding assessment and 
incidence of neuropathy but also purity of data in terms of acknowledgement and 
adjustment for confounding factors. Potential confounding factors were recorded, such 
as duration of infusion within each arm and total cumulative dose planned, as well as 
information regarding concurrent chemotherapy drugs. When considering planned 
cumulative dose, differences of >10% were noted. 
 
Table 2.3  Search strategy for systematic review for scheduling of drug and risk of CIPN 
(Limited to controlled trials and articles in English). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. Oxaliplatin 
2. Cisplatin 
3. Platinum 
4. Paclitaxel 
5. Docetaxel 
6. Taxane* 
7. Vincristine  
8. Vinca alkaloid 
9. Neuropath* 
10. Neurotox* 
11. Schedule 
12. Dens* 
13. Weekly 
14. Frequency 
15. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 
16. 9 OR 10 
17. 11 OR 12 OR 13 OR 14  
18. 15 AND 16 AND 17 
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2.3 RESULTS 
 
2.3.1 Diabetes and chemotherapy induced peripheral neuropathy 
 
A total of 1034 articles matched the search criteria after removal of duplicates. This 
number included many articles not relevant to the risk of CIPN, but were more relevant 
to diabetes as articles on diabetic neuropathy were encompassed within the search 
strategy also. Of the total, 916 could be excluded based on their title. A further 97 
articles were excluded after abstract review leaving 20 articles for full text review and 
inclusion (figure 2.1).  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Flow diagram showing the numbers of studies identified for the systematic 
review of diabetes and risk of developing CIPN 
 
118 selected for abstract review after 
screening of titles  
916 records excluded 
on title screening 
20 full text articles selected for 
assessment of eligibility 
98 records excluded 
on abstract screening 
14 studies included in systematic review  
7 full text papers 
excluded: 
2 did not look at 
association of diabetes 
with CIPN 
4 were cross-sectional 
studies carried out up to 
11 years after 
completion of 
chemotherapy  
1 looked solely at 
diabetic patients 
receiving chemotherapy 
therefore was not 
comparative 
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Excluded studies 
 
Seven studies were excluded; two did not look at association of diabetes with CIPN 
(210, 211) and one study looked solely at patients with diabetes receiving 
chemotherapy for ovarian cancer (212).  Four studies did look for an association with 
diabetes but the assessment of neuropathy was usually >2 years after completion of 
chemotherapy.  In one study, all patients were assessed >2 years after completion of 
oxaliplatin (10), while in the second, assessment was a mean of 6 years after 
chemotherapy (213).  In the final two, assessment was at a median of 37 months (214), 
41 months (cisplatin patients) and 18 months (oxaliplatin patients), respectively (215). 
In these four studies, there was no confirmation that the peripheral neuropathy started 
during or shortly after completion of chemotherapy. 
 
 
Included studies 
 
Fourteen studies were included (table 2.4). One study included four cohorts of patients 
treated with vincristine, taxanes, oxaliplatin and bortezomib. The bortezomib group 
was excluded from this analysis. These cohorts are treated separately for the purpose 
of our analysis. Mean sample size was 251 (range 45-1587) but this is skewed by one 
study with a very large group of 1587 patients treated with oxaliplatin (216). The 
median sample size was 123. Six studies involved oxaliplatin as the index neurotoxic 
drug (91, 93, 94, 97, 106, 216) and six studies focussed on an association with taxane 
induced neuropathy (76, 80, 84, 101, 103, 108). Kanbayashi et al, as mentioned above, 
included separate oxaliplatin, taxane and vincristine cohorts for analysis (78) and the 
final study looked at platinum neurotoxicity, but some of these patients also received a 
taxane drug (217).  
Two studies were prospective in design (80, 106), while the remainder were 
retrospective cohort (78, 84, 91, 93, 94, 97, 101, 108, 216, 217) or case-control studies 
(76, 103). 
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Study findings 
 
Seven of the studies demonstrated no significant effect of pre-existing diabetes upon 
the risk of developing CIPN (78, 80, 84, 97, 101, 103, 216). One of these studies 
demonstrated a trend towards increased risk in diabetic patients whilst showing a 
significantly increased risk with increased BMI (77).  Two studies found an increased 
rate of CIPN in patients without a diagnosis of diabetes. The first showed a significant 
association between no diabetes diagnosis and development of NCI CTC grade >2 
chronic oxaliplatin neuropathy which persisted on multivariate analysis (OR 14.1, 95%CI 
1.3-166.7, p=0.03). This was a study of 85 Japanese patients all receiving oxaliplatin in 
the same dose and schedule (94). The second demonstrated an association with 
increased development of both acute and chronic oxaliplatin neuropathy in non-
diabetic patients compared with diabetic patients which was seen in univariate analysis, 
but this was not seen when entered into a multivariate model (91).  
 
The remaining five studies (76, 93, 106, 108, 217) demonstrated a significant 
association in the opposite direction, with diabetic patients experiencing more CIPN 
based on a number of outcome measures. A prospective cohort study involving 102 
colorectal cancer patients receiving a standard schedule of adjuvant oxaliplatin 
demonstrated a markedly increased rate of NCI CTC grade 2 or greater chronic OIPN in 
those with diabetes, with 8 of 19 diabetic and 6 of 83 non-diabetic patients being 
affected (HR 4.86, 95%CI 1.16-21.50, p=0.03)(106).   
  
De la Morena Barrio et al reported univariate analysis results of a significant increased 
in CIPN of any grade of both earlier onset and longer duration in patients with diabetes 
treated with paclitaxel. In their multivariate model, they demonstrated a higher risk of 
developing NCI CTC grade 2-3  CIPN in diabetic patients (OR 3.34, 95% CI 1.41-7.91, 
p=0.006) along with prolonged symptoms compared with non-diabetic patients (76). 
 
Another study found no increased risk of developing CIPN in diabetic patients but those 
with diabetes who developed CIPN experienced this effect at a lower cumulative dose 
compared to those without diabetes (388mg/m2 compared with 610mg/m2) (93)
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Johnson et al demonstrated an association with diabetes and increased development of 
any grade CIPN in platinum- treated lung cancer patients but this did not take into 
account that some patients received concurrent taxane whilst others did not, leading to 
potential confounding (217).  
 
Kus et al showed no excess risk of developing CIPN in diabetic patients receiving a 
taxane with or without carboplatin. However, in a subgroup of patients who had had a 
diagnosis of diabetes for >5 years, there did appear to be an increased risk when 
compared to non-diabetic patients (OR 3.271, 95%CI 1.34-7.98, p=0.009) (108). It must 
however be noted, that whilst other clinical confounders were clearly considered, there 
is no evidence of formal adjustment for CIPN risk of receiving either paclitaxel or 
docetaxel or differing schedules of these drugs. The numbers of patients with or 
without diabetes in each of the different treatment groups however appeared to be 
well-matched. 
 
Unfortunately, meta-analysis was not possible for this dataset. Either, patient numbers 
with and without diabetes, who did or did not suffer CIPN, were not provided (78, 94), 
the outcome evaluated was inconsistent with other studies (91, 101), the dose/ 
schedule was not provided to allow assessment of suitability for pooling of results (93), 
the treatment received by the patient cohort was too heterogeneous (80, 108, 215, 
217) or, in the case of oxaliplatin studies, there was lack of clarity as to whether acute 
or chronic neuropathy was being assessed (97, 216). 
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Table 2.4. Summary of included papers for systematic review of effect of concurrent diabetes on risk of developing CIPN 
Authors Study design Drug Sample 
size 
Number of 
patients 
with 
diabetes 
Assessment 
tool used 
CIPN outcome 
investigated 
Were other patient-related 
variables accounted for 
Were treatment-related variables 
looked for 
Result with respect to effect of diabetes  
Alejandro et al 
(91) 
Retrospective Oxaliplatin 50 6 ‘defined 
according to 
the oxaliplatin 
label’ 
Any acute or 
persistent 
neuropathy 
Included patients with pre-existing 
PN and this along with age, gender, 
BMI and BSA went into multivariate 
analysis  
Uniform treatment Increased risk in non-DM patients on univariate 
analysis but this did not persist in multivariate 
analysis. 
Bhatnagar et 
al (101) 
Retrospective Taxanes 123 20 Dose 
reduction due 
to CIPN 
Dose reduction due 
to CIPN 
Included patients with pre-existing 
PN. Included age, alcohol excess, 
race and gender in analysis 
Either paclitaxel or docetaxel used 
and included in analysis. 
No effect 
De La Morena 
Barrio et al 
(76) 
Retrospective 
case-control 
study 
Paclitaxel 129 43 NCI CTC Any CIPN, grade 2-3 
CIPN, time to onset of 
CIPN and  duration of 
CIPN 
Excluded pre-existing neuropathy. 
Multivariate analysis including age 
Uniform treatment Starting dose, 
total number of cycles included in 
multivariate analysis  
Increased CIPN, grade 2-3 and delayed recovery 
in patients with DM 
Eckhoff et al 
(103) 
Retrospective 
case-control 
study 
Docetaxel 150 6 NCI CTC Grade 2-4 PN Excluded pre-existing neuropathy. 
Included alcohol, age, BMI and PS in 
analysis 
Two doses (75mg/m2 and 100mg/m2) 
included and adjusted for in analysis 
Trend towards increased risk on univariate 
analysis but no significant effect. 
Johnson et al 
(217) 
Retrospective 
cohort 
Platinum with 
or without 
taxane 
735 85 NCI CTC Any CIPN Pre-existing PN allowed but none in 
the diabetic patients evaluated.  
Type of platinum and whether or not 
taxane concurrently given was 
analysed but association with 
diabetes was univariate analysis and 
didn’t include this 
Increased risk with DM. 
Kanbayashi et 
al (78) 
Retrospective 
cohort 
Taxanes 
 
Oxaliplatin 
 
Vincristine 
58 
 
52 
 
52 
5 
 
6 
 
4 
NCI CTC Any neuropathy Excluded pre-existing PN. Age 
included in analysis 
Did not account for different taxanes 
and slightly variable doses. Some 
taxane patients also received cisplatin 
concurrently 
Uniform treatment for oxaliplatin 
patients 
Vincristine doses and schedules were 
variable 
No effect 
Kus (108) Retrospective 
cohort 
Taxanes with 
or without 
carboplatin 
Taxanes alone 
Taxanes with 
carboplatin 
374 
 
270 
104 
81 
 
59 
22 
NCI CTC and 
Neuropathic 
Pain Symptom 
Inventory 
Any grade and grade 
2-3  
Excluded pre-existing PN and 
alcohol excess 
Looked for association with age and 
gender 
No adjustment for different taxanes 
or schedule 
No effect of DM but significant increased risk for 
those with DM for <5 years 
Oguri et al 
.(94) 
Retrospective 
cohort 
Oxaliplatin 70 14 NCI CTC Any neuropathy Excluded pre-existing neuropathy. 
Also looked for association with age 
and gender. 
Treatment standardised Increased risk in non-DM patients 
Ottaianno et 
al (106) 
Prospective 
cohort 
Oxaliplatin 102 19 NCI CTC Grade 2-3 Excluded pre-existing neuropathy Treatment standardised  Increased risk in diabetic patients with a HR 4.86 
(1.16-21.50, p=0.03) 
Pereira et al 
(80) 
Prospective 
cohort 
Predominantly 
taxanes 
296 (214 
received 
a taxane) 
20 NCI CTC and 
TNSc 
Any neuropathy Included patients with pre-existing 
neuropathy. 
Associations sought with alcohol, 
age, thyroid disease 
Treatment regimen very variable. Not 
everyone received a commonly 
neurotoxic drug. Associations sought 
with different treatment schedules 
No effect 
Ramanathan 
et al (216) 
Retrospective 
cohort 
Oxaliplatin 1587 135 NCI CTC Any neuropathy and 
grade 3 or higher 
(however no clear 
definition between 
acute and chronic PN 
made) 
Included patients with up to grade 
1 pre-existing PN. 
Oxaliplatin given at standard 
schedule with or without 5fU/LV. 
No effect 
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Tanabe (84) Retrospective 
cohort 
Paclitaxel 219 18 NCI CTC Grade 2-3 but also 
time to neuropathy 
and duration of 
neuropathy 
Only excluded those with pre-
existing ‘severe’ neuropathy. 
Alcohol not mentioned 
Associations sought with different 
treatment schedules 
No effect 
Uwah et al 
(93) 
Retrospective 
cohort 
Oxaliplatin 62 15 NCI CTC Grade 2-3 Excluded pre-existing PN. Also 
looked at age and gender, not 
alcohol 
Schedule not mentioned No effect on risk but developed at lower 
cumulative dose in DM patients 
Vincenzi et al 
(97) 
Retrospective 
cohort 
Oxaliplatin 169 29 NCI CTC Grade 2-3 (but no 
clear definition 
between acute and 
chronic OIPN) 
No evidence of consideration of 
pre-existing PN. Age, gender, 
alcohol and other clinical 
parameters investigated. 
Uniform treatment schedule No effect 
DM= diabetic, non-DM = non- diabetic 
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2.3.2 Alcohol and chemotherapy induced peripheral neuropathy 
 
361 studies were identified after removal of duplicates. 336 articles could be removed 
based on title alone, and a further 21 were excluded after abstract review. Nine of 
these 21 abstracts were clearly not relevant to the question being addressed, 11 were 
review articles and one was a case report. Six studies were examined in full, and two 
were excluded (figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Flow diagram of identified studies for the systematic review of effect of 
alcohol consumption and risk of developing CIPN 
 
Excluded studies 
 
The first excluded study was designed to assess the risk factors for persistent 
neuropathy after oxaliplatin chemotherapy for colorectal cancer. Patients completed 
questions pertaining to sensory neuropathy from the Functional Assessment of Cancer 
Therapy/ Gynaecology Oncology Group- Neurotoxicity (FACT/GOG-Ntx) questionnaire 
at least 20 months from the last dose of oxaliplatin (median 37 months). They found a 
trend towards increased persistent neuropathy with regular alcohol consumption 
defined by more than 2 ‘standard’ drinks daily or more than 4 ‘standard’ drinks on a 
weekly basis. However, this study was not included in the systematic review due to the 
403 records identified after removal of 
duplicates 
27 selected for abstract review 
376 excluded on title 
screening 
6 full text records screened for eligibility 
21 excluded on 
abstract screening 
4 included articles 
 
 
 
2 excluded as 
peripheral 
neuropathy assessed 
a long time after 
chemo with no 
confirmation that it 
was due to 
chemotherapy 
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fact there was no reference to assessment of neuropathy at the time of chemotherapy 
to confirm that peripheral neuropathy symptoms were oxaliplatin related. The second 
study performed vibration testing in 45 patients who had received either cisplatin or 
oxaliplatin at a median follow up of 46 and 18 months, respectively, without referral to 
assessments of neuropathy during or shortly after treatment and was therefore 
excluded for the same reason (215).  
 
Included studies 
 
The median sample size was 159.5 (range 33-296). The first was a prospective cohort 
study of women undergoing adjuvant or neoadjuvant chemotherapy for breast cancer 
(80). The second was a prospective study of patients undergoing oxaliplatin 
chemotherapy for hepatocellular carcinoma (218), and the third was a case-control 
study (12) of women receiving docetaxel for early breast cancer. The final study was a 
retrospective cohort study of patients who had undergone FOLFOX chemotherapy for 
colorectal cancer (97). The included studies are listed in table 2.7. 
 
The smallest study, of 33 patients, investigated the combination of gemcitabine with 
oxaliplatin in the treatment of hepatocellular carcinoma. The study was designed and 
powered for its primary endpoint which was overall response rate. There was 
comparison of risk of neurotoxicity between those with alcoholic liver disease and those 
with non-alcohol related liver disease.  In this study three patients developed grade 3 
neurotoxicity as assessed by the oxaliplatin-specific scale, all were in the alcoholic liver 
disease group (3/25) with no grade 3 neurotoxicity in the non-alcoholic liver disease 
cohort (0/21), suggestive of increased risk, but the study size is the major limitation. 
Also, categorising risk according to alcoholic liver disease may not be widely applicable 
outside the field of hepatocellular carcinoma (218).  
 
Vincenzi et al also noted an increased risk of developing CIPN in those patients who 
consumed alcohol (97). They recorded a rate of developing NCI CTC grade 2-3 CIPN of 
69% in patients with a higher alcohol intake compared with 51% in patients with no 
excess alcohol intake according to their definition. A strength of this study is the 
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uniformity of treatment factors but the definition of alcohol excess is essentially one of 
binge drinking (> 5 glasses (men) or >4 glasses (women) in a single episode) rather than 
necessarily reflecting chronic alcohol consumption above accepted recommended limits 
in terms of unitary measurement.  
 
Eckhoff et al (103) did not find an association with alcohol consumption > 1 unit per 
week and development of NCI CTC grade 2-4 neuropathy compared with occurrence of 
grade 0-1 neuropathy (p=0.48). Similarly, Pereira et al did not find any association when 
they compared never drinkers to three categories of alcohol consumers: former 
drinkers, those who consumed <1 alcoholic drink per month and those who consumed 
>1 alcoholic drink per month (80). Both of these studies used very low levels of alcohol 
consumption in their investigations rather than looking at the risk of alcohol excess. 
This is a very different approach to those studies which found a statistically significant 
link with development of CIPN. 
 
Due to the marked differences in study populations, outcome measures and risk 
categories used, meta-analysis was not feasible in this systematic review. The 
suggestion from the evidence available is that low levels of alcohol consumption do not 
appear to increase risk of CIPN, but alcohol taken to excess may possibly do so. 
However, again, no firm conclusions can be drawn due to the limited amount of data 
available. 
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Table 2.5. Table of included studies for the systematic review of association between alcohol consumption and CIPN 
Paper Study type Drug Sample size Definition of 
alcohol excess 
Numbers of pts 
according to 
alcohol intake 
Grading  tool 
for CIPN 
CIPN 
outcome/s 
investigated 
Were other patient related 
variables accounted for 
Were treatment related variables 
accounted for 
Result with respect to effect of 
alcohol 
Eckhoff et al 
(103) 
 
Case-control Docetaxel 150 0 units/wk 
1-14 units/wk 
>14 units/wk 
24 
118 
8 
NCI CTC Grade 2-4 PN Excluded pre-existing neuropathy. 
Included DM, age, BMI and PS in 
analysis 
Two doses (75mg/m2 and 
100mg/m2) included and included 
in analysis 
No effect 
Louafi et al 
(218) 
Prospective Oxaliplatin 33 Alcohol related 
liver disease 
(HCC trial) 
13 Oxaliplatin 
specific scale 
Grade 3 Excluded pre-existing PN. No 
other patient factors investigated 
Standardised treatment Increased risk of grade 3 
neurotoxicity in alcohol-related 
liver disease (25% grade 3 vs 0%) 
Pereira et al 
(80) 
Prospective Predominantly 
taxanes 
296 (214 
received a 
taxane) 
Never drinkers 
Ex-drinkers 
< 1 standard 
drink per day 
>1 standard drink 
per day 
12 
2 
52 
 
15 
NCI CTC and 
TNSc 
Any 
neuropathy 
Included patients with pre-
existing neuropathy. 
Associations sought with DM, age, 
thyroid disease 
Treatment regimen very variable 
Associations sought with different 
treatment schedules but not all 
patients received a commonly 
neurotoxic drug. 
No effect 
Vincenzi et al 
(97) 
Retrospective Oxaliplatin 169 5 or more glasses 
(men) or 4 or 
more glasses 
(women) in a 
single episode 
13 NCI CTC Grade 2-3 No evidence of consideration of 
pre-existing PN. Age, gender, DM 
and other clinical parameters 
investigated. 
Uniform treatment schedule Increased incidence with alcohol 
excess 
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2.3.3 Drug delivery and development of CIPN: Scheduling 
 
This section covers delivering the neurotoxic drug in either less frequent, higher dose 
regimens or lower dose, more frequent, dose dense regimens. Figure 2.3 illustrates the 
flow of identified titles resulting in a collection of 49 articles that met the inclusion 
criteria. The 49 included studies were then sub-divided into drug specific group; 
paclitaxel, docetaxel, ixabepilone, oxaliplatin, cisplatin and vincristine for further 
evaluation. 
 
 
 
 
 
 
 
 
 
                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Flow diagram of identified studies for the systematic review of drug 
scheduling and risk of CIPN 
 
 
278 selected for abstract review 
2281 excluded on title screening 
72 full text records screened for eligibility 
206 excluded on abstract 
screening 
47 included articles 
 
 
 
2556 articles identified after exclusions 
removed plus 3 further studies identified 
through reference searches 
Reasons for exclusion: Duration of 
infusion rather than scheduling: 5 
studies 
Dose as variable not scheduling: 4 
studies 
Dose intensity (same dose, variable 
frequency): 5 
Sequencing of combination 
regimens variable not scheduling: 1 
study 
Too many variables: 10 studies 
Neurotoxicity not specifically 
mentioned: 1 study 
Not comparative: 1 study 
Duplicated population: 1 study 
Feasibility study of dose intensity: 1 
study 
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Docetaxel 
 
Included studies 
 
There were 12 studies in total studying more versus less dose dense schedules of 
docetaxel. The median sample size was 108 (range 31-2466). For five of these studies, 
the primary outcome was a survival or response outcome (62, 126, 219-221). Five 
studies specifically listed toxicity as a primary outcome (222-226); for two of these their 
focus was on haematotoxicity (223, 224). The remaining two studies were primarily 
exploring quality of life outcomes (227).  
 
Sample size and power calculations 
 
In general, neurotoxicity was not a pre-specified primary outcome and therefore most 
studies did not justify their sample size for assessing neurotoxicity. No study specifically 
calculated study sample based on neurotoxicity.  Two studies included a sample size 
calculation based on finding a difference in overall toxicity. The first based sample size 
on the ability to differentiate between an incidence of 30 and 60% of grade 3-4 toxicity 
but did not detail a power calculation (225). The second described a sample size and 
power calculation for detecting a difference in toxicity in general. However, it failed to 
meet its recruitment target of 160 patients and was therefore underpowered (226).  
The expectation therefore is that at least half of the included studies were 
underpowered to detect a clinically relevant difference in the development of CIPN. 
 
 
Study type and randomisation 
 
Eleven of the studies were prospective randomised controlled trials and one was a 
retrospective comparative study (221). Of the 11 randomised studies, seven described 
the method of randomisation (62, 219, 220, 225-228). Risk of randomisation bias overall 
was therefore considered to be low.  
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Potential patient- related confounding factors 
 
Two studies excluded those with pre-existing peripheral neuropathy (220, 229), two 
excluded those with peripheral neuropathy equivalent to grade 2 severity or worse (62, 
219) and one excluded those with greater than grade 2 neuropathy (228). No 
consideration was given to other potential predisposing factors such as concurrent 
diabetes, alcohol excess or BMI, albeit their effect on risk as discussed is not fully 
established. It is to be expected that this level of detail was not considered given the 
fact that neurotoxicity was not a key endpoint in the studies published. Only two 
studies were of first line chemotherapy with no patients receiving prior cytotoxic 
treatment (62, 228). In other studies patients may have been exposed to prior taxane or 
platinum treatment in the adjuvant setting or earlier palliative therapy. One study 
stratified its randomisation to account for previous taxane use (226) and one to account 
for previous platinum use (227).  In the remainder of studies, a patients’ previous 
exposure to neurotoxic chemotherapy may have been a confounding factor. 
 
Potential treatment-related confounding factors 
 
Treatment was generally well standardised and for the majority, the planned 
cumulative dose was similar in both arms (planned totals within 10% of each other). In 
two studies, the planned dose of docetaxel was higher in the more dose dense group, 
720mg/m2 versus 600mg/m2 (224) and 840mg/m2 versus 600mg/m2 (223). In all but one 
study, docetaxel was given without any concurrent chemotherapy and, for the one that 
gave concurrent therapy, it was with doxorubicin which would not be envisaged to 
affect neurotoxicity (223). Most studies described a consistent duration of infusion, but 
in two studies was this not mentioned (220, 227). The studies are summarised in table 
2.6. 
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Table 2.6. Included docetaxel studies for systematic review of dose dense versus less dose dense schedules and effect on risk of CIPN 
Paper Study 
type 
Primary 
cancer 
Sample 
size 
Less dose-
dense 
regimen 
More dose-
dense regimen 
Any 
concurrent 
chemo 
Grading 
tool 
Frequency of CIPN (by grade) Are patient 
factors 
considered 
Are other 
treatment 
related 
factors 
considered 
Difference 
Less dose dense More dose dense 
  Any 2-4 3-4 Any 2-4 3-4 
Camps et al 
(219) 
RCT Lung 259 75mg/m2 
over 1h q21 
until disease 
progression 
or 
unacceptable 
toxicity 
(n=129) 
36mg/m2 over 
30m q7 (6 wks 
on, 2 off) until 
disease 
progression or 
unacceptable 
toxicity  
(n=125) 
No NCI CTC 43 
(33) 
- 1 (1) 47 
(38) 
- 4 (3) Pre-existing 
PN grade >2 
excluded. 
All treatment 
standardised 
No 
significant 
difference 
Chen et al 
(220) 
RCT Lung 161 75mg/m2  
q21 for 8 
cycles 
 (n=33) 
35mg/m2 days 
1,8,15 q28 for 6 
cycles (n=64) 
OR 
40mg/m2 days 
1 and 8 q21 for 
8 cycles (n=64) 
No ECOG 2 (6) - 0 11 
(17) 
 
 
5 (8) 
- 
 
 
- 
0 
 
 
 
 
0 
All pre-
existing PN 
and 
neurological 
conditions 
excluded 
All treatment 
standardised 
(except 
duration of 
infusion not 
stated) 
No 
significant 
difference 
in grade 1-2 
Gridelli et 
al (227) 
RCT Lung 114 75mg/m2 
q21 for 6 
cycles 
(n=106) 
33.3mg/m2 
weekly for 6 
weeks then 2 
week break for 
2 cycles 
(n=108) 
No NCI CTC 19 
(18) 
7 (7) 0 20 
(19) 
7 (7) 2 (2) No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
All treatment 
standardised 
(except 
duration of 
infusion not 
stated) 
No SD 
between 
any grade 
neuropathy 
or grade 3-4 
Lai et al 
(229) 
 
RCT Lung 50 66mg/m2 
over 1h q21 
for 9 cycles 
(n=25) 
33mg/m2 over 
1h days 1 and 8 
q21 for 9 cycles 
(n=25) 
No NCI CTC 18 
(72) 
12 
(48) 
2 (8) 20 
(80) 
13 
(52) 
1 (4) Pre-existing 
PN excluded 
All treatment 
standardised 
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Rivera et al  
(218) 
 
RCT Breast 118 75-
100mg/m2 
over 1h q21 
until disease 
progression 
or 
unacceptable 
toxicity 
(n=59) 
35-40mg/m2 
over 30mins on 
days 1,8,15 q28 
until disease 
progression or 
unacceptable 
toxicity (n=59) 
Nil NCI CTC - - 6 
(10) 
- - 3 (5) No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
All treatment 
standardised 
 
Shimazui et 
al (221) 
Retros
pective 
Compa
rative 
study 
Prostate 31 70mg/m2 
over 2h q21 
until disease 
progression 
or 
unacceptable 
toxicity 
(n=16) 
30mg/m2 over 
2h days 1,8,15 
q28 until 
disease 
progression or 
unacceptable 
toxicity (n=15) 
No NCI CTC 7 
(44) 
- 4 
(25) 
2 
(13) 
- 0 No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
All treatment 
standardised 
Significantly 
more 
neuropathy 
in q21 
group 
Sparano et 
al (126) 
RCT Breast  2466 100mg/m2 
over 1h for 4 
cycles q21 
(n=1236) 
35mg/m2 over 
1h q7 for 12 
weeks 
(n=1230) 
No NS - 197 
(16) 
49 
(4) 
- 197 
(16) 
74 
(6) 
No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
 
All treatment 
standardised 
No 
significant 
difference 
Stemmler 
et al (223) 
RCT Breast 85 75mg/m2 
over 1 h q21 
for 8 cycles 
(n=42) 
35mg/m2 over 
30m days 
1,8,15 q28 for 8 
cycles (n=43) 
Adriamycin 
50mg/m2 
q21 or q28 
NCI CTC 16 
(38) 
4 
(10) 
0 19 
(44) 
9 
(21) 
3 (7) No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
 
Higher 
planned 
cumulative 
dose in dose 
dense arm 
otherwise 
standard 
 
Stemmler 
et al (224) 
RCT Breast 102 75mg/m2 
over 1h q21 
for 8 cycles 
(n=54) 
30mg/m2 over 
30m days 
1,8,15 q28 for 8 
cycles (n=48) 
No NCI CTC 22 
(41) 
8 
(15) 
2 (4) 22 
(46) 
7 
(15) 
0 No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
Higher 
planned 
cumulative 
dose in more 
dose dense 
arm 
otherwise 
standard 
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Tabernero 
et al (225) 
RCT Breast 83 100mg/m2 
q21 (42) until 
progression 
or 
unacceptable 
toxicity 
40mg/m2 
weekly for 6 
weeks then 2 
weeks off (n-41) 
until 
progression or 
unacceptable 
toxicity 
No NCI CTC - - 7 
(17) 
- - 1 (2) No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
All treatment 
standardised 
3 weekly 
significantly 
more 
neurotoxic 
Tannock et 
al (62) 
RCT Prostate 669 75mg/m2 
over 1h q21 
for 10 cycles 
(n=335) 
30mg/m2 over 
30 mins weekly 
for 5 of every 6 
weeks for 5 
cycles (n=334) 
No NCI CTC 100 
(30) 
- - 79 
(24) 
- - Pre-existing 
PN grade >2 
excluded. 
All treatment 
standardised 
 
Walker et 
al (228) 
RCT Breast 89 100mg/m2 
over 1h q21 
for 4 cycles 
(n=44) 
33mg/m2 
weekly for 12 
cycles (n=45) 
No NCI CTC 16 
(38) 
- - 0 (0) 0 (0) 0 (0) Pre-existing 
PN grade >2 
excluded 
All treatment 
standardised 
3 weekly 
significantly 
more 
neurotoxic 
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Meta-analysis 
 
Given that CIPN outcomes were not the focus of most of the studies, the number of 
patients experiencing CIPN was not universally documented but where these were 
available, this data was entered into a meta-analysis. Nine studies presented suitable 
data for development of any grade of CIPN, and ten presented data for development of 
grade 3-4 CIPN. Nine of those included for the grade 3-4 neuropathy analysis used the 
NCI CTC grading scale. One study was excluded (220) as they used the ECOG toxicity 
grading scale. Whilst this is not a problem for the ‘any CIPN’ analysis, as CIPN is either 
present or not regardless of grading scale, this study was excluded for the grade 3-4 
analysis as the definition of grades of the two grading scales was sufficiently different to 
make combining data inappropriate.  
 
There was obvious heterogeneity between the studies. Different studies involved 
different tumour groups and each study chose slightly different doses for their more 
and less dose dense groups, respectively, ranging from 66mg/m2 to 100mg/m2 for the 
less dose dense groups and 30-40mg/m2 for the more dose dense groups. Initially all 
studies described above were entered into the meta-analysis. One study included two 
dose dense arms to compare against their less dose dense arm (220). For the purposes 
of this meta-analysis, these two arms were combined in the more dose dense category 
as they were similar and equivalent to the different dose dense options included from 
different studies. Forest plots were prepared including studies that provided patient 
numbers developing any grade of CIPN and grade 3-4 CIPN, respectively 
 
 
Figure 2.4. Forest plot demonstrating risk of developing any grade CIPN with more dose 
dense docetaxel regimens compared to less dose dense regimens 
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The analysis for development of ‘any grade CIPN’ (figure 2.4) suggests that weekly 
schedules are less neurotoxic than 3-weekly schedules, albeit not statistically 
significantly (OR 0.85, 95%CI 0.68-1.06, I2=51%). This result is clearly skewed by one 
relatively small study of only 89 early breast cancer patients, by Walker et al (228), in 
which 36% of patients in the less dose dense group compared with no patients in the 
more dose dense group experiencing any grade CIPN. They used 100mg/m2 in the less 
dose dense group which is at the top of the range used; however this is a commonly 
utilised, entirely reasonable dose. The more dose dense schedule involved a dose of 
33mg/m2. This dose was utilised by other studies within the analysis with substantially 
higher CIPN rates. 
 
  
 
 
Figure 2.5. Forest plot demonstrating risk of development of NCI CTC grade 3-4 CIPN 
with more dose dense docetaxel regimens compared with less dose dense regimens 
 
Nine of the twelve studies were included in the grade 3-4 analysis with a total of 3564 
patients involved. Two studies did not give numbers of patients developing grade 3-4 
CIPN (62, 228) and one used the ECOG grading scale (220). In the other two studies, 
numbers were not given. Notably, the trend in this analysis is in the opposite direction 
to the ‘any grade’ analysis (figure 2.5; OR 1.26, 95%CI 0.92-1.73, I2=49%), but no 
statistically significant association is demonstrated. This result is particularly affected by 
the largest study included showing a statistically significantly higher risk of developing 
grade 3-4 CIPN in those receiving weekly docetaxel at a dose of 35mg/m2 with an OR= 
1.55 (95% CI 1.07-2.24). In this study, the three weekly dose was 100mg/m2, at the top 
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end of the dose range, so their findings cannot be put down to this variable. The grade 
3-4 meta-analysis does not include the Walker et al study which skewed the ‘any grade’ 
forest plot due to no patients developing neuropathy in their dose dense group which is 
out of keeping with the other studies. 
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 Paclitaxel 
 
Twenty-three studies were identified and are outlined in table 2.7. 
 
Sample size and power calculations 
 
The median sample size was 221 (range 27-2484). For all but three of the studies, 
outcomes related to development of CIPN were secondary endpoints or background 
data. Most studies focused on survival (126, 127, 230-237) or response (233, 238-242) 
outcomes. Only two studies were designed specifically to investigate the issue of 
comparative neurotoxicity of two paclitaxel regimens as their primary endpoint (84, 
243). One was retrospective (84) and the other was a RCT which undertook sample size 
and power calculations for this specific purpose (243). This was the smallest of the 
included studies. A further retrospective study evaluated the incidence of CIPN that 
interfered with dose, and as part of this, compared the two paclitaxel regimens which 
patients received (3). 
 
Study type and randomisation 
 
Nineteen of these were randomized controlled trials and four were retrospective 
comparative studies. All four of the retrospective studies relied on review of medical 
documentation during chemotherapy to record toxicities (3, 84, 234, 244).  Fourteen 
were multicentre studies (126, 127, 230-233, 235, 237-241, 245-247). 
Eight studies described their method of randomisation or specified its nature as 
centrally and independently performed (127, 230, 231, 240-242, 247, 248). 
 
Potential patient-related confounding factors 
 
Four studies stated that patients with any pre-existing peripheral neuropathy were 
excluded from involvement (237, 238, 240, 243). A further study excluded those with 
greater or equal to grade 2 pre-existing neuropathy (241) and two excluded those with 
greater than WHO scale grade 2 neuropathy (239, 242). An additional study stated that 
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they excluded patients with ‘severe neuropathy’ (84). As development of CIPN was not 
a specified outcome for the majority of studies, it is unsurprising that pre-existing 
peripheral neuropathy was not accounted for more robustly. However, one of the 
studies that did specifically state neurotoxicity as its primary outcome stated that it 
excluded patients with pre-existing ‘severe neuropathy’ rather than ‘any neuropathy’ 
which appears somewhat unsatisfactory. This is a source of potential confounding 
outside of the four studies which excluded this factor completely. 
 
Potential treatment-related confounding factors 
 
Treatment was generally well standardised and for the majority the planned cumulative 
dose was similar in both arms (within 10% of total dose). In nine studies, however, the 
planned cumulative doses in the more dose dense groups were >10% greater than the 
planned cumulative doses in the less dose dense groups. In three of these, a cumulative 
dose of 1440mg/m2 was planned in the more dose dense group compared with 
1050mg/m2 in the less dose dense group (84, 230, 234). A further two studies 
compared planned cumulative doses of 1440mg/m2 in the more dose dense group 
against  1080mg/m2  in the less dose dense group (127, 236) and an additional two 
studies compared  planned cumulative doses of 960mg/m2 in the more dose dense 
group versus 700mg/m2 in the less dose dense group (3, 126). The final two of the nine 
studies involved planned cumulative doses of 1600mg/m2 and 1200mg/m2 (241), and 
1200mg/m2 and 900mg/m2 (237), respectively.  
 
For most studies, concurrent chemotherapy was consistent in both the more and less 
dose dense arms. In some studies in which carboplatin was the concurrent agent, the 
dose of carboplatin was also fractionated in the more dose dense paclitaxel arm (239, 
246, 247). The effect of this on neurotoxicity is uncertain although carboplatin’s 
neurotoxic potential is accepted as low. In one study, carboplatin was only given in the 
three-weekly paclitaxel arm and not the weekly cohort (231). Again, it is unlikely to 
make a big difference due to the very low rates of CIPN associated with carboplatin but, 
ideally of course, treatment should be standardised apart from the scheduling of the 
paclitaxel.  
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For six studies, duration of infusion was not stated and therefore confounding from 
unusually long or short infusions or inconsistency could not be assessed in these studies 
(84, 234, 237, 238, 244, 245). In the other studies, the infusion durations were those 
ordinarily used in clinical practice.   It should be noted that one of the identified studies 
was a study of high dose chemotherapy with G-CSF support and therefore is not 
consistent with the others (240). This study was not considered suitable for inclusion in 
the meta-analysis due to the different treatment plan.  
The studies were performed in patient cohorts being treated for breast cancer (3, 84, 
126, 231-233, 240, 241, 245, 246), ovarian cancer (127, 230, 234, 236, 242, 247, 248) or 
lung cancer (235, 237-239, 243, 244). 
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Table 2.7. Included paclitaxel studies systematic review of dose dense versus less dose dense schedules and effect on risk of CIPN 
 
Paper Study 
type 
Primary 
cancer 
Sample 
size 
Less 
frequent 
regimen 
(no. of 
patients) 
 
Dose-dense 
regimen 
(no. of 
patients) 
Any 
concurrent 
chemo 
Grading 
tool 
Frequency of CIPN  (by grade) Are patient 
factors 
considered 
Are other 
treatment 
related factors 
considered 
Difference 
Less dose-dense More dose-dense 
Any 2-4  3-4 Any 2-4  3-4 
Belani et al 
(237) 
 
RCT Lung 444 225mg/m2 
q21 for 4 
cycles  
(n=214) 
 
 
100mg/m2 
weekly  on 
days 1,8,15 
q28 for 4 
cycles 
(n=217) 
Carboplatin 
AUC6 q21 
with 3 
weekly 
paclitaxel 
and q28 
with weekly 
paclitaxel 
NCI CTC - 39 
(18) 
- - 26 
(12) 
- Pre-existing 
neuropathy 
excluded 
All treatment 
standardised 
although 
higher 
cumulative 
dose planned 
in dose-dense 
regimen 
 
3-weekly 
significantly 
more neurotoxic 
Grade 2-3 
neuropathy 
(18% vs 12%)  
Budd et al 
(245) 
RCT Breast 2301 175mg/m2 
q14 for 6 
cycles 
(n=1162) 
80mg/m2 
weekly for 12 
weeks 
(n=1139) 
Nil NCI CTC - - 201 
(17) 
- - 119  
(10) 
No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
 
All treatment 
standardised 
2- weekly more 
neurotoxic 
Chan et al 
(230) 
RCT Ovarian 692 175mg/m2 
over 3 h 
q21 for 6 
cycles 
(n=340) 
80mg/m2  
over 1h 
weekly (Days 
1,8,15, q21) 6 
cycles  
(n=343) 
Carboplatin 
AUC6 
NCI CTC 254 
(75) 
61 
(18) 
7 (2) 233 
(68) 
88 
(26) 
9 (3) No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
All treatment 
standardised 
although 
higher 
cumulative 
dose planned 
in dose dense 
regimen 
Weekly more 
neurotoxic 
No difference in 
grade 3 
neuropathy but 
significantly 
more grade 2-3 
CIPN in weekly 
patients 
 
Du et al  
(236) 
RCT Ovarian 221 180mg/m2 
over 3h q21 
for 6 cycles 
 (n=112) 
80mg/m2 
over 1h days 
1,8,15 q21 for 
6 cycles 
(n=109) 
Carboplatin 
AUC6 
NS: any 
CIPN vs 
no CIPN 
6 (5) - - 7 (6) - - No exclusions 
for pre-
existing PN. 
No other 
clinical 
factors  
mentioned 
All treatment 
standardised 
although 
higher 
cumulative 
dose planned 
in dose dense 
regimen 
 
No significant 
difference 
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Fountzilas 
et al (231) 
RCT Breast 416 175mg/m2 
q21  for 6 
cycles 
(n=131) 
80mg/m2 
weekly for 12 
weeks 
(n=133) 
Carboplatin 
with 3-
weekly 
paclitaxel 
Nil with 
weekly 
paclitaxel 
ECOG - - 7 (5) - - 11 
(8) 
No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
Carboplatin 
received by 3-
weekly group 
only 
Not statistically 
compared 
directly as there 
was a third 
(docetaxel-
receiving) arm in 
the study 
Green et al 
(232) 
RCT Breast 202* 225mg/m2 
q21  for 4 
cycles 
(n=127) 
80mg/m2 
weekly for 12 
weeks 
 (n=75) 
Nil NCI CTC - 65 
(51) 
18 
(14) 
- 27 
(36) 
10 
(13) 
No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
 
All treatment 
standardised 
Weekly less 
neurotoxic for 
grade 2-3 but 
note particularly 
high 3-weekly 
dose. 
Ishii et al 
(243) 
 
RCT Lung 27 200mg/m2 
over 3h q21 
(n=14) 
100mg/m2 
over 1h on 
days 1 and 8 
q21 (n=13) 
Carboplatin 
AUC 6 or 3 
NCI CTC 8 (57) 5 
(36) 
1 (7) 2 
(15) 
0 0 Both pre-
existing PN 
and diabetes 
excluded 
Not clear how 
many cycles 
planned/ 
received in 
each arm 
Weekly 
significantly less 
neurotoxic 
Katsumata 
et al (127) 
RCT Ovarian 631 180mg/m2 
over 3h q21 
for 6 cycles 
(n=319) 
80mg/m2 
over 1h 
weekly for 6 
cycles 
(days 1,8,15 
q21) 
(n=312) 
Carboplatin 
AUC6 
NCI CTC - - 20 
(6) 
- - 21 
(7) 
No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
Treatment 
standardised 
although 
higher 
cumulative 
dose planned 
in dose dense 
arm and some 
patients in 
each arm 
received  >6 
cycles 
No significant 
difference 
Khoo et al 
(241) 
RCT Breast 139* 175mg/m2 
over 3h q21 
for 8 cycles 
(n=72) 
100mg/m2 
over 1h on 
days 1 and 8 
q21 for 8 
cycles (n=67) 
Gemcitabin
e 
NCI CTC - - 2 (3) - - 1 (1) Excluded with 
pre-existing 
PN of grade 2 
or greater or 
uncontrolled 
diabetes  
Lower dose 
gemcitabine 
given in dose-
dense arm 
(100mg/m2 vs 
1250mg/m2) 
and higher 
cumulative 
dose planned 
in dose dense 
arm 
No significant 
difference 
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Lalisang et 
al (240) 
RCT Breast  106 200mg/m2 
over 3h q21 
for 6 cycles 
(n=51) 
175mg/m2 
over 3h q10 
for 6 cycles 
(n=55) 
Epirubicin 
110mg/m2 
q21 in the 3 
weekly arm 
(dose-
escalated) 
and 
epirubicin 
75mg/m2 
q12 in the 
dose dense 
arm 
NCI CTC - - 3 (6) - - 5 (9) Excluded pre-
existing 
neuropathy 
and prior 
taxane 
Different 
epirubicin 
schedule  
although 
wouldn’t be 
expected to 
altered 
neurotoxicity. 
Higher 
cumulative 
dose planned 
in less frequent 
schedule 
 
Perez et al 
(246) 
Concur
rent 
phase 
II trials 
Breast 91 200mg/m2 
over 3h q21 
for 8 cycles 
(n=43) 
80mg/m2 
over 1h on 
days 1,8,15 
q28 for 6 
cycles (n=48) 
Carboplatin 
AUC6 and 
trastuzumab 
for 3-weekly 
arm, 
carboplatin 
AUC2 and 
trastuzumab 
for weekly 
arm 
NCI CTC 38 (88) - 9 
(21) 
35 
(73) 
- 1 (2) No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
No prior 
platinum 
allowed 
Standardised 
treatment. 
Carboplatin 
and 
trastuzumab 
fractionated in 
the weekly 
arm. 
3- weekly more 
neurotoxic 
Pignata et 
al (247) 
 
RCT Ovarian 799 175mg/m2 
q21 for 6 
cycles 
(n=400) 
60mg/m2 
weekly for 18 
weeks 
 (n=399) 
Carboplatin 
AUC6 in less 
dose dense 
arm/ AUC2 
in more 
dose-dense 
arm 
NCI CTC 163 
(41) 
68 
(17) 
10 
(2.5) 
122 
(31) 
24 
(6) 
0 No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
Standardised 
treatment, 
Carboplatin 
fractionated in 
weekly group 
3-weekly 
significantly 
more neurotoxic 
Rosenburg 
et al (242) 
 
RCT Ovarian 205 200mg/m2 
q21 
apparently 
until 
progression 
(n=101) 
67mg/m2 q7 
(days 1,7,15 
of 21 day 
cycle) 
apparently 
until 
progression 
(n=104) 
Nil WHO 86 (85) - 29 
(29) 
84 
(81) 
- 11 
(11) 
Pre-existing 
PN >grade 2 
excluded. 
Pre-existing 
PN patients 
split equally 
between the 
groups.  
 
Those in the 
weekly arm 
received more 
cycles of 
treatment (7 vs 
5.7) 
Weekly less 
neurotoxic 
(p<0.001) 
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Safra et al 
(234) 
Retros
pective 
study 
Ovarian 400 175mg/m2 
q21 for 6-8 
cycles 
(n=267) 
80mg/m2 
days 1,8,15 
q21 for 6-8 
cycles 
(n=133) 
Carboplatin 
AUC 6 in less 
dose-dense 
arm or AUC2 
in weekly 
arm 
NCI CTC 91 (34) - 12 
(4) 
25 
(20) 
- 1 (1) No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
Carboplatin 
fractionated 
and higher 
planned 
cumulative 
dose in weekly 
arm 
Weekly less 
neurotoxic 
Sakakibara 
et al (238) 
RCT Lung 82 200mg/m2 
q21 for an 
unstated 
number of 
cycles 
(n=40) 
70mg/m2 
days 1,7,15 
q21 for an 
unstated 
number of 
cycles (n=42) 
Carboplatin 
AUC 6 q21 
NCI CTC - 17 
(43) 
10 
(25) 
- 5 
(12) 
0 Pre-existing 
PN and 
uncontrolled 
diabetes 
excluded 
Standardised 
treatment 
except for 
duration but 
both groups 
received 
median of 3 
cycles 
Weekly less 
neurotoxic 
Schuette et 
al (239) 
RCT Lung 883 200mg/m2 
q21 for 6 
cycles 
(n=449) 
100mg/m2 
weekly for 6 
of 8 weeks 
for 2 cycles 
(n=434) 
Carboplatin 
AUC6 3-
weekly arm/ 
AUC2 weekly 
arm 
NCI CTC - - 41 
(9) 
- - 19 
(4) 
Pre-existing 
PN of >grade 
2 excluded. 
Standardised 
treatment. 
Fractionated 
carboplatin in 
the weekly arm 
Weekly less 
neurotoxic 
Seidman et 
al (233) 
RCT Breast  617** 175mg/m2 
q21 until 
progression 
or limiting 
toxicity 
(n=383) 
80mg/m2 q7 
until 
progression 
or limiting 
toxicity 
(n=232) 
Randomised 
to 
trastuzumab 
or not 
NCI CTC - - 27 
(12) 
- - 49 
(21) 
No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
Standardised 
treatment 
except some 
patients 
received 
trastuzumab as 
per 
randomisation  
Weekly more 
neurotoxic 
Shimizu et 
al (244) 
Retros
pective 
study 
lung 167 200mg/m2 
q21 for 6 
cycles 
(n=94) 
70mg/m2 
days 1,8,15 
q28 for 6 
cycles (n=73) 
Carboplatin 
AUC6 q21 or 
q28 in less 
dose-dense/ 
more dose-
dense arms 
respectively 
NCI CTC - 17 
(18) 
8 
(8.5) 
- 0 0 No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
Standardised 
treatment 
other than 
total  length of 
cycle (including 
carboplatin) 
Weekly less 
neurotoxic 
Socinski et 
al (235) 
RCT Lung 155 225mg/m2 
q21 for 4 
cycles 
(n=78) 
75mg/m2 
days1,8,15 
q21 for 4 
cycles (n=77) 
Carboplatin 
AUC6 q21 
NS - 15 
(19) 
3 (4) - 10 
(13) 
2 (3) No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
All treatment 
standardised 
No significant 
difference 
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Sparano et 
al (126) 
RCT Breast 2484 175mg/m2 
q21 for 4 
cycles  
(n=1253) 
80mg/m2 q7 
for 12 weeks 
(n=1231) 
Nil NS - 251 
(20) 
63 
(5) 
- 332 
(27) 
98 
(8) 
No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
All treatment 
standardised 
although 
higher planned 
cumulative 
dose in weekly 
arm 
Grade 2-4 
significantly 
worse in weekly 
Grade 2- 20%  vs 
27% 
Speck et al 
(3) 
Retros
pective 
study 
Breast 279 175mg/m2 
q14 for 4 
cycles 
(n=230) 
80mg/m2 q7 
for 12 cycles 
(n=49) 
NS Dose-
limiting 
CIPN 
- - - - - - Excluded pre-
existing 
neuropathy. 
Collected 
data on race, 
BMI, diabetes 
and other 
comorbidities 
Planned 
cumulative 
dose differs by 
>10% (more in 
weekly) 
Dose limiting 
CIPN more 
common in 
weekly 
compared to 
biweekly (24.5 
vs 14.4% 
Tanabe et 
al (84) 
Retros
pective 
study 
Breast 212 175mg/m2 
q21 for 6 
cycles 
(n=188) 
80mg/m2 on 
days 1,8,15 
q21 for 6 
cycles (n=24) 
Nil NCI CTC - - - - - - ‘Severe’ pre-
existing PN 
excluded. 
Diabetes 
recorded with 
no evidence 
of effect on 
CIPN 
All treatment 
standardised 
although 
higher planned 
cumulative 
dose in weekly 
arm 
Trend towards 
weekly being 
less neurotoxic 
on univariate 
analysis but not 
seen in 
multivariate 
analysis 
Wu RCT Ovarian 29 175mg/m2 
monthly 
until 
progressive 
disease or 
limiting 
toxicity 
(n=15) 
60mg/m2 q7 
until 
progressive 
disease or 
limiting 
toxicity 
(n=14) 
Carboplatin 
AUC 6 or 
AUC2 
WHO 10 
(67) 
3 (20) 1 (6) 5 
(36) 
3 
(21) 
1 (7) No exclusions 
for pre-
existing 
neuropathy. 
No other 
clinical 
factors 
mentioned. 
Standardised 
treatment. 
Fractionated 
carboplatin in 
weekly arm. 
No significant 
difference 
*Only 2 arms of this 3 arm study included for our purposes 
**Initial weekly arm received 100mg/m2 but this was amended due to unacceptable toxicity. The group that received the subsequent dose of 80mg/m2 are included in this analysis 
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Meta-analysis 
CIPN outcomes were not the focus of most of the studies so numbers of patients 
experiencing CIPN was not always documented but where these are available, they 
were entered into the meta-analysis. 
 
Combining studies which provided numbers of patients for development of any grade 
CIPN results in a total population of 2455 paclitaxel-treated patients within eight 
different studies (figure 2.6). The overall pooled result suggests that more dose dense 
regimens were significantly less neurotoxic than less dose dense scheduling with an OR 
0.62 (95% CI 0.51-0.74, I2=18%). There are clearly differences between the studies 
limiting the validity of this result. Different doses of paclitaxel in each arm is the most 
important limiting factor, along with subtle differences in scheduling of the more dose 
dense arms. The range of doses span from 175mg/m2 to 200mg/m2 in the less dose 
dense arms and 60mg/m2 to 100mg/m2 in the more dose dense arms. If one were to 
include only studies within a very narrow dose range, for example 175-180mg/m2 and 
70-80mg/m2, respectively, then the results are consistent with the weekly regimens 
resulting in less risk of neuropathy ( OR 0.62 95%CI 0.44-0.87, I2=22%).  
 
 
Figure 2.6. Forest plot demonstrating risk of development of any grade CIPN with more 
dose dense paclitaxel regimens compared with less dose dense regimens  (all studies) 
 
Figure 2.7. Forest plot demonstrating risk of development of any grade neuropathy and 
more dose dense paclitaxel regimens (selected dose range studies only) 
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Again, looking at pooled results for development of NCI CTC grade 3-4 neuropathy, this 
time of 9659 patients within 15 studies, the more dose dense arms appear to be less 
likely to cause NCI CTC grade 3-4 CIPN (figure 2.8; OR 0.65, 95% CI 0.38-1.11). Two 
studies report grade 3-4 neuropathy using the WHO scale (242, 248) and their 
outcomes are detailed in figure 2.9 showing a reduced risk of neuropathy with more 
dose dense schedules which is statistically significant (OR 0.32, 95%CI 0.15-0.67, I2=0%). 
This is clearly heavily influenced by the larger Rosenberg study (242). A further study 
reported numbers of patients developing grade 3-4 neuropathy but used the ECOG 
scale (231).  As this is the only study that used this assessment scale, it was excluded 
from meta-analysis.  
 
 As with the ‘any grade’ comparison, the main limiting factor was the different doses 
used in the more and less dose dense arms with ranges of 60-100mg/m2 in the more 
dose dense and 175-225mg/m2 in the less dose dense arms. If narrower inclusion 
criteria are applied and those using doses outside the most common dose ranges of 
175-180mg/m2 and 70-80mg/m2 are excluded and only studies using the NCI CTC 
criteria are included, then the results look somewhat different and are less convincingly 
in favour of more dense regimens conferring lower neuropathy risk. (figure 2.10; OR 
1.69, 95%CI 1.34-2.14, I2=74%). 
 
 
Figure 2.8. Forest plot demonstrating risk of development of NCI CTC grade 3-4 CIPN and 
more dose dense paclitaxel regimens dose dense paclitaxel regimens (all studies) 
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Figure 2.9. Forest plot demonstrating risk of development of WHO grade 3-4 CIPN with 
more dose dense paclitaxel regimens  
 
 
Figure 2.10. Forest plot demonstrating risk of development of NCI CTC grade 3-4 
neuropathy with more dose dense paclitaxel regimens (selected doses range only) 
 
Nab-paclitaxel 
 
Two studies investigating different schedules of nab-paclitaxel were identified (table 
2.8). One was a randomised controlled trial in 208 breast cancer patients comparing 
overall response rate and toxicity between three different dose schedules of the drug 
(249). The other study was a non-comparative randomised study comparing two 
schedules of nab-paclitaxel in lung cancer treatment. This study closed early due to 
slow recruitment and only 27 patients are included in the analysis (250). These were 
not entered into a meta-analysis as it was not known what grading scale had been used 
to assess neuropathy in either study, the results would have limited value with only two 
involved studies, particularly with the small sample size of one of the pair, and 
additionally, the regimens used were different between the two studies. 
. 
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Table 2.8. Included nab-paclitaxel studies for systematic review of dose dense versus less dose dense schedules and effect on risk of CIPN 
Paper Study type Primary 
cancer 
Sample 
size 
Less 
frequent 
regimen 
(no. of 
patients) 
Dose-dense 
regimen 
(no. of 
patients) 
Any 
concurrent 
chemo 
Grading tool Frequency of CIPN  (by grade) Are patient 
factors 
considered 
Are other 
treatment 
related 
factors 
considered 
Difference 
Less dose dense More dose dense 
Any  2-4 3-4 Any 2-4 3-4 
Seidman et 
al (249) 
 
RCT Breast  208 260mg/m2 
q21 (n=75) 
until 
progression 
or 
unacceptable 
toxicity 
 
260mg/m2 
q14 (n=54) 
until 
progression 
or 
unacceptable 
toxicity 
 
130mg/m2 
q7 until 
progression 
or 
unacceptable 
toxicity 
 
Bevacizumab NS 66 
(88) 
 
 
 
48 
(89) 
- 25 
(33) 
 
 
 
30 
(56) 
66 
(84) 
- 36 
(46) 
Excluded 
pre-existing 
PN >grade 1 
All 
treatment 
standardised 
apart from 
slightly 
differing 
bevacizumab 
schedule 
No SD 
between 3-
weekly and 
weekly arms 
Grilley-Olson 
et al (250) 
 
Non-
comparative 
randomised 
trial 
Lung 27 300mg/m2 
q21 (n=14) 
100mg/m2 
q7 (n=13) 
Carboplatin NS   3 
(21) 
  0 No prior 
chemo but 
no 
exclusions 
for pre-
existing PN 
All 
treatment 
standardised 
Non- 
comparative 
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 Cisplatin 
For cisplatin, two studies, both randomised controlled trials, were identified and are 
outlined in table 2.9. One involved chemotherapy with concurrent radiotherapy for 
cervical cancer (251) and the other evaluated cisplatin schedule in the treatment of 
ovarian cancer (252). The sample sizes were 104 and 40, respectively. The larger of the 
two studies showed no significant difference between neurotoxicity rates. The smaller 
study was specifically designed to investigate neurotoxicity, but no sample size or 
power calculations were reported. They utilised various neurophysiological outcome 
measures in their study design and they reported significantly reduced sensory 
amplitude potentials in patients receiving the less dose dense regimen (cisplatin 
75mg/m2 q21) whilst they remained unchanged in those receiving cisplatin 50mg/m2 on 
a weekly basis (252).  These studies could not be combined in a meta-analysis due to 
the differences in neuropathy assessment scales utilised.
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Table 2.9  Included cisplatin studies for systematic review of dose dense versus less dose dense schedules and effect on risk of CIPN 
Paper Study type Primary 
cancer 
Sample 
size 
Less frequent 
regimen 
(no. of 
patients) 
Dose-dense 
regimen 
(no. of 
patients) 
Any 
concurrent 
chemo 
Grading tool Frequency of CIPN  (by grade) Are patient 
factors 
considered 
Are other 
treatment 
related 
factors 
considered 
Difference 
Less dose dense More dose dense 
Any  2-4 3-4 Any 2-4 3-4 
Cavaletti 
et al (252) 
RCT Ovarian 40* 75mg/m2 q21 
for 6 cycles 
(n=20) 
50mg/m2 q7 
for 9 weeks 
Nil WHO 
Neurologic 
symptom 
score and 
neuropathy 
disability 
score. Sensory 
and motor 
nerve 
conduction 
studies ad 
somatosensory 
and visual 
evoked 
potentials 
7 
(37) 
- - 4 
(21) 
- - Any patients 
with 
conditions 
know to be 
associated 
with PN 
were 
excluded 
All 
treatment 
standard 
Significantly 
reduced 
sensory 
amplitude 
potentials in 
the less 
dose-dense 
group. 
Ryu et al 
(251) 
RCT Cervix 104 75mg/m2 
over 1-2h q21 
for 3 cycles 
(n=53)  
40mg/m2  
over 1-2h q7  
for 6 cycles 
(n=51) 
Concurrent 
RT 
NCI CTC 2 (4) - 0 5 
(10) 
- 0 Previous 
chemo 
excluded 
otherwise 
clinical 
confounders 
not 
mentioned 
All 
treatment 
standardised 
No 
significant 
difference 
Soto Parra 
et al (253) 
RCT Lung 107 70mg/m2 
over 30-60m 
q28 for 3-6 
cycles (n=54) 
70mg/m2 
over 30-60m 
q21 for 3-6 
cycles (n=53) 
Gemcitabine 
at different 
schedules 
SWOG - - 1 (2) - - 0 No mention 
of clinical 
confounders 
Concurrent 
gemcitabine 
differs but 
wouldn’t be 
expected to 
alter 
neurotoxicity 
No 
significant 
difference 
*only 2/3 arms used for our purposes 
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Oxaliplatin 
 
Seven studies were identified (table 2.10). Two were purely looking at schedule of 
oxaliplatin whereas five were comparing XELOX to FOLFOX regimens. Both sets of 
studies were included but this difference is considered. 
 
The two purely oxaliplatin-scheduling studies compared oxaliplatin and capecitabine in 
a three-weekly to a two-weekly schedule. Both were randomised controlled trials, one 
involving 419 patients (254) and the other was smaller with a sample size of 89 patients 
(255). Both were designed to examine progression free survival and sample size and 
power calculations were reported for this outcome rather than neurotoxicity. Method 
of randomisation, and confirmation that this was centrally performed, was stated in 
both studies. The larger of the two studies stated pre-existing peripheral neuropathy as 
an exclusion factor whilst no such criteria were stated for the smaller study. Planned 
cumulative doses were similar and concurrent treatment in both studies was the same. 
This was with capecitabine with the doses differing between the two schedules as 
would be standard. For meta-analysis, the only outcome looked at was development of 
any grade CIPN as the two studies used different grading scales. One used NCI CTC (254) 
whereas the other used WHO (255) (Figure 2.11). Whilst it is reasonable to combine 
occurrence of any grade CIPN, the definition of grade 2, 3 and 4 neuropathy are 
sufficiently different to prohibit combination of these outcomes. 
 
The largest of the five XELOX versus FOLFOX studies was a prospective randomised, 
two-arm, non-inferiority study comparing XELOX (oxaliplatin 130mg/m2 on day 1 q21 
followed by capecitabine 1000mg/m2 orally twice daily on days 1-14) to FOLFOX4  
(oxaliplatin 85mg/m2 over 2h q14 with leucovorin 200mg/m2 given on days 1 and 2 
alongside a 5FU 400mg/m2 bolus and 22 hour infusion of 5FU 600mg/m2) (256). It 
became a 2x2 factorial study with further randomisation to bevacizumab or placebo; 
however for the purposes of this review the bevacizumab containing arm was excluded 
from neurotoxicity assessment. This still left 1307 patients with metastatic colorectal 
cancer who received either XELOX or FOLFOX4 without bevacizumab for assessment of 
neurotoxicity. The study was powered for progression-free survival assessment. No 
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exclusions were made for pre-existing neuropathy or other potential influencing factors 
for CIPN and there was no differentiation between acute and chronic OIPN. No 
significant difference was seen in sensory neurotoxicity rates between the two arms. 
 
The second largest study (257), compared the same two oxaliplatin-containing 
chemotherapy regimens, again in patients with metastatic colorectal cancer. Again, the 
randomisation method was outlined, and the study was appropriately sized and 
powered for its primary endpoint which was progression-free survival. No exclusion 
factors that would have precluded patients with pre-existing neuropathy were 
mentioned. There was no differentiation of acute or chronic OIPN; however the rates of 
reported neurosensory toxicity were vastly lower than the Cassidy study (256). For 
example, the rate of any grade neuropathy in the FOLFOX-4 group was 17% in the 
Rothenberg study(257)  versus 80% in the Cassidy study in both largely Caucasian study 
populations which both excluded any prior oxaliplatin therapy. This raises the suspicion, 
although it cannot be confirmed, that perhaps the Rothenberg study was reporting 
chronic OIPN whereas the Cassidy study may have been reporting combined acute and 
chronic toxicity. Similar to Cassidy et al however, the Rothenberg study did not show 
any difference in the incidence of neurosensory neuropathy. 
 
The third randomised controlled trial comprised 306 patients and this time compared 
XELOX (as described above) with FOLFOX-6 (oxaliplatin 100mg/m2 administered over 2 
hours followed by leucovorin 400mg/m2 and 5FU 400mg/m2 as an IV bolus followed by 
5FU 2400-3000mg/m2 over 46 hours and repeated every 14 days) (258). Patients with a 
history of neuropathy were excluded. Randomisation process was described, and the 
study was designed and powered to meet its primary endpoint which was tumour 
response rate by central review. No differentiation was made between acute and 
chronic OIPN; however the rates of neurosensory toxicity (95% for FOLFOX6 and 90% 
for XELOX) suggest that both types of neurotoxicity were reported together. There was 
no significant difference in these rates of any grade of neuropathy, but a significantly 
higher rate of grade 3-4 OIPN was seen in the FOLFOX group (26% versus 11%, 
p<0.001). 
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All three of these randomised controlled studies stated that they used the NCI CTC 
grading scale for assessing toxicities. As the dose of oxaliplatin is different in the 
Ducreux study (258) this is a concern for inclusion in meta-analysis. The other two 
studies would be consistent enough in design and treatment strategy to be suitable; 
however there was real concern that the neuropathy outcome reported was different 
due to the notable difference in reported rates between studies.  
 
The remaining two studies were both prospective, non-randomised studies (96, 259). 
The larger of these two studies used a modified FOLFOX regimen of oxaliplatin 
85mg/m2 over 2h q14 with leucovorin 200mg/m2 given on days 1 and 2 alongside a 5FU 
400mg/m2 bolus and followed by a 46 hour infusion of 5FU 2400mg/m2 (96). The 
primary outcome was incidence of severe neurotoxicity although no sample size or 
power calculation was described. The investigators looked for association between the 
regimen and an increased risk of developing severe CIPN as defined by grade 3-4 CIPN 
or grade 2 CIPN lasting for >7 days. This study was therefore not eligible for inclusion in 
meta-analysis due to this different outcome measure. They found a significantly 
increased risk of CIPN with the FOLFOX regimen with 39% of patients meeting the case 
definition compared to 19% in the three-weekly XELOX group (p<0.01 on uni- and 
multivariate analysis).    
 
The final study in this category, another prospective non-randomised study of 150 
chemo-naive colorectal cancer patients included patients treated with either FOLFOX4 
or XELOX as described above. The aim of the study was to compare neurotoxicity rates 
between the two treatments. Patients with pre-existing PN, diabetes and alcohol excess 
were excluded. Cumulative doses were found to be similar in the two groups. Acute 
neurotoxicity was similar in both arms but there was a significantly increased incidence 
of chronic CIPN in patients treated with FOLFOX4 (64/77 versus 44/73 of XELOX patients 
experiencing at least grade 1 CIPN) (259). 
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Table 2.10. Included oxaliplatin studies for systematic review of dose dense versus less dose dense schedules and effect on risk of CIPN 
Paper Study type Primary 
cancer 
Sample 
size 
Less 
frequent 
regimen 
(no. of 
patients) 
Dose-dense 
regimen 
(no. of patients) 
Any 
concurrent 
chemo 
Grading 
tool 
Frequency of CIPN  (by grade) Are patient 
factors 
considered 
Are other 
treatment 
related 
factors 
considered 
Difference 
Less dose dense  More dose dense 
Any  2-4 3-4 Any 2-4 3-4 
Argyriou et al 
(259) 
Prospective 
non-
randomised 
study 
CRC 150 130mg/m2  
q21 for 8 
cycles (n=73) 
85mg/m2 over 
2h q14 for 12 
cycles (n=77) 
Capecitabine 
as XELOX in 
3-weekly 
treatment 
and 5FU/LV 
as FOLFOX 
for 2-weekly 
NCI CTC 
(stated) 
and TNSc 
44 
(60) 
43 
(59) 
9 
(12.3) 
64 
(83) 
45 
(59) 
8 
(10) 
Pre-existing 
PN, diabetes 
and alcohol 
excess were 
excluded. 
XELOX 
versus 
FOLFOX 
rather than 
simply 
scheduling 
of oxaliplatin 
FOLFOX (2 
weekly) 
more 
neurotoxic 
than XELOX 
(3 weekly) 
Baek et al (96) 
 
Prospective 
non-
randomised 
study 
CRC 366 130mg/m2 
q21 until 
progression 
or 
unacceptable 
toxicity 
(n=79) 
85mg/m2 q14 
until progression 
or unacceptable 
toxicity (max 12 
cycles if 
adjuvant)(n=287) 
Capecitabine 
as XELOX in 
3-weekly 
treatment 
and 5FU/LV 
as FOLFOX 
for 2-weekly 
NCI CTC 15 
(19 
  111 
(39) 
  Pre-existing 
PN 
excluded, 
various 
clinical 
factors 
considered 
XELOX 
versus 
FOLFOX 
rather than 
simply 
scheduling 
of oxaliplatin 
FOLFOX (2 
weekly) 
more 
neurotoxic 
than XELOX 
(3 weekly) 
Cassidy et al 
(256) 
RCT CRC 1307 130mg/m2 
q21 until 
progression 
or 
unacceptable 
toxicity 
(n=655) 
85mg/m2 q14 
until progression 
or unacceptable 
toxicity (n=648) 
Capecitabine 
as XELOX in 
3-weekly 
treatment 
and 5FU/LV 
as FOLFOX4 
for 2-weekly 
NCI CTC 534 
(82) 
- 114 
(17) 
515 
(80) 
- 107 
(17) 
No exclusion 
criteria 
related to 
pre-existing 
PN 
XELOX 
versus 
FOLFOX 
rather than 
simply 
scheduling 
of oxaliplatin 
No 
significant 
difference 
Ducreux et al 
(258) 
RCT CRC 306 130mg/m2 
over 2h q21 
for 8 cycles 
(n=156) 
100mg/m2 over 
2h q14 for 12 
cycles (n=150) 
Capecitabine 
as XELOX in 
3-weekly 
treatment 
and 5FU/LV 
as FOLFOX6 
for 2-weekly 
NCI CTC 139 
(90) 
- 17 
(11) 
141 
(95) 
- 38 
(26) 
Pre-existing 
PN excluded 
XELOX 
versus 
FOLFOX 
rather than 
simply 
scheduling 
of oxaliplatin 
Significantly 
less G3/4 
PN with 
XELOX 
Hurwitz et al 
(254) 
RCT CRC 419 130mg/m2  
q21 until 
progression 
or 
unacceptable 
toxicity 
(n=208) 
85mg/m2 q14 
until progression 
or unacceptable 
toxicity (n=211) 
Capecitabine 
at different 
doses per 
arm 
NCI CTC 63 
(30) 
- 17 (8) 56 
(27) 
- 15 
(7) 
Pre-existing 
PN 
excluded. 
Other 
clinical 
confounders 
not 
mentioned 
Different 
doses of 
capecitabine 
as is 
standard 
otherwise 
standardised 
No 
significant 
difference 
reported  
for 
neuropathy 
and 
peripheral 
sensory 
neuropathy 
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Rothenberg et 
al (257) 
RCT CRC 627 130mg/m2 
over 2h q21 
for 8 cycles 
(n=311) 
85mg/m2 over 
2h q14 for 12 
cycles (n=308) 
Capecitabine 
as XELOX in 
3-weekly 
treatment 
and 5FU/LV 
as FOLFOX4 
for 2-weekly 
NCI CTC 40 
(12) 
17 
(5) 
1 (<1) 50 
(17) 
14 
(5) 
5 
(2) 
No stated 
exlusion for 
pre-existing 
PN 
XELOX 
versus 
FOLFOX 
rather than 
simply 
scheduling 
of oxaliplatin 
No 
significant 
difference 
reported 
Scheithauer et 
al (255) 
RCT CRC 89 130mg/m2 
over 2h q21 
for 8 cycles 
(n=45) 
85mg/m2 q14 
for 12 doses 
(n=42) 
Capecitabine 
different 
schedules 
WHO 36 
(80) 
23 
(52) 
7 (16) 35 
(83) 
19 
(45) 
5 
(12) 
No mention 
of clinical 
confounders 
Different 
doses of 
capecitabine 
No 
significant 
difference 
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Figure 2.11. Forest plot demonstrating risk of development of any grade CIPN with more 
dose dense oxaliplatin (all patients receiving concurrent oxaliplatin and capecitabine) 
 
It can be seen from figure 2.11 that there is very little difference to be seen in these 
studies between the neurotoxicity of two- versus three-weekly oxaliplatin when given 
with capecitabine.  
 
Meta-analysis was not performed for the XELOX versus FOLFOX studies due to the 
differences described above. The only two studies which could be combined in the 
meta-analysis based on consistency of study design and doses were the studies by 
Cassidy et al (256)  and Rothenberg et al (257); however their hugely different 
neurotoxicity rates and lack of description of acute versus chronic neurotoxicity would 
make combining results questionable. 
 
Ixabepilone 
 
Two studies were identified (table 2.11), one with a sample of 171 (260) patients and 
one with a sample size of 90 (261). Both were in the setting of advanced breast cancer 
and focussed on overall response rate (261) and 6 month progression free survival 
(260), respectively. One was designed as a comparative study, whilst one was a 
randomised, non-comparative study (261). Both allowed patients with pre-existing 
neuropathy to enter, albeit one excluded those with greater than grade 1 symptoms at 
trial entry (260). Both considered that prior taxane may be relevant to their results. The 
schedules of ixabepilone were similar but not exactly the same. The numbers of 
patients experiencing CIPN in the studies have been entered into a meta-analysis, but 
the slight differences in treatment plan need to be considered a limitation of pooled 
data results (figure 2.12). 
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Table 2.11. Included ixabepilone studies for systematic review of dose dense versus less dose dense schedules and effect on risk of CIPN 
Paper Study type Primary 
cancer 
Sample 
size 
Less frequent 
regimen 
(no. of 
patients) 
Dose-dense 
regimen 
(no. of 
patients) 
Any 
concurrent 
chemo 
Grading tool Frequency of CIPN  (by grade) Are patient 
factors 
considered 
Are other 
treatment 
related 
factors 
considered 
Difference 
Less dose dense More dose dense 
Any  2-4 3-4 Any 2-4 3-4 
Rugo et al 
(261) 
 
Randomised 
non-
comparative 
trial 
Breast  90 40mg/m2 
over 3h q21 
for 4 cycles 
then 
32mg/m2 
over 3h q21 
until 
progression 
or 
unacceptable 
toxicity 
(n=45) 
16mg/m2 
over 1h 
weekly until 
progression 
or 
unacceptable 
toxicity 
(n=45) 
Bevacizumab NCI CTC 36 
(80) 
- 11 
(24) 
34 
(76) 
- 8 
(18) 
No exclusion 
criteria for 
clinical 
confounders. 
Stratifies for 
prior taxane 
only 
Different 
schedule of 
bevacizumab 
in the dose 
dense group 
otherwise 
standard 
Not set up 
for 
comparison 
Smith et al 
(260) 
RCT Breast  171 40mg/m2 
over 3h q21 
until 
progression 
or 
unacceptable 
toxicity 
(n=89) 
16mg/m2 
over 1h on 
days 1,8,15 
q28 until 
progression 
or 
unacceptable 
toxicity 
(n=82) 
Nil NCI CTC 38 
(43) 
24 
(27) 
14 
(16) 
26 
(32) 
17 
(21) 
7 
(9) 
Pre-existing 
PN> grade 1 
was 
excluded. No 
other clinical 
confounders 
mentioned. 
Similar 
proportion 
of patients 
with prior 
taxanes in 
each arm 
All 
treatment 
standardised 
No 
significant 
difference 
reported 
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(a) 
 
(b) 
 
 
Figure 2.12. Forest plot demonstrating risk of development of (a) any CIPN and (b) NCI 
CTC grade 3-4 CIPN with more and less dose dense ixabepilone schedules, respectively 
 
Looking at the forest plots, it can be seen that the combined study data suggests a 
trend to more dose dense scheduling being less neurotoxic. Only 261 patients were 
involved in the pooled population, however, which is clearly a limitation. 
 
Vincristine 
 
No studies examining dose-density of vincristine were identified. Dosing of vincristine is 
far more uniform at an almost universal dose of 1.4mg/m2, generally capped at a total 
dose of 2mg due to the occurrence of CIPN. Studies of dose intensity were available 
investigating two-weekly versus three-weekly R-CHOP (Rituximab, Cyclophosphamide, 
Vincristine, Doxorubicin and Prednisolone combination therapy for Non-Hodgkin 
Lymphoma). These showed no significant difference in the neurotoxicity of the different 
regimens (262-264) but did not meet inclusion criteria for the search strategy. 
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2.4 DISCUSSION 
 
The results for the systematic reviews of how diabetes and alcohol intake influence the 
risk of CIPN showed no conclusive outcome and were not amenable to meta-analysis. A 
general limitation of the included studies was that most were retrospective, and many 
had only a very small number of patients with the diagnosis/ exposure of interest.  
 
Overall, there is no clear answer as to whether diabetes affects susceptibility to CIPN. 
Most studies were small and confounding factors were rife. Of the larger series, the 
cohort of 1587 colorectal cancer patients treated with oxaliplatin had some strengths in 
that all patients had a standardised dose and schedule of the neurotoxic agent, but 
unfortunately, the lack of differentiation of acute or chronic neuropathy is a limitation. 
This likely results from its retrospective nature making these more subtle but important 
clinical differences more challenging (216). The second largest study in this category 
gives an overall impression of the neurotoxicity of platinum- based chemotherapy for 
lung cancer in general. However, the results pertaining to risk associated with diabetes 
may be confounded by the differential neurotoxicity of the chemotherapy with some 
patients receiving two neurotoxic drugs rather than one.  
 
There does not appear to be sufficient evidence to change treatment decisions with 
regard to neurotoxicity for diabetic patients who do not have pre-existing symptomatic 
neuropathy. A prospective study to determine the influence of diabetes on neuropathy 
risk using validated assessment tools is needed in view of the prevalence of diabetes in 
the population and the potential morbidity associated with neuropathy. Ideally, such a 
prospective study should include screening for diabetes at the start of chemotherapy as 
it has been reported that 18.5% of diabetes cases are undiagnosed, translating into an 
estimated prevalence of undiagnosed diabetes of 1.7% (265). This is particularly 
important given the use of steroids during chemotherapy which may result in 
hyperglycaemia. It would be important to collect data on other postulated risk factors 
and standardise treatment. Data on BMI and BSA would also be important to collect 
due to reports that higher BMI (106) or BSA (91, 96) may increase the risk of CIPN, and 
the clear potential crossover with diabetes risk. If BMI or BSA was found to be 
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associated with risk of CIPN this may have implications regarding dosing of taxane or 
oxaliplatin chemotherapy in obese patients. 
 
Further study into the effects of alcohol would be more challenging. As demonstrated in 
the identified studies, definition of alcohol excess is not straightforward and would be 
unlikely to satisfactorily account for an individuals’ historical alcohol consumption. 
From the systematic review, there is a suggestion that sustained alcohol excess 
resulting in liver disease may be associated with increased risk but it could postulated 
that this was due to other factors such as reduced metabolism of the drugs.  
 
In terms of scheduling for taxanes, in doses in standard UK practice, the suggestion 
from these meta-analyses is that, for docetaxel there is no convincing effect of dose 
density on neuropathy risk however for paclitaxel the results seen largely suggest that 
more dose dense, weekly schedules are associated with a lower risk of CIPN. 
Heterogeneity of dosing in the studies identified however, effects the validity of 
conclusions. The choice of drug scheduling is at  present very much more likely to be 
determined by efficacy concerns rather than toxicity.  
 
With regard to oxaliplatin, simply changing schedule of oxaliplatin from two weekly to 
three weekly does not appear to change the incidence of neurotoxicity based on two 
studies (254, 255) and meta-analysis within this review. Two prospective non-
randomised studies however, raised an interesting finding, that two weekly oxaliplatin 
regimens with intravenous 5-FU were more neurotoxic than the XELOX regimen (259, 
266). As fluoropyrimidines are only rarely associated with neuropathy, the difference 
seen in the non-randomised studies between FOLFOX and XELOX is unexpected given 
the lack of differential neurotoxicity seen in the purely scheduling studies. It raises the 
question as to whether the choice of fluoropyrimidine in fact alters the neurotoxic 
potential of the regimen. One of the randomised controlled studies supports this 
finding with XELOX causing less grade 3-4 sensory neurotoxicty, but the study was 
limited by the unusually high dose of oxaliplatin (100mg/m2) in their FOLFOX regimen 
(258).  The larger randomised controlled trials do not support this finding with no 
significant difference seen. Numerically there are more cases of grade 3-4 neuropathy 
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seen in the Rothenberg study (5 cases in the FOLFOX group, 2% versus 1 case in the 
XELOX group, <1%) (257) but this was not statistically significant. The largest RCT did 
not show any such trend (256). The strength of the randomised controlled trials is 
clearly their superior methodology and their size. However, as they are designed to look 
at efficacy outcomes rather than toxicity, they are limited by their lack of consideration 
to pre-existing neuropathy or its risk factors and the lack of accurate description of the 
neurotoxicity outcome in question. To answer the question raised in this review 
regarding increased neurotoxicity of FOLFOX compared with XELOX, it would require a 
randomised study but with chronic neurotoxicity as a specified outcome with 
assessments of chronic neuropathy at each cycle and after completion of therapy using 
a validated assessment method. Such a study should also ideally incorporate patient 
related outcome measures. 
 
Oxaliplatin-induced chronic neuropathy is a difficult to manage, treatment-limiting 
effect commonly seen in colorectal cancer management. If it were to be confirmed that 
FOLFOX results in less neurotoxicity, this may have a large impact on choice of regimen 
particularly in the adjuvant setting and reduce the burden of this adverse effect on 
survivorship without compromising efficacy of the regimen. The barrier to such a study 
would be that other factors such as the need for an indwelling venous line for 5FU, 
differential risk of mucositis and diarrhoea may effect interest and therefore 
recruitment to any such study. 
 
2.5 CONCLUSION 
 
There is insufficient evidence at present to clearly define an at-risk group of patients for 
the development of CIPN with taxanes, oxaliplatin or vincristine. As discussed through 
the literature review in Chapter 1, African American patients may be at higher risk of 
vincristine related neuropathy and patients with a high BMI may also be at greater risk 
of CIPN in general. The factors systematically reviewed in this chapter are not clearly 
related to increased risk of CIPN, but further study of the influence of diabetes and BMI 
would be of particular value.  Treatment factors such as total cumulative dose, dose per 
cycle and duration of infusion are important but more prospective studies are 
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warranted to explore inter-individual risk based on patient-related factors and these 
have been outlined above. Other factors needing investigation include genetic variation 
either in pathways determining drug metabolism or in pathways that may influence 
susceptibility of nerves to damage or impede recovery mechanisms.  This is dealt with 
in chapters 3 and 4. 
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CHAPTER 3 
 
 
 
THE MOLECULAR GENETICS OF 
CHEMOTHERAPY-INDUCED PERIPHERAL 
NEUROPATHY: A SYSTEMATIC REVIEW 
 
 
 
 
 
 
 
 
 
 
 83 
3.1 INTRODUCTION 
 
As well as considering clinical risk factors for developing CIPN, inter-individual 
differences in drug effects may also be affected by genetic variation. It can be 
speculated that differences in various aspects of the process of metabolism of the drug 
may be affected by genetic variation in individuals and impact on the exposure of the 
individual to the drug, its efficacy and its toxicity. This could be in phase I metabolism 
(variations altering cytochrome P450 (CYP) enzyme activity), phase II metabolism 
(variations altering glucuronidation) or drug transport affecting elimination processes 
(alterations in efflux carriers for example, the ATP-binding cassette (ABC) transporters 
in the cell membranes of hepatocytes, or import carriers, such as organic anion 
transporter (OAT) in cell membranes of renal tubule cells and hepatocytes). It may also 
be hypothesised that genetic variations in the target tissues will determine 
susceptibility to efficacy or toxicity.   
There have been concerns in the literature regarding methodological quality of 
pharmacogenetics studies (267) so whilst examining available study results it is also 
important to evaluate the strength of that evidence.   
 
Increasingly there have been pharmacogenetics studies investigating genetic variants 
which may predispose to CIPN. This systematic review will aim to evaluate the current 
evidence on the effect of genetic variants on the development of CIPN, which SNPs 
have been studied, and the quality and strength of this evidence. 
 
3.2 METHODS 
 
Search strategy 
Medline, Scopus, CINAHL, and the HuGENet database were originally searched on 
23/02/2014 applying the strategy outlined in table 3.1 but repeated on 20/01/2016. 
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Table 3.1. Details of search strategy 
Number Search term 
1 chemotherapy.mp 
2 paclitaxel.mp 
3 docetaxel.mp 
4 taxane.mp 
5 oxaliplatin.mp 
6 cisplatin.mp 
7 platinum.mp 
8 vincristine.mp 
9 vinc*.mp 
10 geno*.mp 
11 genetic*.mp 
12 pharmacogen*.mp 
13 haplotyp*.mp 
14 variant.mp 
15 allel*.mp 
16 SNP.mp 
17 polymorphism.mp 
18 neurotoxicity.mp 
19 *peripheral neuropathy*.mp 
20 neuropath*.mp 
21 *sensory impairment*.mp 
22                            1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 
23 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 
24 18 OR 19 OR 20 OR 21 
25 22 AND 23 AND 24 
mp= title, original title, abstract, name of substance word, subject heading word 
*= any ending to the word 
 
Study selection 
Studies reported in English in populations undergoing cancer treatment with cytotoxic 
chemotherapy known to be associated with CIPN, which investigated an association 
between one or more genetic factors and neuropathy outcomes were included. The 
scope of the review was limited to cytotoxic chemotherapy and studies of novel, 
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biological agents, such as bortezomib or thalidomide were excluded. Case studies were 
also excluded. 
 
 The search results were compiled, duplicates removed and screened (JC). Papers that 
were clearly not relevant were excluded by title or abstract and for the remaining, 
potentially relevant studies, full papers were examined (JC) to identify the final set of 
manuscripts meeting the inclusion criteria. Bibliographies of included studies were 
checked for overlooked papers. Care was taken to identify the authors, geographical 
location and time period of the study to minimise the risk of including the same dataset 
more than once. If the same or overlapping datasets were identified in multiple 
publications, the larger dataset was included for meta-analysis purposes. 
 
Data extraction 
 
Relevant methodological and clinical data were collected through use of a data 
extraction form developed  with reference to both the HuGeNet Reviews Handbook 
(268) and a specialist review of methodological issues in pharmacogenetic studies(267).  
The forms were piloted on five studies and once amendments were made, they were 
completed for each study by two independent reviewers (JC plus either LC or FA). Any 
discrepancies were referred to a third reviewer (RL or DC).  
 
Statistical analysis  
 
The studies were grouped by class of chemotherapy drug investigated and the genetic 
variants examined. Where multiple studies investigated the same SNP for the same 
drug, providing they reported the numbers of patients with or without neuropathy per 
genotype, they were combined in a meta-analysis.  Forest plots were prepared using 
RevMan V5.0 (269) using the Mantel-Haenszel method and assuming a random effects 
model to allow for heterogeneity. Extent of heterogeneity between studies was 
estimated using the I2 statistic. Plots were stratified for ethnicity as recommended by 
HuGENet (268) with effect sizes both per ethnic stratum and overall estimated. Where 
ethnicity was not stated in the study, the predominant ethnicity represented was 
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assumed depending on the country of origin of the study. For the purpose of calculating 
the effect estimate, a dominant mode of inheritance was assumed, i.e. the effect 
estimate represented that for heterozygotes and mutant homozygotes combined 
versus wild-type homozygotes as this was in line with the majority of published papers. 
 
 
 
3.3 RESULTS 
 
 
After applying the search strategy, 1779 titles were identified after removal of 
duplicates with a further 15 articles identified for review from hand searching reference 
lists from review articles. From these, 134 warranted full text review and 93 met criteria 
for inclusion (Figure 3.1). Three relevant abstracts were identified with no full text 
article yet published. These will be mentioned but were not included in our full analysis 
(86, 270, 271). Two papers were identified in Japanese but unfortunately translation 
was not possible and they were excluded as pre-stated. 
93 studies were therefore included in the systematic review. Five of these were genome 
wide association studies (72, 82, 85, 272, 273), a sixth presented selected genotyped 
and imputed results from a genome wide association study but the full GWAS results 
were not published (274). 16 studies investigated SNP(s) in a single candidate gene (71, 
73, 275-289) The remainder of the studies studied multiple candidate SNPs in one or 
more genes. Six studies were conducted in a paediatric population (72, 73, 289-292) the 
remainder in adults. 
Two studies compared chemotherapy to chemotherapy combined with a targeted 
agent with neurotoxic potential (thalidomide (276)  and bortezomib (293) respectively).  
For these papers only the chemotherapy-alone arm was included in this review. 
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Figure 3.1. Flow of identified references 
 
 
 
 
 
 
Records identified 
from database 
search   n= 2022 
Records excluded from abstract review        n= 204 
Articles selected for full text review, n=135   
 
 
Records identified after duplicates 
removed   n=1779 
38 excluded 
1 relevant letter to editor but insufficient information for inclusion in 
methodological review. Included for discussion only (1)[ 
18 looked at genetics of other outcomes, for example, response, 
survival, other toxicities but not peripheral neuropathy 
8 Possibly looked at genetics of neuropathy but not specifically stated 
4 appeared to look at the association with toxicity all together rather 
than at separate toxicities 
1 investigated Charcot Marie Tooth disease and vincristine induced 
peripheral neuropathy 
1 used SNPs to stratify treatment, not looking at relationship between 
polymorphisms and peripheral neuropathy 
1 GWAS of paclitaxel- induced cytotoxicity using a lymphoblastoid cell 
line 
1 excluded as involved bortezomib only 
1 excluded as duplicated pharmacogenetic study in the same 
population (early publication, later expanded cohort with same SNPs 
included) 
1 excluded as investigating epigenetics 
1 excluded as investigating IHC of protein expression within tumour 
samples and clinical outcome 
2 excluded as correspondence related to previous published work 
 
Included studies, n=93 
Records excluded from title alone  n= 1437 
3 abstracts found for which no full text article found 
 
Records identified 
through other 
means    n=15  
 
  
4 unreviewable (2 in Japanese, 1 not obtainable but appears to look 
at PG of pharmacokinetics only and one conference paper which 
could not be accessed) 
 
 88 
3.3.1 Assessment of methodological quality of included studies 
The results from assessing the included papers against the methodological checklist are 
summarised below. 
 
 
Sample size 
Nine studies included both a discovery set and a replication set (72, 82, 100, 272, 273, 
294-296). Another four (297-300) studies included two treatment arms which were 
analysed separately, each involving either a different potentially neurotoxic agent, or 
the same potentially neurotoxic drug but in a different schedule. One of these studies 
also separated their cohorts into discovery and replication cohorts (299). A further 
study analysed their cohort in separate groups according to ethnicity (281) All of these 
patient cohorts are treated separately for the purposes of investigating sample size. 
With these considerations taken into account, the median sample size was 118.0 (IQR 
73-209). Only six studies mentioned an a priori sample size calculation (73, 277, 280, 
301-303). One study made a post-hoc estimation of power (304) and a further study 
stated upfront the minimal odds ratio detectable given their sample size (88).  
Study design 
Of the 93 included studies, 43 were prospective cohort studies (82, 88, 90, 98, 272, 274, 
276, 277, 280, 282, 283, 286, 288, 291, 293, 297, 298, 300, 302-326) and 22  were 
retrospective analyses from cohorts  with clearly described, prospectively  recorded 
clinical data, many  part of a separate prospective clinical trial (72, 85, 89, 100, 273, 275, 
279, 287, 290, 295, 299, 327-336); 21 were retrospective cohort studies (71, 73, 94, 95, 
215, 217, 278, 281, 284, 285, 289, 294, 296, 337-345) and one study included a mix of 
prospectively and retrospectively recruited patients (301). Five were case-control 
studies (41, 103, 292, 346, 347), one of which used a control group of healthy blood 
donors who had not been exposed to the potentially neurotoxic agent (346).     
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Selection of investigated genes 
In general, all studies provide some explanation for the selection of genes chosen for 
investigation. Explanations for the selected SNPs were occasionally absent. Some 
papers provided a very broad statement, usually a necessity when many associations 
are being sought. 
 
Reliability of genotypes 
Method of genotyping was reported in all studies, although in some the description was 
very brief allowing only limited assessment of quality. In 56 (60%) of the studies there 
was no mention of specific quality control procedures being undertaken. Only 29 
studies state that genotyping personnel were blinded to clinical outcome data. 39 (42%) 
of the non-genome wide studies (90, 94, 95, 276, 278, 280-282, 284, 288, 290, 292, 297, 
299-303, 305, 311, 315, 316, 318, 319, 321-324, 329, 330, 332, 333, 336, 337, 342, 344-
346, 348) compared their genotyping results to previously published data, which may 
be used as a basic method of looking for problems with genotyping. 
Six of the studies carried out genotyping on formalin fixed paraffin embedded (FFPE) 
tumour samples (277, 278, 332, 336, 343) or peritumoural tissue (294) rather than 
peripheral blood samples. There is some controversy over whether tumour sample 
genotyping is a reliable method for this type of study and whether results obtained 
from such samples and those obtained from peripheral blood can be considered 
comparable. Some authors have demonstrated almost complete concordance in 
genotyping certain genes in blood and FFPE tumour samples (349, 350) whereas others 
have shown more discrepancy (351). 
 
Missing genotype data 
For 29 of the 87 non-GWA studies it is clear that no genotyping data was missing (71, 
88, 89, 94, 215, 276-280, 284, 288, 289, 291, 305, 308, 309, 311, 313, 314, 325, 327, 
329, 331, 335, 337, 338, 348). For the six studies utilising a genome wide approach (72, 
82, 85, 272-274) and four studies which genotype a large array of SNPs (293, 295, 296, 
328) parameters for excluding SNPs or subjects were clear. For 39 studies some missing 
genotype data was evident  (41, 73, 90, 95, 98, 100, 103, 217, 276, 282, 283, 292, 294, 
297-300, 302, 306, 307, 310, 312, 316-320, 322-324, 332, 333, 336, 341-344, 346, 347), 
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but only in six of these was there an explanation for missingness (100, 282, 322-324, 
343). For 16 studies, it cannot be determined from the information provided whether 
or not there is missing genotype data (281, 285-287, 290, 301, 303, 304, 318, 321, 326, 
330, 339, 340, 345). In no study was there evidence of checks that data was missing at 
random.  
 
Population stratification 
Only seven studies (7.5%) mentioned accounting for population stratification (72, 82, 
274, 291, 295, 296, 328). Five used principle component analysis (72, 82, 274, 295, 296), 
the sixth genotyped ancestry informative markers and correlated these with self-
reported race (291). The seventh study also included SNPs to estimate individual 
ancestry and stated that population admixture proportions were determined using 
Bayesian clustering algorithms (328). 
 
40 studies involved a single ethnic group; 25 Caucasian populations (85, 89, 90, 103, 
217, 273, 274, 278, 280, 289, 290, 294, 301, 304, 305, 308, 318, 333-338, 343, 344) and 
15 East Asian populations (94, 272, 286-288, 302, 311, 314, 315, 319, 324, 327, 331, 
341, 348). 22 studies involved mixed populations (41, 71-73, 82, 95, 98, 100, 279, 281, 
291, 292, 296, 300, 321-323, 328, 330, 332, 342, 347) and in 31 studies ethnicity was 
not mentioned. In the 22 mixed ethnicity studies, one study analysed their cohort by 
separate ethnic groups (281), five accounted for this by population stratification (72, 82, 
291, 296, 328) and four studies adjusted for ethnicity in their analysis (292, 300, 330, 
347). The remaining 12 did not appear to account for the mixture. 
Hardy Weinberg Equilibrium 
61 of the 93 included studies stated that they checked that genotypes were in HWE (82, 
85, 88, 89, 94, 95, 98, 100, 103, 272-274, 276-279, 281, 284, 286, 287, 290, 293-306, 
312-315, 318, 320-325, 328-330, 333, 334, 336, 337, 339, 341-344, 348).  
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Mode of inheritance 
For three studies, this point is not applicable (229, 280, 288) (one looking at the length 
of the common allele containing a CAG motif (280), for one no homozygote wild-type 
patients existed (288) and for one no homozygote variants existed (331). In the 
remaining 89 studies, 25 studies (71, 85, 88, 89, 217, 271, 289, 295-297, 301, 303, 304, 
318, 320-323, 328, 330, 336, 342-344, 347) made a clear specific statement about how 
they were going to analyse their genotype data with regard to mode of inheritance. 
However, six of these stated that they were analysing using more than one type of 
assumption (88, 297, 303, 304, 343, 347). In 28 studies (94, 95, 100, 274, 279, 284-286, 
291, 294, 307, 309, 311, 313, 315, 316, 318, 319, 323-325, 327, 329, 335, 338, 341, 345, 
348), although not explicitly stated, it was apparent from the results which mode(s) had 
been assumed. In the remaining studies, assumed mode(s) could not reliably be 
determined. 
 
Multiple testing 
 
Only three studies clearly did not require adjustment for multiple testing (one SNP, one 
outcome, one mode of inheritance clearly stated) (280, 281, 289). Of the remainder, 21 
made an adjustment for multiple testing (41, 72, 89, 217, 286, 287, 291-293, 295, 304, 
308, 315, 321, 328, 330, 337, 342-344, 347). All GWAS set appropriate levels of 
significance to reflect the multiple tests involved. 
 The lack of adjustment is particularly important to note where studies are reporting 
positive results (71, 90, 94, 95, 98, 100, 276, 285, 294, 298, 300, 301, 305-307, 319, 325-
327, 338, 341, 348) or a trend towards a positive result (275, 316, 340). All of the 
genome wide association studies set appropriate levels of significance to reflect the 
multiple tests involved. 
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3.3.2 Chemotherapy and clinical considerations and their impact on phenotype 
definition 
Chemotherapy factors 
The neurotoxic drugs studied are summarised in table 3.2. 
Table 3.2. Summary of drugs investigated (total adds up to >93 as some studies included 
more than one neurotoxic drug) 
 
 
A major methodological flaw noted was that in some of the cohorts some patients were 
receiving multiple concurrent neurotoxic drugs. In two of the cisplatin studies, some of 
the patients received vinblastine concurrently (338, 347), and in one study, some of the 
patients concurrently received either vindesine or docetaxel (286). In four studies, 
either carboplatin or cisplatin were used as the index drug (98, 217, 287, 343) 
notwithstanding it is well established that carboplatin is significantly less neurotoxic 
than cisplatin. In two of these studies, to further compound the issue of differentially 
neurotoxic treatments, some patients concurrently received paclitaxel (217, 343). 
Paclitaxel and a platinum are often concurrently given, but in two of the paclitaxel 
Neurotoxic Drug Number of studies 
Oxaliplatin 35 (88-90, 94, 95, 272, 273, 277-280, 294, 
297, 298, 300, 302-304, 306, 307, 309, 311-
314, 316, 319, 320, 325, 327, 331, 332, 339, 
348) 
Oxaliplatin OR cisplatin 1 (215) 
Cisplatin 6 (282, 286, 298, 308, 338, 347) 
Cisplatin OR carboplatin 4 (98, 217, 287, 343) 
High dose carboplatin 1 (78) 
Paclitaxel (some with carboplatin) 29 (82, 85, 100, 274, 275, 281, 283, 285, 288, 
296, 299, 301, 305, 315, 318, 321-323, 326, 
328, 330, 334-336, 340, 342, 344-346) 
Docetaxel (some with carboplatin) 4 (103, 276, 299, 329) 
Paclitaxel OR docetaxel (some with 
carboplatin) 
3 (295, 337, 341) 
Docetaxel AND cisplatin 1 (317) 
Vincristine 11 (41, 71-73, 284, 289-293, 324) 
Ixabepilone 1 (310) 
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studies, only some of the patients received concurrent cisplatin whilst others received 
the far less neurotoxic carboplatin (285, 301) . Another study looked at the combination 
of two highly neurotoxic drugs, docetaxel and cisplatin in all patients (317). Where 
treatment was uniformly with two neurotoxic agents, conclusions can only be drawn 
about the combination treatment rather than the individual drugs involved. 
In addition, some studies included different drug regimens (82, 88, 89, 95, 100, 103, 
272, 280, 281, 285, 294, 296, 301, 303, 305, 310, 321-324, 326, 328, 330, 333, 335, 338, 
340, 342, 343, 346). Some studies adjust for this (72, 95, 100, 103, 294, 295, 298, 301, 
333, 338, 347) but others did not leading to confounding as different regimens of the 
same drug may be differentially neurotoxic (226, 237, 242, 243, 247).  
For instance, some investigators have shown that FOLFOX4 is a more neurotoxic 
regimen than XELOX (259) and a number of studies have demonstrated differential 
neurotoxicity of weekly versus three-weekly taxanes (226, 237, 242, 243, 247), albeit 
some are contradictory.   
A further limitation is that a significant proportion of studies did not make it clear that 
definitions were set regarding a minimum dose of neurotoxic drug received to be 
classified as a control. For example in the majority of studies there was no assurance 
that consideration was given to patients who may have stopped chemotherapy early 
due to other toxicities or disease progression.  
24 studies stated clear appropriate minimum dose criteria (95, 215, 272, 277-280, 287, 
288, 293, 295, 302, 305, 316, 319-323, 325, 331, 335, 342, 343). Other studies adjusted 
for total dose received (88, 289, 294, 338, 347, 348) or used cumulative dose (82, 85, 
274, 281, 285, 296, 301, 336, 340, 345) or a time point in their outcome (71, 100, 105, 
275, 276, 318, 334); however for 45 studies, this was left as a potential source of 
inaccurate phenotyping. One case-control study chose their control group from a 
population of healthy volunteers with no exposure to the neurotoxic agent (346). 
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Other clinical considerations 
 
Baseline characteristics 
24 studies excluded all patients with a history of symptomatic peripheral neuropathy 
(85, 88-90, 94, 95, 103, 217, 272, 277, 278, 280, 294, 295, 300, 301, 304, 321-323, 326, 
327, 342, 345). A further nine excluded those with >grade 2 peripheral neuropathy at 
baseline (71, 283, 293, 298, 299, 310, 336), a peripheral neuropathy score of >3 (275) or 
disabling peripheral neuropathy (348).  
The remaining studies made no mention of excluding patients with pre-existing 
neuropathy. Whether the risk of developing CIPN was affected by diabetes or excessive 
alcohol intake is controversial but only a few studies acknowledged these factors by 
excluding affected patients or considering either diabetes (94, 103, 281, 286, 290, 296, 
301, 308, 321, 323, 329, 345) or alcohol excess (103, 277, 278, 280, 301, 327, 345), as 
covariates. 
Assessment of neuropathy 
 
There was variation found in terms of assessment of neuropathy and neurotoxicity 
endpoints used. The majority of studies (63/93) used NCI CTC grading to document 
presence and severity of neuropathy. Six studies of oxaliplatin induced peripheral 
neuropathy used the oxaliplatin specific scale (95, 298, 302, 304, 316, 320) and three 
studies each used the WHO toxicity grading scale (273, 282, 317)  and Total Neuropathy 
Score (TNSc) (88, 277, 278), respectively. One study used both NCI CTC and TNSc (89) 
and one used both the NCI CTC and oxaliplatin grading scale (298).  Two paediatric 
studies used the Children’s Cancer Group toxicity grading system (41, 292) and one 
used a global toxicity score (290). Two studies correlated genotype information with 
results of neurophysiological testing (215, 280). Six studies used other lesser known 
scales including a PNP score (275) a ‘specific neurotoxicity score’ (306), the scale for 
CIPN (SCIN) (338), a neurotoxicity scale resulting in an ‘N score’ (305), the Michigan 
neuropathy screening instrument (347) and one defined by the authors in their text 
which appeared consistent with NCI CTC (300). Three studies performed by the same 
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group used the EORTC CIPN20 scale to define case and control groups. Questionnaires 
were completed by patients at consecutive cycles and their results plotted. They used 
rate of change of scores to define cases with a significantly increased rate of change 
and controls, with a significantly slower rate of change and excluded those that 
approximated to the median rate of change slope (321-323). The measurement tool 
used was not stated in four of the studies (310, 314, 315, 318). The various methods of 
documenting presence and severity of neuropathy are outlined in table 3.3. 
 
Table 3.3: Methods of assessment of CIPN  
Assessment tool 
NCI CTC 63 
WHO 3  (273, 282, 317)  
Oxaliplatin specific scale 6 (95, 298, 302, 304, 316, 320) 
TNSc 3  (88, 277, 278) 
CCG 2  (41, 292) 
Neurophysiological methods 2  (215, 280) 
Other score 10   (275, 290, 300, 305, 306, 
321-323, 338, 347) 
Not clear 4  (310, 314, 315, 318) 
More than one grading scale stated 2  (89, 298) 
NCI CTC= National Cancer Institute Cancer Common Terminology Criteria, WHO= World health Organisation, TNSc= Total 
Neuropathy Scale clinical, CCG= Childrens Cancer Group 
 
Different groups looked at different CIPN outcomes including occurrence of any grade, 
> grade 2 or >grade 3 CIPN or either time to neuropathy or cumulative dose at 
occurrence of grade 2 neuropathy. In 57 studies, outcomes were pre-specified, whilst in 
others (28/93), this became apparent in the results, and in the remainder the 
neuropathy outcome was not clearly defined (8/93).  
Acute versus chronic oxaliplatin neurotoxicity 
An issue specific to oxaliplatin studies is that consideration is required of the two 
distinct forms of neuropathy that it is associated with. An acute neurotoxicity which 
occurs in the majority of patients treated often occurs immediately following 
administration, is transient and associated with dysaethesia on exposure to cold. A 
chronic, cumulative form of neuropathy affects a smaller proportion of patients and 
develops after repeated dosing. Acute neurotoxicity may be due to a channelopathy, 
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whereas it is thought that the chronic form of neuropathy is likely to be due to 
accumulation of platinum in the dorsal root ganglion. As it is likely that different 
mechanisms are responsible for each form of neurotoxicity, studies investigating a 
pharmacogenetic association of increased risk should clearly define which form of the 
toxicity they are investigating. Fifteen studies specifically looked at chronic 
neurotoxicity (88-90, 94, 95, 215, 272, 277, 278, 294, 297, 316, 320, 325, 327) and one 
study specifically looked at acute neurotoxicity (280). The remaining 19 studies did not 
explicitly make a differentiation. The oxaliplatin specific scale is scored in a way that at 
least in part differentiates acute and chronic neuropathy by taking into account the 
duration of symptoms, however only three (298, 302, 304) of the 19 studies used this.   
 
3.2.3 Genetic associations investigated and meta- analysis 
 
The array of SNPs investigated was extensive but what follows is a presentation of SNPs 
which have been investigated in numerous studies for certain drug classes. All included 
studies are summarised in tables 3.4-3.8. Where meta-analyses have been performed 
this is stated in the text. Table 3.9 details which meta-analyses were performed and 
reasons why others were not. 
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Table 3.4. Included oxaliplatin-based studies for systematic review of pharmacogenetics of CIPN 
First author 
(Year) 
Index 
drug(s) 
SNPs investigated  
(those underlined 
highlight statistically 
significant 
ssociations) 
Country Ethnicity Ethnicity 
uniform, 
mixed-
adjusted 
for or 
mixed 
Test for 
population 
substructure 
Primary 
tumour 
Assessment 
tool for CIPN 
CIPN endpoints 
investigated 
Sample size 
(number of 
‘cases’ 
according to 
the authors 
definition) 
Schedule/ 
dose 
uniform, 
adjusted for 
or mixed 
Minimum 
dose for 
controls 
Potential 
clinical 
confounders 
accounted 
for 
HWE 
checked 
Genotype 
QC 
measures 
described 
Mode of 
inheritance 
used in 
analysis 
stated 
Multiple 
testing 
adjustment 
Antonacopolou 
(2010) 
Oxaliplatin ITGB3 L33P Greece NS NS No CRC TNSc Development 
of neuropathy 
55 (34) Uniform Yes Excludes pts 
with pre-
existing PN, 
DM, alcohol 
abuse 
Yes Yes Evident in 
results 
(recessive 
model) 
Single SNP  
Argyriou (2009) Oxaliplatin SCN2A R19K Greece European Uniform No CRC TNSc Development 
of any grade 
and grade 1 vs 
grade 2 
62 (36) Uniform Yes Excludes pts 
with pre-
existing PN, 
DM, alcohol 
abuse 
Yes NS Unclear Single SNP 
Argyriou (2013) Oxaliplatin SCN4A (rs2302237), 
SCN9A (rs67406030), 
SCN10A (rs12653942, 
rs6800541) 
Greece, 
Spain, 
Italy 
NS NS No CRC TNSc Development 
of neuropathy 
and severity  
200 (145) Adjusted Dose 
used in 
outcome 
Excludes any 
pre-existing 
PN 
Yes NS Yes (3 
modes used 
in analysis) 
No 
Basso (2011) Oxaliplatin SK3 CAG motif 
polymorphism 
Italy Caucasian Uniform No CRC, 
pancreas  
and 
biliary 
clinical 
examination
, NCS and 
needle EMG 
Neurophysiolog
ical change 
40 (28) Mixed NA, Acute 
neurotoxi
city 
All pre-
existing PN 
and alcohol 
abuse 
excluded 
Yes NS Not 
applicable 
Single 
outcome 
Boige (2010) Oxaliplatin 20 SNPs in ERCC1, 
XPD, GSTM1, GSTT1, 
GSTP1, UGT1A1, TS, 
MTHFR 
NS NS NS No CRC NCI CTC Development 
of grade 2-4 
neuropathy 
Sequential 
chemo arm: 
132 (66) 
Combination 
chemo arm: 
175 (111) 
Uniform No No NS NS Yes (more 
than one 
mode used) 
No 
Cecchin (2013) Oxaliplatin 57 SNPs  in 29 genes 
incl ABCB1, ABCC1, 
ABCC2, ABCG2, 
GSTP1, GSTT1, 
GSTM1, ERCC1, XPD, 
XRCC1, SCN2A and 
AGXT 
 
Italy Caucasian Uniform No Colorecta
l 
Oxaliplatin 
specific scale 
Development 
of grade 2-4 
neuropathy 
144 (56) Uniform No Excluded 
any pre-
existing PN 
and any 
concurrent 
neurotoxic 
drugs 
NS NS Analysed 
using three 
models and 
most 
significant 
was 
reported 
Yes 
Chai (2012) Oxaliplatin GSTP1 Ile105Val, 
ERCC1 C118T, XRCC1 
Arg399Gln, ABCB1 
(C3435T, G2677T/A), 
MTHFR C677T, 
UGT1A1 (*6,*27, 
*28), DPYD 
(*2,*5,*9), TYMS 
6bpins/del  
China Han 
Chinese 
Uniform No CRC NS NS 73 (NS) Uniform No No Yes Yes Unclear No 
Chen (2009) Oxaliplatin GSTP1 Ile105Val, 
ERCC C118T, XPD 
Lys751Gln 
Taiwan Chinese Uniform No CRC NCI CTC Development 
of grade 3-4 
166 (33) Uniform No  Excluded 
pre-existing 
PN, DM or 
alcohol 
abuse 
Yes NS Evident in 
results 
(dominant) 
No 
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Chua (2009) Oxaliplatin ERCC1 C118T, MTHFR 
C677T, XRCC1 
Arg399Gln 
Australia Mixed  Mixed No CRC NCI CTC Development 
of grade 3-4 
118 (20) Uniform No No Yes NS Unclear No 
Cortejoso 
(2013) 
Oxaliplatin ABCB1 (C3435T, 
G2677T/A, C1236T), 
ERCC1 C118T, XPD 
Lys751Gln, XRCC1 
Arg399Gln, GSTP1 
Ile105Val, GSTT1, 
UGT1A1 (G3156A, 
*28) 
Spain NS NS No CRC NCI CTC Development 
of grade 3-4 
106 (13) NS No No NS Yes Unclear No 
Custodio (2014) Oxaliplatin 34 SNPs in 15 genes 
incl rs2230641 in 
CCNH and rs3114018 
in ABCG2 
Spain Caucasian Uniform No CRC NCI CTC  Development 
of grade 2 
lasting for >7 
days or grade 3 
Exploratory 
206 (48); 
validation 
181 (72)  
Adjusted Dose 
used in 
outcome 
Excluded 
those with 
pre-existing 
PN 
Yes NS Evident in 
results 
(dominant 
and possibly 
some 
additive) 
No 
Fernandez- 
Rozadilla 
(2013) 
Oxaliplatin GWAS Spain Caucasian Uniform No CRC WHO Development 
of grade 2-4 or 
grade 1 if cycles 
<4 or in 
cycles>4 and 
dose reduction 
or delayed 
based on time 
over expected 
length of 
course 
133 phase 1 
(47); 324 
phase 2 
(225) 
NS No No Yes Yes Unclear Yes 
Gamelin (2007) Oxaliplatin GSTP1 (Ile105Val and 
Ala114Val), AGXT 
(154C>T, 155C del, 
156Cins, Duplication 
74bp intron 1, 
576T>A, 588G>A, 
630G>A, 640G>A, 
819C>T, 820G>A, 
853T>C, 860G>A, 
A1119T, A1142G), 
ABCC2 (24C>T, 
3972C>T), GRHPR 
(103del, 295C>T, 
AAGTdel) 
France French 
Caucasian 
Uniform No CRC NCI CTC Development 
of grade 2-3 
135 (28) Uniform No Excluded  
pre-existing 
PN 
Yes NS Unclear No 
Goekkhurt 
(2009) 
Oxaliplatin 
and cisplatin 
GSTP1 Ile105Val, 
GSTM1, GSTT1, 
ERCC1 (C118T, 
C8092A), XPD 
(Lys751Gln, 
Asp312Asn), XRCC1 
Arg399Gln, XPA 
A23G, TS (1494del6, 
VNTR 28bp repeat, 
VNTR +G/C SNP), 
MTHFR (C677T, 
A1298C), MTR 
A2756G, OPRT 
Gly213Ala 
Germany 
and 
Switzerla
nd 
NS NS No Upper GI NCI CTC Development 
of grade 3-4 
Oxaliplatin 
arm: 71 
Cisplatin 
arm: 63  
(12-15) 
Adjusted 
and 
analysed 
separately 
No Excluded 
those with 
PN> grade 1 
NS NS Unclear No 
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Hong (2010) Oxaliplatin ERCC1 (C8092A, 
C118T), XPD 
(Lys751Gln, 
Asp321Asn, C156A), 
XRCC1 (Arg399Gln, 
Arg194Trp, 
Arg280His), GSTP1 
Ile105Val, AGXT 
(I340M), CYP2A6 (-
48G/T), MTHFR 
A1298C, TS (TSER, 3’-
utr and 5’G/C) 
Korea NS NS No CRC NCI CTC Development 
of grade2-4 
52 (8) Uniform No No Yes NS Evident in 
results 
(dominant) 
No 
Kanai (2012) Oxaliplatin GSTP1 Ile105Val, 
AGXT (Pro11Leu, 
Ile340Met) 
Japan Japanese Uniform No CRC Oxaliplatin 
specific scale 
Development 
of grade 2-3 
82 (44) Uniform Unclear No Yes NS Unclear No 
Keam (2008) Oxaliplatin GSTP1 Ile105Val, 
ERCC1 (C118T, 
C8092A), XPD 
(Lys751Gln, C156A, 
Asp312Asn), XRCC1 
Arg399Gln 
Korea NS NS No Upper GI NCI CTC NS 73 (13 any 
grade; 1 
grade 3-4) 
Uniform No No NS NS Evident in 
results 
(dominant) 
No 
Kumamoto 
(2013) 
Oxaliplatin  GSTP1 Ile105Val, 
GSTT1, GSTM1, 
ERCC1 C118T, ERCC2 
Lys751Gln, MTHFR 
Ala677Val, TS 5’UTR 
VNTR, TS 3’UTR 6bp 
ins/del 
Japan Japanese Uniform No CRC NCI CTC Development 
of grade 2-4 
63 (43-44) Uniform Yes No Yes NS Evident in 
results 
(dominant) 
No 
Kweekel (2008) Oxaliplatin GSTP1 Ile105Val Netherlan
ds 
Mixed: 
mainly 
Caucasian 
Mixed No CRC NCI CTC Development 
of any 
neuropathy 
and grade 3-4  
91 (60 any 
grade, 5 
grade 3-4) 
Uniform Yes No Yes NS Evident in 
results 
(appears 
looked at 
dominant, 
recessive 
and no 
assumption) 
Single SNP 
Lai (2009) Oxaliplatin XPD Lys751Gln, TSER 
28bp polymorphism 
Taiwan Chinese Uniform No CRC NCI CTC Development 
of grade 3-4 
188 (30) Uniform Yes No Yes NS Not 
applicable 
No 
Lecomte (2006) Oxaliplatin GSTP1 (Ile105Val, 
Ala114Val), GSTM1, 
GSTT1 
France Mixed 
(White, 
African, 
Asian) 
Mixed No CRC, 
upper GI 
and 
pancreas 
Oxaliplatin 
specific scale 
Development 
of grade 3 
64 (15) Adjusted Yes Excluded 
pre-existing 
PN 
Yes NS Evident in 
results (one 
dominant, 
one no 
assumption, 
two 
recessive) 
No 
Lee (2013) Oxaliplatin 20 SNPs in GSTP1, 
GSTM1, GSTT1, 
ERCC1, XPD, XRCC1 
(Arg399Gln),ABCC2,A
GXT, TS, MTHFR 
Korea Korean Uniform No CRC NCI CTC  Development 
of grade 2-4 
292 (51) Uniform No. 
No. of 
cycles 
used as 
covariate 
Exclude 
patients 
with a 
history of 
disabling PN 
NS Yes Evident in 
results 
(dominant) 
No 
Li (2010) Oxaliplatin  GSTP1 Ile105Val China NS NS No Gastric Oxaliplatin 
specific scale 
Development 
of grade 3-4 
92 (12) Uniform Yes No Yes Yes Yes 
(dominant) 
Single SNP 
Liu (2013) Oxaliplatin GSTP1 Ile105Val, 
ERCC1 C118T, XPD 
Lys751Gln, XRCC1 
Arg399Gln 
China NS NS No Upper GI NCI CTC Development 
of grade 3-4 
126 (NS) Uniform Yes No NS NS Evident in 
results 
(dominant) 
No 
 100 
McLeod (2010) Oxaliplatin ABCB1 
(C1236T,C3435T, 
G2677T), ABCC1 
(rs2074087, 
rs2230671), ABCC2 
(rs717620, 
rs8187710, 
rs7080681, 
rs2273697, 
rs374066), ABCG2 
C421A,  CYP3A4 (*1B 
and *3), CYP3A5 (*3C 
and *6), DPYD (*2A, 
*5, *6, *9A), ERCC1 
C118T, ERCC2 -
1989A>G, 2133C>t, 
2251 A>G, GSTM1, 
GSTP1 (Ile105Val and 
Ala114Val), MTHFR 
(C677T, A1298C, 
G1793A), TYMS 
(1494del, TSER), 
UGT1A1 (*93,*28), 
XRCC1 Arg399Gln. 
USA and 
Canada 
Mixed 
(White, 
Black NOS, 
Asian, 
Hispanic, 
Other) 
NS No CRC ‘Parathesias 
that 
interfered 
with daily 
activities or 
caused 
disability 
were 
classified as 
grade 3 or 4, 
respectively' 
Development 
of grade 3-4,  
probability of 
discontinuing 
treatment due 
to 
neurotoxicity, 
time to 
development of 
neurotoxicity 
 299  
FOLFOX4 
arm; 
 107 IROX 
arm 
(44 cases in 
total) 
Uniform; 
arms 
analysed 
separately 
No Excluded all 
pre-existing 
PN 
Yes NS Unclear No formal 
adjustment, 
considerati
on given in 
interpretati
on 
Nishina (2013) Oxaliplatin GSTP1 Ile105Val, 
ERCC1 (C118T, 
C8092A), XPD 
(Asp312Asn, Lys 
751Gln) 
Japan Japanese Uniform No CRC NCI CTC Development 
of any grade 
and 3-4 
68 (65 any 
grade, 11 
grade 3-4) 
Uniform No No Yes NS Evident in 
results 
(dominant) 
No 
Oguri (2013) Oxaliplatin GSTP1 (Ile105Val), 
ERCC1 (C118T, 
C8092A), 9 SNPs in 
TAC1, FOXC1, ITGA1, 
ACYP2, DLEU7, BTG4, 
CAMK2N1, FARS2  
Japan Japanese Uniform No CRC NCI CTC Development 
of grade 2 
lasting >7 days 
or grade 3-4 
and time to 
development of 
grade 1 
70 (22 grade 
2 > 7 days or 
grade 3-4)) 
Uniform No Excluded all 
pre-existing 
PN 
Yes NS Evident in 
results 
(dominant) 
No 
Pare (2008) Oxaliplatin  ERCC1 (C118T, 
G19716C, C8092A), 
XPD Lys751Gln, 
GSTP! Ile105Val, XPD 
(Arg194Trp, 
Arg280His, 
Arg399Gln) 
Spain NS NS No CRC Oxaliplatin 
specific scale 
Development 
of grade 2-3 
126 (71) Uniform No No NS Yes Evident in 
results 
(dominant) 
No 
Ruzzo (2007) Oxaliplatin GSTP1 Ile105Val, 
GSTM1, GSTT1, 
ERCC1 C118T, XPD 
(Arg399Gln, 
Asp312Asn), XRCC3 
Thr241Met, MTHFR 
(C677T, A1298C), TS 
(VNTR and SNP and 
6bp ins/del) 
Italy NS NS No CRC Specific 
neurotoxicit
y scale 
Development 
of grade 3 
166 (17) Uniform No No Yes NS Unclear No 
Ruzzo (2014) Oxaliplatin GSTP1 (Ile105Val), 
GSTM1, GSTT1, 
ERCC1 C118T, XPD 
(Lys751Gln, 
Asp312Asn), XRCC3 
(Thr241Met), ABCC1 
Italy NS NS No CRC NCI CTC Development 
of grade 2-4 
neuropathy 
517 (132) Mixed No No Yes No Yes: 
dominant, 
recessive 
and additive 
No 
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(rs2074087), ABCC2 
(rs3740066, 
rs1885301, 
rs4148386), MTHFR 
(C677T, A1298C), TS 
(VNTR and SNP and 
6bp ins/del) 
Seo (2009) Oxaliplatin  GSTP1 Ile105Val, 
GSTM1, GSTT1, 
ERCC1 (C118T, 
C8092A), TS-UTR, 
multiple UGT1A1 
SNPs. 
Korea NS NS No Upper GI NCI CTC Development 
of grade 3-4 
75 (12) Uniform No No Yes NS Evident in 
results 
(dominant) 
No 
Terrazzino 
(2015) 
Oxaliplatin Rs10486003, rs2338, 
rs843748, rs797519, 
rs4936453, 
rs12023000, 
rs17140129, 
rs6924717 
Italy Caucasian Uniform No CRC NCI CTC and 
TNSc 
Development 
of grade 2-4 
chronic 
neuropathy 
150 ( 71) Mixed No Pre-existing 
neuropathy 
excluded 
Yes Yes Yes (log 
additive and 
dominant) 
Yes 
Won (2011) Oxaliplatin GWAS Korea ‘homogen
ous’ 
Uniform No CRC NCI CTC Development 
of grade 2 for 
>7 days or 
grade 3 
Exploratory 
96 (39); 
validation 
247 (85)  
NS Yes Excluded all 
pre-existing 
PN 
Yes Yes Unclear Yes 
Zarate (2010) Oxaliplatin GSTM1, GSTT1, 
ERCC1 C118T, 
UGT1A1 promoter 
region 
polymorphism, TYMs 
28bp repeats 
Spain NS NS No CRC NCI CTC Development 
of grade 2-3 
60 Uniform No No Yes Yes Unclear No 
Table 3.5. Included cisplatin- based studies for systematic review of pharmacogenetics of CIPN 
First author 
(Year) 
Index 
drug(s) 
SNPs investigated  
(those underlined 
highlight statistically 
significant  
associations) 
Country Ethnicity Ethnicity 
uniform, 
mixed-
adjusted for 
or mixed 
Test for 
population 
substructure 
Primary 
tumour 
Assessment 
tool for CIPN 
CIPN endpoints 
investigated 
Sample size 
(number of 
‘cases’ 
according to 
the authors 
definition) 
Schedule/ 
dose 
uniform, 
adjusted for 
or mixed 
Minimum 
dose for 
controls 
Potential 
clinical 
confounders 
accounted 
for 
HWE 
checked 
Genotype 
QC 
measures 
described 
Mode of 
inheritance 
used in 
analysis 
stated 
Multiple 
testing 
adjustment 
Alberola (2004) Cisplatin MTHFR C677T Spain NS NS No Lung WHO score Development 
of grade 3-4 
neuropathy 
208 (8) Uniform Yes No NS NS Unclear Single SNP 
Fung (2012) Cisplatin 90 SNPs in GSTP1, 
COMT, TPMT 
Italy Mixed 
(White, 
Asian, 
Other) 
Mixed 
adjusted 
No Testicular Michigan 
neuropathy 
screening 
instrument 
MNSI score >1 66 (25) Adjusted No but 
cum dose 
adjusted 
for 
No Yes ‘previousl
y 
reported’ 
Different 
modes 
reported 
Yes 
Goekkhurt 
(2009) 
Cisplatin GSTP1 Ile105Val, 
GSTM1, GSTT1, 
ERCC1 (C118T, 
C8092A), XPD 
(Lys751Gln, 
Asp312Asn), XRCC1 
Arg399Gln, XPA 
A23G, TS (1494del6, 
VNTR 28bp repeat, 
VNTR +G/C SNP), 
MTHFR (C677T, 
A1298C), MTR 
Germany 
and 
Switzerla
nd 
NS NS No Upper GI NCI CTC Development 
of grade 3-4 
Cisplatin 
arm: 63  
(12-15) 
Adjusted 
and cisplatin 
and 
oxaliplatin 
groups 
analysed 
separately 
No Excluded 
those with 
PN> grade 1 
NS NS Unclear No 
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A2756G, OPRT 
Gly213Ala 
Khrunin (2009) Cisplatin GSTP1 (Ile105Val, 
Ala114Val), GSTM1, 
GSTT1, GSTA1 
(rs3957357), GSTM3 
(rs1799735, rs7483), 
ERCC1 (C118T, 
rs3212986), XPD 
(Asp312Asn, 
Lys751Gln), XRCC1 
(arg194Trp, 
Arg280His, 
Arg399Gln), TP53 
(rs17878362, 
rs1042522, 
rs1625895), CYP2E1 
(96bp ins, rs2031920, 
rs6413432, 
rs2070676)  
Russia Eastern 
Slavonic 
Uniform No Ovarian NCI CTC Development 
of grade 2-3 
95 (31) Uniform No Diabetes 
excluded 
Yes NS Unclear Yes 
Xu (2012) Cisplatin 20 SNPs in CTR1 gene China Han 
Chinese 
Uniform No Lung NCI CTC  Development 
of grade 1-3 
204 (126) Uniform 
cisplatin 
different 
concurrent 
drug (some 
neurotoxic) 
 
Yes No Yes NS Evident in 
results 
(dominant) 
Yes 
 
Table 3.6. Included taxane studies for systematic review of pharmacogenetics of CIPN 
First author 
(Year) 
Index 
drug(s) 
SNPs investigated  
(those underlined 
highlight statistically 
significant  
associations) 
Country Ethnicity Ethnicity 
uniform, 
mixed-
adjusted for 
or mixed 
Test for 
population 
substructure 
Primary 
tumour 
Assessment 
tool for CIPN 
CIPN endpoints 
investigated 
Sample size 
(number of 
‘cases’ 
according to 
the authors 
definition) 
Schedule/ 
dose 
uniform, 
adjusted for 
or mixed 
Minimum 
dose for 
controls 
Potential 
clinical 
confounders 
accounted 
for 
HWE 
checked 
Genotype 
QC 
measures 
described 
Mode of 
inheritance 
used in 
analysis 
stated 
Multiple 
testing 
adjustment 
Docetaxel studies 
Eckhoff (2015) Docetaxel GSTP1 (Ile 105Val, 
Ala114Val), 
ABCB1 (G2677T, 
C1236T, C3435T), 
TUBB2A (rs909964, 
rs909965, rs9501929, 
rs3734492, rs 
13219681), NAT2 
(rs1799931), ERCC1 
(rs3212986), APT7A 
(rs2227291), CYP3A5 
(*3), CYP3A4*1B, 
CHST3 (rs4148950, 
rs1871450), SLCO1B3 
(rs11045585), 
SLC10A2 (rs2301159) 
  
Denmark Western 
European 
Uniform No Breast NCI CTC Development 
of grade 2-4  
150 (75) Adjusted Minimum 
one dose 
only 
Excluded 
pre-existing 
PN and 
accounted 
for DM and 
alcohol 
Yes Yes Evident  in 
results 
No 
Marsh (2007) Docetaxel 
(with 
carboplatin)  
27 SNPs in 16 genes 
including ABCB1, 
ABCC 1and 2, ABCG2, 
UK NS NS No Ovarian NCI CTC Development 
of grade 2-4 
266-296 in 
discovery 
set (57) 
Uniform, 
paclitaxel 
and 
No Excluded 
those with 
PN> grade 1 
Yes NS Unclear Yes 
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CYP1B1, CYP2C8, 
CYP3A4, CYP3A5, 
ERCC1, XPD, GSTP1 
and XRCC1 
docetaxel 
cohorts 
analysed 
separately 
Mir (2009) Docetaxel GSTP1 (Ile105Val and 
Ala114Val), GSTM1, 
GSTT1 
France NS NS No Breast, 
lung, 
prostate 
and other 
NCI CTC Development 
of grade 2-4 
58 (10) Uniform No 
 
No NS Yes Evident in 
results 
(dominant) 
No 
Sissung (2008) Docetaxel ABCB1 C1236T, 
G2677T/A, C3435T 
USA NS NS No Prostate NCI CTC Probability of 
development 
CIPN during 
docetaxel 
therapy as a 
function of time 
23 (NS) Uniform Uses time 
in 
outcome 
No Yes NS Unclear No 
Paclitaxel studies 
Abraham 
(2014) 
Paclitaxel GWAS (selected SNPs 
published incl 
rs3213619, 
rs2032582, 
rs1045642 (ABCB1), 
rs9501929 (TUBB2A), 
CYP2C8*4, rs8187710 
and rs17222723 
(ABCC2), CYP1B1*3, 
rs 301927 (EPHA6), 
rs3829306 (SLCO1B1 
UK European Uniform Yes Breast NCI CTC Development 
of grade 2-4 
neuropathy 
Cumulative 
dose at grade2 
1335 (360) Uniform Dose 
used in 
outcome 
No Yes Yes Unclear Yes 
Apellaniz-Ruiz 
(2015) 
Paclitaxel Whole exome 
sequencing CYP3A4 
Spain NS NS No Breast 
and ovary 
NCI CTC NCI grade, 
development of 
grade 3 
neuropathy, 
treatment 
modifications 
due to 
neuropathy 
236 Mixed 
regimens 
Cumulativ
e dose 
adjusted 
for 
Pre-existing 
PN excluded 
and effect of 
DM and 
alcohol 
examined 
No  Yes  Yes No 
Baldwin (2012) 
 
Exploratory 
cohort 
 
European 
replication set 
 
African 
American  
Paclitaxel GWAS USA Mixed  Analysed in 
ethnically 
uniform 
cohorts 
Yes Breast NCI CTC Cumulative 
dose at grade 2  
Maximum 
observed grade 
of neuropathy 
 
855 (206) 
 
 
 
 154 (21) 
 
 
 
 117 (33) 
Uniform Dose 
used in 
outcome 
No NS GWAS Evident in 
results (uses 
a mixture of 
additive, 
dominant 
and 
recessive) 
Yes 
Bergmann 
(2012) 
Paclitaxel CYP2C8 (*3, 
rs1058930, 
rs7909236, 
rs17110453), 
CYP3A4*1B, SLCOB3 
(rs 60140950, 
rs7311358), ABCB1 
(C1236T, G2677T/A, 
C3435T, rs9282564, 
rs2229109, 
rs2214102), CYP1B1 
(rs1056836), CYP3A5 
rs776746, ABCC1 Rs 
504348, ABCC10 
Denmark 
and 
Sweden 
Scandana
vian 
Uniform No Ovarian NCI CTC Time to 
increase of NCI 
CTC grading to 
2 points above 
baseline NS 
92(75 any 
grade, 17 
grade 3) 
Uniform No.  
Time 
used in 
outcome 
No Yes NS Yes 
(additive) 
No 
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rs2125739, ABCC2 (rs 
17222723, 
rs8187710, 
rs2273697), ABCG2 
(rs2231142, 
rs2231137) 
Bergmann 
(2011) 
Paclitaxel CYP2C8*3, ABCB1 
(C1236T, G2677T/A, 
C3435T), and 
exploratory analysis 
in SNPs in CYP3A5, 
ABCC1, ABCC2, 
ABCG2, ABCC10, 
CYP1B1 and SLCOB3. 
Denmark 
and 
Sweden 
Scandana
vian 
Uniform No Ovarian NCI CTC Time to 
increase of NCI 
CTC grading to 
2 points above 
baseline 
119 (81 any 
grade, 3 
grade 3) 
Uniform No.  
Time 
used in 
outcome 
Excluded pts 
with PN> 
grade 2 
Yes NS Yes 
(additive) 
No 
Bergmann 
(2012) 
Paclitaxel GWAS Scandan-
avian 
cohorts 
Caucasian Uniform No Ovarian NS  Development 
of grade 2-4 
and time to 
neuropathy  
239 (65) Uniform No.  
One 
outcome 
used time 
to event 
analysis 
No Yes NS Evident in 
results 
(recessive) 
No 
Beutler (2014) Paclitaxel 49 Charcot Marie 
Tooth genes 
examined 
USA Mixed Mixed No Breast, 
ovarian, 
lung, 
H&N, 
uterine 
and 
‘other’ 
Rate of 
change in 
EORTC 
CIPN20 
Rapid increase 
in CIPN20 score 
versus slow 
progression of 
CIPN20 scores 
119 (73) Mixed 
regimens 
Minimum 
no. of 
questionn
aires but 
small 
Pre-existing 
neuropathy 
excluded 
and diabetes 
status 
recorded 
Yes Yes Unclear 
(evidently 
dominant 
from 
validation 
paper) 
Yes 
Boora (2015) Paclitaxel/ 
carboplatin 
ARHGEF10 
(rs9567362, 
rs2294039, 
rs17683288) 
USA Mixed Mixed No Ovarian, 
lung, 
uterinel, 
breast, 
H&N 
Rate of 
change in 
EORTC 
CIPN20 
scores 
Rapid increase 
in CIPN20 score 
versus slow 
progression of 
CIPN20 scores 
75 (47) Small 
variability in 
paclitaxel 
dose, 
uniform 
schedule 
Minimum 
no. of 
questionn
aires 
thereby 
at least 3 
cycles 
Excluded 
pre-existing 
neuropathy 
Yes No but 
QC in 
place 
Dominant No 
Boso (2014) Paclitaxel ABCB1 (C3435T, 
C1236T, G2677A/T), 
ABCC2 (rs17222723, 
rs2804402, 
rs3740066, 
rs8187710), 
ABCG2(rs2622604) 
CYP1B1*3, CYP2C8 
(*2, *3, *4, HapC, 
rs1341164, 
rs1934951), CYP3A4 
(*1B, *16), CYP3A5 
(rs776746), ERCC1 
(Asn118Asn, 
Gln504Lys), ERCC2 
(Lys751Gln, 
Asp288Asn), GSTM3 
(rs1799735), GSTP1 
(Ala114Val, 
Ile105Val, 
rs8191439), XRCC1 
(Gln399Arg, XPC 
(Gln902Lys), MTHFR 
(Glu429Ala, 
Spain Caucasian  Uniform No Breast NCI CTC Development 
of grade 2-4 
neuropathy 
43 (13) Uniform No No Yes Yes Dominant No but 
lower p 
value to 
reflect 
exploratory 
nature 
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Ala222Val), Also 
SNPs in  RRM1, 
NOS3, NQO1, SOD2, 
TP53 UGT1A1 
(rs10929302, 
rs4124874, 
rs4148323), UGT1A9 
(rs7586110, 
rs17868323),  and 
CBR3  
Chang (2009) Paclitaxel ABCB1 (G2677T/A, 
C3435T) 
Korea NS NS No Breast NCI CTC  Development 
of grade 3-4 
108   (12) Uniform No Excluded 
pre-existing 
PN > grade 1 
NS NS Unclear No 
de Graan 
(2013) 
Paclitaxel CYP3A4*22, 
CYP2C8*3, 
CYP2C8*4, ABCB1 
C3435T 
Netherlan
ds 
Mixed  NS No Breast, 
ovarian, 
UGI, lung, 
H&N, CUP 
NCI CTC Development 
of any grade, 
severity and 
grade 3 
Exploratory 
261 (2 grade 
3; 20 grade 
2 or greater; 
106 any 
grade); 
validation  
239 (113 any 
grade) 
Adjusted Time 
used in 
outcome 
No Yes NS For 
CYP3A4*22  
evident in 
results 
(dominant) 
No 
Green 2008 Paclitaxel CYP2C8 (*1B, *1C, 
*2, *3, *4, *5, *6, *7, 
*8 and P404A), 
ABCB1 (G2677T/A 
and C3435T), 
CYP3A4*1B 
Sweden Caucasian Uniform No Ovarian NCI CTC Development 
of grade 1-2 
33 (NS) Mixed dose 
not schedule 
Yes No Yes NS No 
assumption 
for CYP3A5, 
dominant 
for CYP2C8  
No 
Green 2011 Paclitaxel CYP2C8-HapC, 
CYP3A5*3 
Sweden Caucasian Uniform No Ovarian Neurotoxicit
y scale (N 
score) 
?any grade- not 
clear 
33 (12) Mixed dose 
not schedule 
Yes No NS NS Unclear No 
Hasmats (2012) Paclitaxel Initially 123 SNPs in 
candidate toxicity 
genes with 11 finally 
selected 
Spain and 
Sweden-  
NS NS No Breast, 
ovarian, 
lung, CUP 
NCI CTC Cumulative 
dose at grade 2 
neuropathy 
94 (NS) Mixed Cum. 
dose used 
in 
outcome 
No NS Yes Unclear No 
Hertz (2012) Paclitaxel CYP1B1*3, 
CYP2C8*3, CYP3A4 
*1B, CYP3A5*3C, 
ABCB1*2 
USA White 
and 
African 
American 
and other 
Mixed 
adjusted 
No Breast NCI CTC Development 
of grade 3-4 
109 (12) Mixed  No No Yes Yes Yes Yes 
Hertz (2013) Paclitaxel CYP2C8*3 USA White 
and 
African 
American 
Analysed in 
ethnically 
uniform 
cohorts 
No 
 
Breast NCI CTC Cumulative 
dose at grade 2 
neuropathy 
411 in three 
sets; A 
European 
American 
set 209 pts; 
An African 
American 
set 107 pts 
and a 
combined 
mixed race 
group total 
411 (76 ) 
Mixed No. 
Cumulativ
e dose 
used in 
outcome 
No Yes NS Yes Single 
outcome 
Hertz (2014) Paclitaxel CYP2C8 *2 and *4 
plus 1275 SNPs 
including rs492338 in 
USA White 
and ‘Non-
Caucasian 
Analysed in 
a uniform 
caucasian 
and a mixed 
Yes Breast NCI CTC Development 
of grade 2-4 
neuropathy and 
cumulative 
288 (49) in 
Caucasian 
cohort and 
124 (28)  in 
Mixed No. 
Cumulativ
e dose 
No Yes Yes Yes 
(dominant 
for CYP2C8 
variants, no 
Yes 
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ABCG2 (significant in 
Caucasian cohort) 
‘non-
caucasian’ 
cohort 
dose at grade 2 
neuropathy 
non-
Caucasian 
cohort 
used in 
outcome 
assumption 
evident for 
the 
remainder) 
Hu (2016) Paclitaxel 
with 
carboplatin 
CYP3A5*3 China Chinese Uniform No Ovarian NCI CTC Not pre-stated. 
From results 
development of 
any grade 
neuropathy 
75 (30) Uniform Yes No No No NA (only 2 
genotypes in 
cohort) 
No (single 
SNP) 
Kulkarni (2014) Paclitaxel RWDD3 (rs2296308) 
and TECTA (rs1829) 
USA Mixed mixed No Breast, 
ovarian, 
lung, 
H&N, 
others 
Rate of 
change of 
EORTC 
CIPN20 
score 
Rapid change in 
CIPN20 score 
versus slow 
progression of 
CIPN20 score 
119 (73) Mixed Minimum 
no. of 
questionn
aires but 
small 
Pre-existing 
neuropathy 
excluded 
Yes Yes Dominant 
and additive 
No 
Lambrechts Paclitaxel/ 
carboplatin 
26 SNPs in 18 genes 
ABCB1 (C1236T, 
C3435T, G1199A), 
ABCC1(rs2230671, 
rs2074087), ABCC2 
(rs2073337, 
rs12762549), ABCG2 
(rs2231142), ABCA1 
(rs363717), SCLO1B3 
(rs4149117, 
rs11045585), CYP1B1 
(rs1056836), CYP3A4 
(rs2740574), CYP3A5 
(rs776746), TP53 
(rs1042522), MAPT 
(rs11568305), GSTP1 
(Ilw105Val, 
Ala114Ala), ERCC1 
(rs11615, 
rs3212961), ERCC2 
(Asp312Asn), 
SLC12A6 
(rs7164902), 
SERPINB2 (rs6104), 
PPARD (rs2076169), 
ICAM1 (rs1799969) 
Belgium 
and 
luxembur
g 
Mixed Mixed No Ovarian NCI CTC Appears to be 
any grade but 
not clearly 
specified 
265 (48 
grade 2-3) 
Unclear Yes Pre-existing 
neuropathy 
excluded 
Yes Yes Additive Yes 
Leandro- Garcia 
(2013) 
Paclitaxel GWAS  Spain and 
Sweden 
Caucasian Uniform No Breast, 
ovarian, 
lung 
NCI CTC Cumulative 
dose at grade 2 
neuropathy 
144 (69) Uniform Dose 
used in 
outcome 
Excluded 
pre-existing 
PN 
Yes Yes Yes 
(additive) 
Yes 
Lee (2014) Paclitaxel ABCB1 (G2677T/A, 
C3435T, rs1128503), 
CYP1B1 (rs1056836), 
CYP2C8*5, 
CYP3A4*18, 
CYP3A5*3 and a 
group of SNPs 
selected for putative 
gemcitabine effects 
(including RRM1) 
Korea Korean Uniform No Breast NS Appears to be 
any grade but 
not specifically 
stated 
85 (NS) Uniform NS No NS Yes Evident in 
results 
(dominant) 
Yes 
Marsh (2007) paclitaxel 
(with 
carboplatin) 
27 SNPs in 16 genes 
including ABCB1, 
ABCC 1and 2, ABCG2, 
CYP1B1, CYP2C8, 
CYP3A4, CYP3A5, 
UK NS NS No Ovarian NCI CTC Development 
of grade 2-4 
Paclitaxel 
266-296 in 
discovery 
set (147) 
Uniform, 
paclitaxel 
and 
docetaxel 
No Excluded 
those with 
PN> grade 1 
Yes NS Unclear Yes 
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ERCC1, XPD, GSTP1 
and XRCC1 
analysed 
separately 
Ofverholm 
(2010) 
Paclitaxel CYP2C8*3, 
CYP3A4*1b, ABCB1 
(G2667T/A, C3435T) 
Sweden NS NS No Breast 
and 
ovarian 
NCI CTC All patients 
recruited as 
they had grade 
1-2 neuropathy 
36 Mixed Controls 
did not 
receive 
paclitaxel 
Cases 
selected 
when they 
developed 
PN 
Yes NS Unclear No 
Park (2014) Paclitaxel GSH3  (rs6438552), 
MAPT (haplotype 1, 
rs242557) 
Australia NS NS No Mixed 
(mainly 
breast) 
NCI CTC and 
NCS 
Development 
of grade 2/3 
neuropathy and 
NCS outcomes 
21 (7) Mixed No Excluded all 
pre-exicting 
PN and 
causative 
conditions 
for PN 
NS NS NS No 
Sissung (2006) Paclitaxel ABCB1 G2677T and 
C3435T 
Germany NS NS No Solid 
tumours 
PNP score Development 
of any 
neuropathy 
22 (NS) Mixed 
(duration of 
infusion only 
variable) 
Uses time 
in 
outcome 
PNP score 
>3 prior to 
therapy 
excluded 
NS NS Unclear No 
Sucheston 
(2011) 
Paclitaxel 20 and 9 SNPs in 
FANCD2 and 17 and 
12 SNPs in BRCA1  
USA Mixed  Mixed 
adjusted 
Yes Breast NCI CTC Development 
of grade 3-4 
888 (107) Mixed No No Yes Yes Yes (Additive 
and 
dominant 
depending 
of MAF) 
Yes 
Combined taxane cohorts (paclitaxel and docetaxel analysed together) 
Kim (2009) Paclitaxel 
and 
docetaxel 
with 
paclitaxel or 
carboplatin 
GSTP1 Ile105Val, 
GSTM1, GSTT1, 
ERCC1 (C118T, 
C8092A), XPD 
Lys751Gln, XRCC1 
(Arg399Gln, 
Arg194Trp), ABCB1 
(C3435T, G2677T/A) 
Korea Korean Uniform No Ovarian NCI CTC Development 
of grade 3-4 
118 (18) Mixed No No NS NS Evident in 
results (at 
least some 
appear 
dominant) 
No 
McWhinney- 
Glass (2013) 
Paclitaxel 
and 
docetaxel 
(with 
carboplatin) 
1261 SNPs in 60 
genes incl SOX10, 
BCL2, OPRM1, TRPV1 
UK NS NS Yes Ovarian NCI CTC Development 
of grade 2-4 
Exploratory 
404 (91); 
validation 
404 (91) 
Adjusted Yes Excluded all 
pre-existing 
PN 
 NS Yes Yes 
Rizzo (2010) Taxanes CYP2C8 (*1, *2, *3 
and *4), CYP1B1 (*1 
and *3), ABCB! 
(C1236T, G2677T/A, 
C3435T) 
Italy Caucasian Uniform No Breast NCI CTC Development 
of any 
neuropathy  
86 (7) Mixed No No Yes NS Unclear Yes 
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Table 3.7. Included vincristine-based studies for systematic review of pharmacogenetics of CIPN 
First author 
(Year) 
Index 
drug(s) 
SNPs investigated  
(those underlined 
highlight statistically 
significant  
associations) 
Country Ethnicity Ethnicity 
uniform, 
mixed-
adjusted for 
or mixed 
Test for 
population 
substructure 
Primary 
tumour 
Assessment 
tool for CIPN 
CIPN endpoints 
investigated 
Sample size 
(number of 
‘cases’ 
according to 
the authors 
definition) 
Schedule/ 
dose 
uniform, 
adjusted for 
or mixed 
Minimum 
dose for 
controls 
Potential 
clinical 
confounders 
accounted 
for 
HWE 
checked 
Genotype 
QC 
measures 
described 
Mode of 
inheritance 
used in 
analysis 
stated 
Multiple 
testing 
adjustment 
Aplenc (2003) Vincristine CYP3A4*1B, CYP3A5 
(*3 and *6) 
Mainly 
USA 
Mixed 
(White, 
African 
American 
and 
Other) 
Mixed No ALL CCG criteria Development 
of grade 3-4 
neuropathy 
533 (27/28) NS No (but 
ALL study 
so early 
stopping 
less likely) 
No Yes NS Yes 
(dominant) 
Yes 
Broyl (2010) Vincristine 3404 SNPs  incl 
multiple SNPs found 
to be associated 
Netherlan
ds, 
Germany 
and 
Belgium 
NS NS No Myeloma NCI CTC Development 
of grade 2-4 
neuropathy 
183 (11 
early onset, 
17 late 
onset) 
Uniform Yes Excluded 
those with 
>2 PN 
NS NS Unclear Yes 
Cho (2010) Vincristine GSTP1 Ile105Val, 
GSTT1, GSTM1 
Korea Korean Uniform No DLBCL NCI CTC Development 
grade 3-4 
94 (2) Uniform No No Yes NS Evident from 
results 
(dominant) 
No 
Diouf (2015) Vincristine GWAS USA Mixed Mixed Yes ALL NCI CTC (or 
a similar 
modified 
version) 
Development 
of grade 2-4 
neuropathy 
222 (64) in 
one cohort 
99(22) in a 
second 
Adjusted Yes NS NS Yes NS, 
evidently 
recessive for 
the 
significant 
SNP 
Yes 
Egbelakin 
(2011) 
Vincristine CYP3A5 *3, *6, *7 USA Mixed  NS No ALL NCI CTC looks at a 
number of 
different 
outcomes * 
107 (105 any 
grade, 57 
grade 3) 
Uniform Time used 
in 
outcome 
Excluded 
those with 
PN> grade 1 
NS NS Yes 
(recessive) 
No 
Guilhaumou 
(2011) 
Vincristine CYP3A4, CYP3A5, 
ABCB1 (SNPs not 
specified) 
France Caucasian Uniform No Paediatric 
solid 
tumours 
Global 
toxicity 
score  
Global toxicity 
score greater or 
equal to 3 
24 (8) Uniform No No NS NS Unclear No 
Gutierrez- 
Camino (2016) 
Vincristine CEP72 (rs924607) Spain Spanish 
of 
European 
backgrou
nd 
Uniform No ALL NCI CTC Development 
of grade 2-4 
neuropathy 
during 
induction phase 
142 (36) Uniform Yes No NS NS Yes. 
Recessive 
Single 
outcome 
Kim (2008) vincristine 
1.4mg/m2 
max 2mg 
ABCG2 Q141K, V12M Korea Korean Uniform No DLBCL NCI CTC Development 
of any grade 
and grade 3-4  
145 (6 grade 
3-4) 
Uniform No No Yes NS Evident in 
results 
(dominant) 
No 
Kishi (2007) Vincristine CYP3A5*3, 
CYP3A4*1B, GSTP1 
Ile105Val, GSTM1, 
GSTT1, ABCB1 
(G2677T/A, C3435T), 
MTHFR (C677T, 
A1298C), NR3C1 
A1088G, SLC1 9A1 
80A>G, TPMT 
(G238C, G460A, 
A719G), TYMS 
enhancer repeat, 
UGT1A1 promoter 
USA Mixed  Mixed 
adjusted 
Yes ALL NCI CTC Development 
of grade 2-4 
233 (44)  No No Yes NS Evident in 
results 
(mixed) 
Yes 
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repeat, VDR intron 
8G>A and Fok1 
Moore (2011) vincristine  CYP3A5*3 and *6 Australia Mixed 
(White 
90%, 
Pacific 
Islander, 
Aborigina
l, Asian) 
NS No Leukaemi
a, 
lymphom
a, CNS 
and other 
NCI CTC Development 
of grade 3-4 
43 (6) Uniform  No Yes NS Unclear No 
Sepe (2012) Vincristine GSTP1 Ile105Val, 
GSTM1, GSTT1, 
MTHFR C677T, TS 
28bp ins, UGT1A1 TA 
ins, TMPT (416 and 
719) plus unspecified 
SNPs in CYP3A4 and 
CYP 3A5 
USA Mixed 
(White, 
Black 
NOS, 
Asian, 
Hispanic, 
Other) 
Mixed 
adjusted 
No ALL CCG toxicity 
grading 
Development 
of any 
neuropathy 
557 (23) Uniform No (but 
ALL and 
unlikely to 
be much 
variation) 
No Yes Yes Unclear Yes 
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Table 3.8. Included miscellaneous studies for systematic review of pharmacogenetics of CIPN 
First author 
(Year) 
Index 
drug(s) 
SNPs investigated  
(those underlined 
highlight statistically 
significant 
associations) 
Country Ethnicity Ethnicity 
uniform, 
mixed-
adjusted for 
or mixed 
Test for 
population 
substructure 
Primary 
tumour 
Assessment 
tool for CIPN 
CIPN endpoints 
investigated 
Sample size 
(number of 
‘cases’ 
according to 
the authors 
definition) 
Schedule/ 
dose 
uniform, 
adjusted for 
or mixed 
Minimum 
dose for 
controls 
Potential 
clinical 
confounders 
accounted 
for 
HWE 
checked 
Genotype 
QC 
measures 
described 
Mode of 
inheritance 
used in 
analysis 
stated 
Multiple 
testing 
adjustment 
Single drugs only studied by one group 
Ekhart (2008) Carboplatin CYP2B6 (C64T, 
C1459T, A785G, 
G516T), CYP2C9 
(*2,*3), CYP2C19*2, 
CYP3A4 (*1B, *3), 
CYP3A5 (*2, *3), 
GSTA (C-69T, G-52A), 
GSTP1 (Ile105Val, 
Ala114Val), 
ALH1A1*2, 
ALDH3A1*2 
Netherlan
ds 
Caucasian Uniform No Breast, 
ovarian 
and germ 
cell 
NCI CTC Development 
of grade 2-3 
113 (8) Adjusted No No NS NS Unclear No 
Fountzilas 
(2013) 
Ixabepilone ABCB1 (C2677T, 
C1236T, C3435T), 
CYP3A4*16, CYP2C8 
rs1152080 
Greece NS NS No Breast NS NS 64 (12 grade 
3, 48 any 
grade) 
NS No Excluded 
those with 
PN> grade 1 
NS NS Unclear No 
Mixed cohorts of differentially neurotoxic platinums 
Brouwers 
(2009) 
Oxaliplatin 
or cisplatin  
GSTP1 (Ile105Val), 
GSTM1, GSTT1 
Netherlan
ds 
NS NS No CRCl, 
lung, 
testicular, 
yolk sac 
and H&N 
Questionnai
re, 
neurological 
and 
vibration 
tests 
vibration 
testing 
abnormalities 
45 (26) NS Yes No Yes NS Unclear No 
Joerger (2012) Cisplatin 
and 
carboplatin 
24 SNPs in 15 genes 
including ERCC1, 
GSTP1, GSTM1, 
RRM1, XRCC1, 
XRCC3, XPD10, 
XPD23, REQ1, CDK, 
SLC28A1/2, RAD54L, 
DCK. 
Netherlan
ds 
Mixed  
(White 
95%, 
Black, 
Asian, 
Other) 
Mixed No Lung NCI CTC Development 
of ‘severe PNP' 
(not defined) 
137 (7) Mixed No No NS NS Unclear No 
Xu (2012) Cisplatin OR 
Carboplatin 
22 SNPs in eIF3  China Han 
Chinese 
Uniform No Lung NCI CTC  Development 
of grade 2-3 
282 (111) Uniform 
cisplatin but 
different 
concurrent 
drug (some 
neurotoxic) 
No Diabetes 
excluded 
NS NS Unclear Yes 
Mixed study cohorts with more than one high-risk neurotoxic drug 
Fung (2012) Cisplatin but 
some 
patients 
received 
concuurent 
vinblastine 
90 SNPs in GSTP1, 
COMT, TPMT 
Italy Mixed 
(White, 
Asian, 
Other) 
Mixed 
adjusted 
No Testicular Michigan 
neuropathy 
screening 
instrument 
 
 
MNSI score >1 66 (25) Adjusted No but 
cum dose 
adjusted 
for 
No Yes ‘previousl
y 
reported’ 
Different 
modes 
reported 
Yes 
Isla (2004) Docetaxel 
AND 
cisplatin 
ABCB1 C3435T, 
ERCC1 C118T, XPD 
(Lys751Gln, 
Spain NS NS No Lung WHO Development 
of grade 2-4 
62 (26-39) Uniform No No Yes Yes Unclear No 
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Asp312Asn), RRM1 -
37C/A,  
Johnson (2015) Cisplatin Or 
carboplatin 
(some with 
paclitaxel) 
174 SNPs across 43 
genes including 
GSTP1 Val114Ala, 
ERCC1 Gln504Lys, 
ERCC2 (Lys751Gln, rs 
1799787, rs238415, 
rs50871)and SNPs in 
ABCC1, 2,3 and 
ABCC4, XRCC1, 
RRM1, MGMT,  
GPX2,3,5 and 6 and 
GPX7. APEX1, 
CD3EAP, CYP2C9, 
GCLC, GCLM, GSR, 
GSS, GSTA2,3,4 and 
5, GSTM2,4 and 5, 
GSTO 1 and 2, GSTZ1, 
MSH 2, 3 and 6, 
OGG1, RAD50,51,52 
and 54B, XPA, XPC. 
USA Caucasian Uniform No Lung NCI CTC Development 
of CIPN 
400 (141) Mixed No Excluded 
pre-existing 
PN and DM 
Yes Yes Additive Yes 
Lamba (2014) Cisplatin OR 
carboplatin 
(some with 
paclitaxel) 
57 SNPs: full list not 
available in paper 
USA Caucasian Uniform No NSCLC NCI CTC Appears to be 
development of 
grade 3-4 
neuropathy 
86 (5) Mixed Number 
of cycles 
adjusted 
for 
No Yes Yes Mulitple: 
dominant, 
co-dominant 
or additive 
Yes 
Leandro- Garcia 
( 2012) 
Paclitaxel 
with 
carboplatin 
or cisplatin 
TUBB2A -112 A>G, -
157A>G, -101T>C 
Sweden 
and Spain 
NS NS No breast, 
ovarian, 
lung, 
bladder, 
urinary 
tract, 
GCT, H&N 
NCI CTC Cumulative 
dose at grade 2 
neuropathy 
214 (107) NS Dose 
used in 
outcome 
No Yes Yes Evident in 
results 
(dominant) 
No 
Leskela (2010) Paclitaxel 
with 
carboplatin 
or cisplatin 
CYP2C8(*3, *4, HapC, 
*1B), CYP3A4*1B, 
CYP3A5*3, ABCB1 
(G2677T, C1236T, 
C3435T, rs9282564), 
SLCO1B1 rs4149056, 
SLCO1B3 (rs4149117, 
rs7311358)  
Spain Spanish NS No Breast, 
Ovarian, 
Lung, 
uterus, 
peritonea
l, H&N 
and GCT 
NCI CTC Cumulative 
dose at grade 2 
neuropathy 
118 (58) Adjusted Dose 
used in 
outcome 
Excluded 
pre-existing 
PN 
NS Yes Yes 
(additive) 
No 
Oldenburg 
(2007) 
Cisplatin 
although 
almost half 
also had 
vinblastine 
GSTP1 Ile105Val, 
GSTM1, GSTT1 
Norway Caucasian Uniform No Testicular Scale for 
Chemothera
py Induced 
Neurotoxicit
y (SCIN) 
3 categories 
based on SCIN 
score as 
categorical 
variables 
238 (116 any 
grade 
paraesthesia 
58 ‘quite a 
bit- very 
much’) 
Adjusted No but 
cumulativ
e dose 
adjusted 
for 
No NS NS Evident in 
results (at 
least one 
recessive) 
No 
Xu (2012) Cisplatin but 
some 
patients also 
received 
vindesine or 
docetaxel 
20 SNPs in CTR1 gene China Han 
Chinese 
Uniform No Lung NCI CTC  Development 
of grade 1-3 
204 (126) Uniform 
cisplatin 
different 
concurrent 
drug (some 
neurotoxic) 
 
Yes No Yes NS Evident in 
results 
(dominant) 
Yes 
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Glutathione S-transferases 
 
GSTP1 
 
The GSTP1 Ile105Val SNP (rs1695) was the most commonly studied variant with 44 
studies investigating a possible association with CIPN (82, 90, 94, 95, 98, 103, 215, 273, 
274, 279, 291, 292, 294, 295, 297-300, 302-304, 306-309, 311-314, 316, 319, 320, 324, 
325, 327, 329, 333, 338, 339, 341, 342, 344, 347, 348) Thirteen of these also examined 
the Ala114Val polymorphism in GSTP1 (90, 95, 103, 274, 294, 295, 297, 299, 304, 308, 
329, 333, 342). 
 
GSTP1 and platinums 
 
27 studies investigated a link with oxaliplatin- induced peripheral neuropathy. Of these, 
four reported a significantly reduced risk in those patients demonstrating the AA 
phenotype (Ile/Ile) (307, 319, 325, 327), whilst a further study demonstrated a trend 
towards this outcome (302). In keeping with this, two studies found a significantly 
increased risk of neuropathy (306) or of discontinuing FOLFOX chemotherapy due to 
neuropathy (300) with the GG (Val/Val) genotype. In contradiction to these results, 
however, three studies found a significantly increased risk of neuropathy with the AA  
genotype (95, 320, 329) with a fourth study showing a trend towards this result (316). A 
total of 16 studies of GSTP1 Ile105Val showed no significant difference in the risk of 
neuropathy with oxaliplatin (90, 94, 273, 279, 294, 297, 303, 304, 309, 311-314, 325, 
339, 348). Two studies including both oxaliplatin and cisplatin treated patients in a 
combined analysis showed an increased risk with the AA genotype (298) and no 
significant difference (215), respectively.  
 
For cisplatin alone, one study demonstrated a significantly reduced risk of neuropathy 
with the GG genotype (338), a second showed the opposite effect (98) and two showed 
no significant difference (308, 347). A single carboplatin study showed no evidence of 
effect (333). 
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For oxaliplatin and GSTP1 Ile105Val, enough data was presented to allow meta-analysis. 
Of the 27 studies, 11 had to be excluded due to insufficient results available (215, 273, 
294, 303, 304, 312-314, 325, 339, 348). Six studies (279, 298, 300, 309, 311, 327) could 
be included in association with development of NCI CTC grade 3-4 neuropathy, five 
studies were included for association with NCI CTC grade 2-4 neuropathy (90, 94, 297, 
307, 319). Of the studies that utilised the oxaliplatin-specific scale, four studies could be 
included in respect to development of grade 3-4 neuropathy (302, 306, 320, 352) and 
three with grade 2-4 neuropathy (302, 316, 320). Two studies presented data for 
development of any grade neuropathy (279, 320). Overall meta-analysis of included 
studies showed no evidence of significant association (figure 3.2). 
 
 
 
Figure 3.2. Forest plots demonstrating pooled odds ratios for included studies for 
association between GSTSP1 Ile105Val and oxaliplatin neuropathy a) NCI CTC grade 3-4 
b) NCI CTC grade 2-4 c) oxaliplatin specific scale grade 3-4 and d) oxaliplatin specific 
scale grade 2-4 and e) any grade 
a) 
b) 
c) 
d) 
e) 
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GSTP1 and taxanes 
Nine studies investigated GSTP1 Ile105Val and taxanes, but two of these involved the 
same population of patients (295, 299). Of these, one study showed an increased risk 
with the AA genotype (329) and in the other seven patient populations, no significant 
difference was seen (82, 103, 274, 295, 299, 341, 342, 344). One study reported an 
association between carrying a variant of rs1138272 (Ala114Val) and development of 
grade 2 or greater peripheral neuropathy with docetaxel in a cohort of breast cancer 
patients (OR 3.82, 95%CI 1.34-11.09) (103). Only one study (329) presented their full 
results, therefore meta-analysis was not possible. 
 
GSTP1 and vincristine 
Three studies investigated GSTP1 Ile105Val in vincristine-induced neuropathy but none 
demonstrated a significant association (291, 292, 324). Insufficient data was available to 
proceed to meta-analysis. 
GSTM1  
GSTM1 deletion and its impact on risk of neuropathy was investigated in 20 studies.  
GSTM1 and platinums 
Of 11 oxaliplatin studies (95, 297, 298, 300, 303, 304, 306, 309, 312, 319, 348), one 
reported  GSTM1 null subjects were more likely to develop >grade 2 CIPN (319). Four 
mixed platinum studies showed no effect of GSTM1 deletion (98, 215, 298, 338). One 
cisplatin study showed a protective effect of the GSTM1 null genotype (308) along with 
a reduced risk with certain GSTM3 genotypes.  
Sufficient data was presented in four oxaliplatin trials to include in the meta- analyses: 
two in association with development of NCI CTC grade 3-4 neuropathy (298, 309) and 
two in association with development of NCI CTC grade 2-4 (297, 319). No significant 
association was seen; OR 1.01 (95% CI 0.52-1.95, I2=17%) and OR1.79 (95% CI 0.62-5.23, 
I2=69%) for grade 3-4 and 2-4 neuropathy, respectively. 
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GSTM1 and taxanes 
Two taxane based studies (329, 341) demonstrated no significant effect of GSTM1 
deletion on risk of neuropathy. Insufficient data was presented to allow meta-analysis. 
 
GSTM1 and vincristine 
Three vincristine (291, 292, 324) studies demonstrated no effect of GSTM1 deletion. 
Insufficient data was presented to allow meta-analysis. 
 
 
 
 
(b)
 
 
Figure 3.3. Forest plot for association between GSTM1 deletion and development of (a) 
NCI CTC grade 3-4 neuropathy (b) NCI CTC grade 2-4 neuropathy with oxaliplatin 
 
(a) 
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GSTT1 
19 studies using oxaliplatin (95, 297, 303, 304, 306, 309, 312, 319, 339, 348), oxaliplatin 
or cisplatin (215, 298), cisplatin (308, 338), taxanes (329), and vincristine (42, 43, 92) 
showed no effect of GSTT1 deletion on risk of neuropathy. Seven of the nine oxaliplatin 
studies (94, 95, 297, 298, 307, 309, 319) were suitable for meta-analysis with no 
statistically significant pooled effect demonstrated (OR 0.74, 95% CI 0.25-2.17, I2=0% 
and OR 1.22, 95% CI 0.73-2.03, I2=0% for NCI CTC grade 3-4 and 2-4 neuropathy, 
respectively)  (figure 3.4). 
 
(a) 
 
(b)   
      
 
Figure 3.4. Forest plots for association between GSTT1 deletion and development of (a) 
NCI CTC grade 3-4 neuropathy and (b) NCI CTC grade 2-4 neuropathy with oxaliplatin 
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Excision Repair Cross Complementing (ERCC) genes   
  
29 studies examined an association with ERCC1. ERCC1 is implicated in platinum 
resistance and is therefore a biologically plausible target to examine with regard to 
platinum toxicity.           
 ERCC1  
Platinum 
One study demonstrated an association of the ERCC1 C118T SNP with time to 
development of grade 1 chronic oxaliplatin- induced neuropathy (94). The other 20 
studies investigated an association with oxaliplatin (94, 294, 297, 298, 300, 303, 304, 
306, 307, 309, 311-314, 319, 325, 327, 332, 339, 348) while three investigating cisplatin 
or carboplatin (98, 298, 308) showed no statistically significant association with 
neuropathy.  
Only six of the 20 oxaliplatin studies (297, 298, 300, 309, 319, 332) were eligible for 
inclusion in the meta-analysis, but no statistically significant association was shown (OR 
0.87, 95% CI 0.47-1.62, I2=0% and OR 1.22 0.77-1.95, I2= 0% for C118T and NCI CTC 
grade 3-4 and 2-4, respectively, and OR 2.33, 95% CI 0.91-5.95, I2= and OR 1.88, 95%CI 
0.78-4.52 for C809A and NCI CTC grade 3-4 and 2-4 neuropathy, respectively). 
Only six of the 20 oxaliplatin studies (297, 298, 300, 309, 319, 332) were eligible for 
inclusion in the meta-analysis, but no statistically significant association was shown (OR 
0.87, 95% CI 0.47-1.62, I2=0% and OR 1.22 0.77-1.95, I2= 0% for C118T and NCI CTC 
grade 3-4 and 2-4, respectively, and OR 2.33, 95% CI 0.91-5.95, I2= and OR 1.88, 95%CI 
0.78-4.52 for C809A and NCI CTC grade 3-4 and 2-4 neuropathy, respectively). 
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a) 
 
  
 
b) 
 
Figure 3.5. Forest plots for association of ERCC1 C118T and a) NCI CTC grade 3-4 
neuropathy and b) NCI CTC grade 2-4 neuropathy with oxaliplatin 
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(a) 
 
(b) 
 
 
Figure 3.6. Forest plot for association between ERCC1 C809A and development of (a) NCI 
CTC grade 3-4 neuropathy and (b) NCI CTC grade 2-4 with oxaliplatin 
Taxane/ taxane-platinum  
One study initially showed an increased risk of developing grade 3-4 neuropathy with 
taxane- platinum combination treatment with the CC genotype of ERCC1 C8092A on 
univariate analysis but significance was not maintained in a multivariate model (341). 
Three studies in two cohorts of taxane/platinum-treated patients  (295, 299, 342) and 
one docetaxel study (103) showed no evidence of association. One study in 43 breast 
cancer patients treated with weekly paclitaxel demonstrated a significant association 
with carrying at least one variant allele at rs3212986 (Gln504Lys) and development of 
grade 2-4 neuropathy (p 0.006)(344). These studies could not be combined in meta-
analysis due to insufficient data presented. 
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ERCC2 
Multiple SNPs in ERCC2 were examined across 25 studies (98, 294, 295, 297-300, 303, 
304, 306-308, 311-313, 317, 319, 325, 327, 331, 339, 341, 342, 344, 348) looking at 
platinum, platinum/taxane or taxane- treated patients. None showed an association 
with an increased risk of developing peripheral neuropathy either individually or in 
meta-analysis. A small number of oxaliplatin- based studies gave individual numbers 
involved and were able to be included in the meta-analysis (figures 3.7 and 3.8). 
 
 
 
 
 
 
Figure 3.7. Forest plots for association of ERCC2 Lys751Gln and development of (a) NCI 
CTC grade 3-4 neuropathy and (b) NCI CTC grade 2-4 neuropathy with oxaliplatin 
 
 
(a
) 
b) 
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Figure 3.8. Forest plot for association between ERCC2 C156A and development of NCI 
CTC grade 2-4 neuropathy with oxaliplatin  
 
X ray repair cross-complementing gene 1 (XRCC1) 
  
XRCC1  
 
Platinum 
One study reported a protective effect of the GG genotype of XRCC1 Arg399Gln against 
grade 2-4 neuropathy in a Korean population receiving oxaliplatin (348). All further 
studies demonstrated no effect of this SNP (98, 294, 295, 298-300, 303, 304, 306-308, 
312-314, 325, 332, 339, 341, 348) or others including Arg194Trp (295, 304, 307, 308, 
341), Arg280His (294, 304, 308, 348), rs3213239 (304), rs12611088 and rs3213255 
(294). Five of 13 oxaliplatin-based studies could be included in the meta-analysis for 
association with XRCC1 Arg399Gln (298, 300, 307, 332, 348). This did include the one 
study which reported a significant association, but overall no evidence of statistically 
significant association was seen (figure 3.9; OR 0.82, 95% CI 0.38-1.78, I2=21% and OR 
0.98, 95% CI 0.2-4.85, I2=69%, for NCI CTC grade 3-4 and 2-4, respectively). 
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Figure 3.9. Forest plots showing association between XRCC1 Arg399Gln and 
development of (a) NCI CTC grade 3-4 and (b) NCI CTC grade 2-4 neuropathy with 
oxaliplatin  
 
Alanine glyosylate aminotransferase gene (AGXT) 
AGXT has been investigated by virtue of being involved in the oxalate pathway which is 
one of the metabolites of oxaliplatin. Five groups of investigators looked for an 
association with oxaliplatin- induced peripheral neuropathy and the I340M and 
Pro11Leu SNPs in this gene. One study couldn’t perform this analysis due to 
homogeneity of genotype in their Korean population (348), three showed no effect 
(302, 304, 307), but one study demonstrated that the minor allele haplotype of these 
polymorphisms conferred a significantly higher risk of both acute and chronic 
neurotoxicity of NCI CTC grade 2 or higher in a Caucasian population (90). Three of 
these studies presented sufficient data for inclusion in a meta- analysis (90, 302, 307), 
however only two could be entered as the third used a different assessment scale 
 
a) 
b) 
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(302). This showed no significant association (OR 5.23, 95% CI 0.21-129.57, 
I2=84%)(figure 3.10). 
Figure 3.10. Forest plot for association between AGXT I340M and development of NCI 
CTC grade 2-4 neuropathy with oxaliplatin 
 
X ray repair cross-complementing gene 1 (XRCC1) 
  
ATP- Binding Cassette (ABC) transporters 
A summary of the results for this group of genes are reported below but insufficient 
data was presented in the papers to allow any pooled analysis of results. Only one 
oxaliplatin (300) and two paclitaxel studies (100, 346) presented their results per 
neuropathy outcome for each genotype of ABCB1 SNPs and one of the paclitaxel 
populations was from the study which used healthy blood donors as controls (346) 
making this inconsistent with the other study. 
 
ABCB1 
 
ABCB1 and platinum 
 
Five studies demonstrated no effect of the C3435T (294, 300, 304, 314, 339), G2677T/A 
(294, 300, 314) or C1236T (300, 304, 339) SNPs.  
 
ABCB1 and taxanes/taxane platinum combination 
 
22 studies (82, 100, 103, 274-276, 283, 295, 299, 301, 305, 315, 317, 318, 330, 336, 337, 
341-344, 346) investigated an association with ABCB1 polymorphisms and neuropathy 
in 21 patient cohorts. Abraham et al (274) found correlations with maximum grade 
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neuropathy and cumulative dose to sensory neuropathy in three SNPs; rs2032582 (OR 
1.19, 95%CI 1.04-1.36,p=0.02), rs1045642 (OR 0.83, 95%CI 0.72-0.95, p=0.009) and 
rs3213619 (OR 0.51, 95%CI 0.31-0.85, p=0.004).  
Two studies demonstrated a trend for association both in paclitaxel treated patients; 
One showed a trend for a reduced risk of neuropathy in patients with the CC genotype 
of the C3453T SNP treated with paclitaxel (275) and another showed a trend towards 
reduced risk in paclitaxel treated patients who were wild type for the 2677 SNP (305). 
These and the remaining studies did not find statistically significant associations. 
ABCB1 and vincristine 
Two studies investigated polymorphisms in this gene in patients treated with 
vincristine. One studied the C3435T and the G2677T/A polymorphisms (291) but in the 
other study it was not clear which polymorphisms were investigated (290). Neither 
study showed any association. 
ABCB1 and ixabepilone 
This single study investigated C3435T, G2677T/A and C1236T SNPs without any 
significant association found (310). 
ABCC1 
ABCC1 and oxaliplatin  
Cecchin et al (304) found a significant association between the minor allele at 
rs2074087 and development of grade >2 CIPN (OR= 0.43, 95% CI 0.22-0.86, p=0.017) 
using an additive model. McLeod (300) and Ruzzo (303) reported no significant 
association with investigated SNPs (including rs2074087). 
ABCC1 and taxanes 
Seven studies (82, 274, 299, 318, 336, 342, 343) investigated one or more 
polymorphisms in this gene. None demonstrated an association. 
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ABCC1 and vincristine 
One study was performed in a myeloma population in which >3000 SNPs chosen for 
potential functional effects were investigated. Permutation testing was carried out to 
account for the large number of tests. Among the numerous associations found, 
rs3887412 in ABCC1 was found to be associated with an increased risk of grade 2-3 
neuropathy after two or three cycles of vincristine (OR 3.36, 95% CI 1.47-7.67, p 5.70 
x10-3) (293). 
ABCC2 
 
ABCC2 and oxaliplatin 
 
Five groups investigated various SNPs in ABCC2. Cecchin et al reported a significant 
association with a number of SNPs in this gene and occurrence > grade 2 CIPN (304). 
Four oxaliplatin studies demonstrated no significant association (90, 300, 303, 348). 
 
ABCC2 and taxanes 
 
Six taxane studies showed no association between SNPs in this gene and neuropathy 
(82, 299, 318, 336, 343, 344). However, the large Abraham et al study noted 
associations with two SNPs (rs8187710 and rs17222723) in ABCC2 from imputed 
genotype information indicating odds ratios of 0.71 and 0.72 respectively with 
imputation r2 =1 (274).  
ABCG2 
ABCG2 and oxaliplatin 
Three studies investigated polymorphisms in ABCG2. Custodio et al showed an 
association between carriers of the AA genotype in rs3114018 with severe oxaliplatin 
induced peripheral neuropathy (OR2.67, 95% CI 0.95-4.41, p 0.059) which when 
combined with their other positive finding (rs2230641 in CCNH), reached statistical 
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significance (294). Cecchin et al (304) demonstrated an association with rs2622604, 
however this fell below the significance threshold after adjustment for multiple testing. 
The third study looked at a single different SNP in ABCG2 and did not show any 
significant association (300). 
ABCG2 and taxanes 
Seven studies have been done looking at different SNPs without indication of any 
association (274, 295, 299, 318, 336, 342, 344). Lamba et al investigated a cohort of 
patients largely treated with paclitaxel with cisplatin or carboplatin and found a 
protective effect with the variant allele at rs13120400 (OR 0.27, 95%CI -2.47- -0.15, 
p=0.027) (343). 
 
ABCG2 and vincristine 
One study showed no association in this population having investigated the rs2231142 
and rs2231137 polymorphisms (284). 
 
ABCG1 
One study that screened 288 Caucasian breast cancer patients treated with paclitaxel 
for 564 genetic markers (after exclusions) found that ABCG1 (rs492338) crossed the 
exploratory significance threshold of  =0.001 (homozygous mutant vs homozygote 
wild-type genotype OR=4.7, 95% CI 1.64-15.57, p=0.002). This was not however 
replicated in the non- Caucasian patients (296). 
Cytochrome P450 gene family 
CYP3A4 
CYP3A4 and platinum 
One oxaliplatin (300) and one high dose carboplatin (333) study investigated and 
demonstrated no effect of the *1B or *3 variants. 
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CYP3A4 and taxanes  
No association has been shown with the *1B  
(82, 103, 274, 299, 301, 305, 318, 330, 342, 344, 346), *3 (82), *18 (58) *2 (274, 
336),*16 variants (274, 344). One large trial of paclitaxel-treated patients of 
predominantly Caucasian origin showed that in female patients there was a significant 
association with CYP3A4*22 and development of grade 3 neuropathy in both 
exploratory and replication cohorts (100). Importantly though there were only two and 
six patients, respectively, with grade 3 neurotoxicity. A group performing whole exome 
sequencing of the CYP3A4 gene in eight patients with grade 3 paclitaxel-induced 
neuropathy patients identified rare and novel variants, *20, *25 and *27, which along 
with other CYP3A4 variants, resulted in reduced enzyme expression and were 
associated with a significantly higher risk of severe neuropathy and a higher probability 
of requirement of neuropathy-induced treatment modification in a population of 228 
patients. They showed a trend towards treatment modification due to CIPN with the 
*22 variant (345).  The only data available that could be combined in meta-analysis was 
the CYP3A4*22 results from the exploratory and replication cohorts within the DeGraan 
study (figure 3.11). This showed a statistically significant association with development 
of NCI CTC grade 2-3 (OR 2.37, 95% CI 1.10-5.12, I2=0%) and 3-4 (OR 13.98, 95%CI 3.17-
61.75, I2=0%), respectively, although not with any grade neuropathy (OR 1.28, 95% CI 
0.68-2.38, I2=25%). 
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(a) 
 
(b)
(c) 
 
Figure 3.11. Forest plot for the association of CYP3A4*22 and development of a) NCI CTC 
grade 3-4, (b) NCI CTC grade 2-4 and (c) any grade neuropathy with paclitaxel 
 CYP3A4 and vincristine 
Of four vincristine studies, one showed a trend for reduced risk of neuropathy with the 
*1B allele (41) but none showed any statistically significant association (290-292) 
CYP3A4 and ixabepilone 
The ixabepilone study (310) showed no effect of the *16 variant. 
CYP3A5 
CYP3A5 platinum 
Again a single oxaliplatin study (300) and a high dose carboplatin study (333) showed no 
significant association. 
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CYP3A5 and taxanes 
Twelve paclitaxel studies (82, 274, 288, 299, 301, 315, 318, 330, 335, 336, 342, 344) and 
one docetaxel study (103) were identified. CYP3A5*3 was the most commonly studied 
variant. One study showed a significantly reduced risk of neuropathy in 118 patients 
associated with the *3 variant (per allele HR 0.51, 95%CI 0.3-0.86, p=0.012) (301), while 
the reminder showed no significant difference.  
CYP3A5 and vincristine 
Of six studies (41, 71, 73, 290-292), three showed at least a trend for association. In two 
of the vincristine studies there is likely to be overlap of the paediatric population used 
as they both genotyped subgroups from the CCG-1891 trial (41, 292). One group 
showed a significantly reduced risk of neuropathy with the *3 variant allele (291), while 
a further study showed a trend in this direction (41). One was contradictory and 
reported the opposite effect (71). CYP3A5 expressor status was entered into meta-
analysis for two eligible studies (figure 3.12). This showed a lack of significant 
association (OR 0.49, 95% CI 0.19-1.30, I2=0%) (71, 73). 
 
 
Figure 3.12. Forest plot for association between CYP3A5 expression and development of 
NCI CTC grade 2-4 neuropathy with vincristine  
 
CYP2C8 
CYP2C8 polymorphisms were exclusively investigated in studies focussing on anti-
microtubule agents, paclitaxel, docetaxel and ixabepilone. 17 studies were identified, all 
except one (315) included the *3 allele. The *3 allele was reported as statistically 
increasing the risk of sensory neuropathy in two studies (HR per allele 1.93, 95% CI 
1.05-3.55, p=0.006 and HR per allele 1.72, 95% CI 1.05-2.82, p=0.032, respectively) 
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(281, 301). A third study by Hertz et al using at least some of the same population 
showed that patients with a ‘low metaboliser CYP2C8 phenotype’ (those with *2,*3 or 
*4 variants) were at increased risk of neuropathy, although *2 and *4 SNPs were not 
independently associated (296). In addition a further study has shown increasing motor 
neuropathy with the *3 SNP (OR not stated) (305) and a fifth has reported a trend in 
this direction (330). Only two studies presented sufficient data for inclusion in meta-
analysis of this association (figure 2.13) (100, 330). Leskela et al also demonstrated a 
reduced risk of neuropathy with the HapC allele (301). The remainder of the studies 
reported no significant effects in investigated SNPs (82, 100, 299, 310, 315, 318, 335-
337, 343, 344, 346).  
 
 
Figure 3.13. Forest plot for the association of CYP2C8*3 and development of NCI CTC 
grade 3-4 neuropathy with paclitaxel 
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Table 3.9. Details of studies included in meta-analyses and reasons for exclusions 
Variant Drug  Number 
of 
studies 
Meta-
analysis 
performed 
Y/N 
Outcomes  Studies included Studies excluded and 
reason 
GSTP1 
Ile105Val 
Oxaliplatin  27 Y Any grade CIPN 
 
NCI CTC grade 2-4 
NCI CTC grade 3-4 
 
Oxaliplatin-
specific scale 
grade 2-4  
 
Oxaliplatin-
specific scale 
grade 3-4 
2 studies  (279, 
320) 
 
5 studies (90, 94, 
297, 307, 319) 
6 studies (279, 298, 
300, 309, 311, 327) 
 
3 studies (302, 316, 
320) 
 
 
4 studies (302, 306, 
320, 352) 
11 were excluded due to 
insufficient results 
presented (215, 273, 294, 
303, 304, 312-314, 325, 
339, 348) 
 Cisplatin  4 N NA No eligible studies Insufficient definition of 
outcome (98) 
Inconsistent outcome 
measure (338, 347) 
Insufficient data 
presented (308)  
 Taxanes 9 N NA Only 1 study 
presented numbers 
of patients per 
genotype (329) 
Insufficient data 
presented (82, 103, 295, 
299, 341, 342, 344) 
 Vincristine 3 N NA Only 1 study 
presented numbers 
of patients per 
genotype(324) 
Insufficient data 
presented (291, 292) 
GSTP1 
Ala114Val 
Oxaliplatin 5 N 
 
 
NA No eligible studies Different assessment 
scales used and different 
outcomes studied (90, 
95, 297) 
Insufficient data reported 
(294, 304) 
 Cisplatin 1 N NA No eligible studies Single study, insufficient 
data reported (308) 
 Taxanes 6 N NA No eligible studies Insufficient data reported 
(103, 274, 295, 299, 329, 
342) 
GSTM1 
deletion 
Oxaliplatin 11 Y NCI CTC Grade 2-4 
 
NCI CTC Grade 3-4 
 
2 studies (297, 319) 
 
3 studies (298, 300, 
309) 
Data reported but 
different assessment 
scale used (95) 
Insufficient data reported 
(304, 306, 312, 348) 
Insufficient data plus 
mixed with cisplatin (215) 
 Cisplatin 4 N NA Only one study 
reported data per 
genotype (298) 
Insufficient data (98, 308, 
338) and regimens with 
differing neurotoxic 
potential (98, 338) 
 Taxanes 2 N NA Only one 
(docetaxel) study 
reported data per 
genotype (329) 
Insufficient data 
presented (paclitaxel) 
(341) 
 Vincristine 3 N NA Only 1 study 
presented numbers 
of patients per 
genotype (324) 
Insufficient data 
presented (291, 292) 
GSTT1 
deletion 
Oxaliplatin 9 Y NCI CTC grade 2-4 
 
NCI CTC grade 3-4 
2 studies (297, 319) 
 
2 studies (298, 309) 
Data presented but 
different assessment 
scale used (95). 
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Insufficient data 
presented (306, 312, 339, 
348) 
 Cisplatin 3 N NA Only one study 
reported data per 
genotype (298) 
Insufficient data (308, 
338) and regimens with 
differing neurotoxic 
potential (338) 
 Taxane 2 N NA Only one 
(docetaxel) study 
reported data per 
genotype (329) 
Insufficient data 
presented (paclitaxel) 
(341) 
 Vincristine 3 N NA Only 1 study 
presented numbers 
of patients per 
genotype (324) 
Insufficient data 
presented (291, 292) 
ERCC1 
C118T 
Oxaliplatin 20 Y NCI CTC grade 3-4 
 
NCI CTC grade 2-4 
4 studies (298, 300, 
309, 332) 
 
4 studies (94, 297, 
307, 319) 
Insufficient data 
presented (294, 303, 304, 
306, 311-314, 325, 327, 
339, 348)  
 Cisplatin 3 N NA Only one study 
presented numbers 
of patients per 
genotype (298) 
Insufficient data 
presented (98, 308) 
 Taxanes 
(with 
carboplatin) 
3 N NA No eligible studies Insufficient data 
presented (295, 299, 
341) 
ERCC1 
C8092A 
Oxaliplatin 8 Y NCI CTC grade 3-4 
 
NCI CTC grade 2-4 
2 studies (298, 309) 
 
2 studies (94, 307) 
Insufficient data 
presented (304, 311, 313, 
348) 
 Cisplatin 2 N NA Only one study 
presented numbers 
of patients per 
genotype (298) 
Insufficient data 
presented (308) 
 Taxanes 
(with 
carboplatin) 
3 N NA No eligible studies Insufficient data 
presented (295, 299, 
341) 
ERCC2 
Lys751Gln 
Oxaliplatin 16 Y NCI CTC grade 3-4 
 
NCI CTC grade 2-4 
2 studies (298, 331) 
 
3 studies (297, 307, 
319) 
Insufficient data 
presented (294, 300, 303, 
304, 306, 311-313, 325, 
327, 348) 
 Cisplatin 3 N NA Only one study 
presented numbers 
of patients per 
genotype (298) 
Insufficient data 
presented (98, 308) 
 Taxanes 
(with 
carboplatin) 
3 N NA No eligible studies Insufficient data 
presented (295, 299, 
341) 
ERCC2 
Asp312Asn 
Oxaliplatin 10  NCI CTC grade 3-4 Only one study 
presented numbers 
of patients per 
genotype (298) 
2 studies(297, 307) 
Insufficient data 
presented (294, 303, 304, 
306, 311, 313, 348) 
 Cisplatin 3 N NA Only one study 
presented numbers 
of patients per 
genotype(298) 
Insufficient data 
presented (98, 308) 
ERCC2 
C156A 
Oxaliplatin 4 Y NCI CTC grade 2-4 2 studies (297, 307) Insufficient data 
presented (313, 348)  
XRCC1  
Arg399Gln 
Oxaliplatin 14 Y NCI CTC grade 3-4 
 
NCI CTC grade 2-4 
3 studies (298, 300, 
332) 
 
Insufficient data 
presented (294, 303, 304, 
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2 studies (307, 348) 306, 312-314, 325, 332, 
339) 
 Cisplatin 3 N NA Only one study 
presented numbers 
of patients per 
genotype (298) 
Insufficient data 
presented (98, 308) 
 Taxanes 
(with 
carboplatin) 
3 N NA No eligible studies Insufficient data 
presented (295, 299, 
341) 
XRCC1 
Arg194Trp 
Oxaliplatin 2 N NA Only one study 
presented numbers 
of patients per 
genotype (307) 
Insufficient data 
presented (304) 
 Taxanes 
(with 
carboplatin) 
2 N NA No eligible studies Insufficient data 
presented (295, 341) 
XRCC1 
Arg280His 
Oxaliplatin 4 N NA Only one study 
presented numbers 
of patients per 
genotype (307) 
Insufficient data 
presented (294, 304, 
348) 
AGXT 
I340M 
Oxaliplatin 5 Y NCI CTC grade 2-4 2 studies (90, 307) Data presented but 
different assessment 
scale (302) 
Insufficient data 
presented (304, 348) 
AGXT 
Pro11Leu 
Oxaliplatin 4 N NA Only one study 
presented numbers 
of patients per 
genotype (90) 
Insufficient data 
presented (302, 304, 
348) 
ABCB1 
C3435T 
Oxaliplatin 5 N NA Only one study 
reported numbers 
of patients per 
genotype (300) 
Insufficient data 
presented (294, 304, 314, 
339) 
 Taxanes 21 N  NA Only one study 
remaining after 
exclusions (100) 
Insufficient data 
presented (82, 103, 274-
276, 283, 299, 301, 305, 
315, 318, 330, 336, 337, 
341-344) 
Inconsistent control 
group used (346). 
Two highly neurotoxic 
agents used concurrently 
(317) 
ABCB1 
G2677T/A 
Oxaliplatin 3 N NA Only one study 
reported numbers 
of patients per 
genotype (300) 
Insufficient data 
presented (314, 339) 
 Taxanes 17 N NA No eligible studies Insufficient data 
presented (82, 103, 274-
276, 283, 299, 301, 305, 
315, 318, 336, 337, 341, 
343, 344). 
Inconsistent control 
group used (346) 
  
ABCB1 
C1236T 
Oxaliplatin 3 N NA Only one study 
reported numbers 
of patients per 
genotype (300) 
Insufficient data 
presented (304, 339) 
 Taxanes 16 N NA No eligible studies Insufficient data 
presented (82, 103, 200, 
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274-276, 299, 301, 305, 
318, 336, 337, 342-344)  
CYP3A4*1B Taxanes 11 N NA No eligible studies Insufficient data 
presented  
(82, 103, 274, 299, 301, 
305, 318, 330, 342, 344, 
346) 
 Vincristine 2 N NA One study reported 
numbers of 
patients with 
neurotoxicity per 
genotype (41) 
Insufficient data 
presented (291) 
CYP3A4*2 Taxanes 2 N NA No eligible studies Insufficient data 
presented (274, 336) 
CYP3A4*16 Taxanes 2 N NA No eligible studies Insufficient data 
presented (274, 344) 
CYP3A4*22 Taxanes 1 Y NCI CTC grade 3-4 
neuropathy, grade 
2-4 neuropathy 
and any grade 
neuropathy 
Exploratory and 
replication cohorts 
within one study 
(100) 
 
CYP3A5*3 Taxanes 8 N NA Only one study 
presents numbers 
of patients per 
genotype (288) 
Insufficient data 
presented (82, 103, 200, 
301, 318, 335, 336, 342) 
 Vincristine 4 Y NCI CTC grade 3-4  2 studies (71, 73) Insufficient data 
presented (41, 291) 
CYP3A5*3C Taxanes 2 N NA No eligible studies Insufficient data 
presented (299, 330) 
CYP3A5*6 Vincristine 3 N 
 
NA No eligible studies Insufficient data 
presented (73). 
Data presented but 
different outcomes and 
classification used (41, 
71) 
CYP2C8*3 Taxanes 16 Y NCI CTC grade 3-4 2 studies (100, 330) Insufficient data 
presented (82, 274, 281, 
296, 299, 301, 305, 318, 
335-337, 343, 344, 346) 
CYP2C8*4 Taxanes 8 N NA Only one study 
presented data per 
genotype (100) 
Insufficient data 
presented (82, 274, 296, 
299, 301, 337, 344) 
CYP2C8*1B Taxanes 4 N NA No eligible studies Insufficient data 
presented (82, 274, 301, 
344) 
CYP2C8*2 Taxanes 5 N NA No eligible studies Insufficient data 
presented (82, 274, 305, 
337, 344) 
CYP2C8 
*HapC 
Taxanes 5 N NA No eligible studies Insufficient data 
presented (82, 274, 301, 
335, 344) 
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3.3.4 Significant associations in other less commonly investigated variants  
Platinum studies 
Antonacopoulou et al showed an increased severity of chronic oxaliplatin- induced 
peripheral neuropathy with the TT genotype at residue 33 of the ITGB3 gene in 55 
FOLFOX-4 treated patients in a single candidate SNP study (p= 0.044) (277). Argyriou et 
al investigated a link between the SCNA genes (coding for voltage- gated sodium 
channel proteins) and showed an association between SCN4A rs2302237 (OR 2.47, 
95%CI 1.04-5.85, p= 0.037) and increased risk of chronic oxaliplatin of any grade in a 
cohort of 200 patients treated with either FOLFOX or XELOX. Four SNPs were 
investigated without adjustment for multiple testing and analysis was undertaken using 
dominant, recessive and overdominant models. The overdominant (and presumably 
most positive) model is presented (88). 
Basso et al investigated oxaliplatin related acute neurotoxicity specifically after one 
cycle of treatment, and a possible genetic link with nerve hyperexcitability through 
variation in a calcium-dependent potassium channel abundantly present in the 
peripheral nervous system encoded by the SK3 gene. They reported that of their 
relatively small population, those with the 13-14 CAG repeat allele may be more 
susceptible to the acute neurotoxicity seen with oxaliplatin, whilst those with >15 
repeats may be protected (OR with >15 repeats; 0.381, 95%CI 0.247-0.590, p=0.001) 
(280).  
Johnson et al (217) genotyped a cohort of 400 lung cancer patients treated with a 
platinum agent. Some of these patients received a taxane. The heterogeneity of the 
treatment received is a limitation but whether or not patients received a concurrent 
taxane was accounted for in a multivariate analysis. Rs3753752 in the GPX7 gene was 
found to have a significant association with development of CIPN after adjustment and 
correction for multiple testing with the variant allele associated with an OR 1.7 (95%CI 
1.20-2.40, p=0.0028). 
Taxane studies
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A large study analysing SNPs in the Fanconi anaemia/ BRCA pathway in 888 breast 
cancer patients receiving either weekly or bi-weekly paclitaxel demonstrated 
association of four SNPs in the FANCD2 gene with development of grade 3-4 
neurotoxicity rs7648104; OR 1.86, 95%CI 1.3-2.65; rs7637888; OR 1.87, 95% CI 1.30-
2.67; rs6786638; OR 1.90, 95% CI 1.32-2.72; rs6442150; OR 1.89, 95% CI 1.32-2.72) 
(328). Imputed results for these SNPs from a GWAS failed to confirm an association (HR 
0.93, 95% CI 0.77-1.13, p=0.46 for all four SNPs) (274). 
A study of ovarian cancer patients from a phase III trial population treated with either 
paclitaxel or docetaxel with carboplatin investigated 1261 SNPs within 60 genes (295). 
They divided their cohort into a discovery and a replication set, and both groups 
contained docetaxel- and paclitaxel- treated patients. Correction for multiple testing 
was performed. 69 SNPs were associated with development of grade 2 or greater CIPN 
in the discovery set, of which four of these associations were confirmed in the 
replication set. These four SNPs were rs139887 (SOX10) (OR 1.77 95% CI 1.21-2.59, 
p=0.001), rs2849380 (BCL2) (OR 2.82 95%CI 1.16-6.88, p=0.013), rs544093 (OPRM1) (OR 
1.67 95%CI 1.017- 2.73, p=0.015) and rs879207 (TRPV1) (OR 1.62 95%CI 1.11- 2.37, 
p=0.002). OPRM1 has been  associated with sensitivity to pain (353).  
SNPs involved in the variability of beta- tubulin expression were retrospectively 
investigated in 214 paclitaxel-treated patients. A large variation in the expression of 
beta-tubulin IIa was demonstrated with variants in the TUBB2A gene (-101 and -112) 
whilst increasing transcription of the protein product conferred protection from CIPN 
(HR 0.62 95% CI 0.42-0.93, p=0.021) (285). Imputed genotype data from the Abraham 
study demonstrated an association with the TUBB2A rs9501929 SNP (HR 1.6 95%CI 
1.18-2.18) (274). In contradiction to these results, Eckhoff et al found no association 
with four SNPs in the TUBB2A gene, including rs9501929 (HR not stated) and CIPN in a 
case-control study of 150 docetaxel treated breast cancer patients (103). 
Lee et al (315) investigated candidate SNPs selected for having a role in either paclitaxel 
or gemcitabine metabolism or action in a cohort of 85 patients receiving both drugs. 
They demonstrated an increased risk of CIPN for those with the AA genotype for rs9937 
in RRM1 although this was not repeated on multivariate analysis. Of note RRM1 was 
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selected for a role in gemcitabine action rather than being thought to affect paclitaxel 
effect. 
Beutler et al investigated for association of development of paclitaxel- induced 
peripheral neuropathy with SNPs in genes known to be implicated in Charcot-Marie-
Tooth (CMT) disease. They included patients from an observational study investigating 
the occurrence of CIPN with either weekly or three-weekly paclitaxel. 73 cases and 46 
controls were identified using rate of change of EORTC CIPN20 scores throughout 
treatment. Two genes were found to be implicated in development of CIPN; variants in 
PRX and three non-synonymous SNPs in ARHGEF10 (321). The same group replicated 
the association of three ARHGEF10 SNPs using similar methodology in a separate 
prospectively recruited cohort. They confirmed the increased risk of CIPN associated 
with ARGHGEF10 variants, in particular rs9657362 (OR 3.56, p=0.018) (322). 
Vincristine studies 
In vincristine induced peripheral neuropathy, Kishi et al noted a significant association 
with VDR intron 8 AA genotype and increased risk of peripheral neuropathy (OR2.16, 
95% CI 1.03-4.51, p=0.042 (291) and Sepe et al reported a positive association with 
TSbp 28 insertion (292). 
 
3.3.5 Genome wide association studies 
 
Oxaliplatin 
 
Five genome- wide association studies are included in this review. The Abraham study is 
part of a genome-wide association study but only replication data of putative SNPs have 
been published so far. Two further genome- wide association studies were identified 
but only the abstracts are available for these and are mentioned but not included in the 
full systematic review (271, 354). 
  
The first genome wide study performed involved 96 and 247 Korean patients in 
discovery and replication sets, respectively. They were treated with oxaliplatin and 
association was sought for those who experienced > grade 2 neuropathy or those 
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experiencing grade 2 chronic neuropathy for > 7 days. They identified nine significant 
SNPs, the most significant association that they observed was in TAC1 (rs10486003) (OR 
0.32, 95%CI 0.19-0.52, p=4.84x10-7). The TAC1 gene encodes four members of the 
tachykinin family, including substance P, which are thought to act as neurotransmitters 
[Gene, 2017 #4112] . Four other SNPS were found to be significant in a multiple 
regression analysis (rs2338 (OR2.27, 95%CI 1.58-3.26,p=4.63x10-6), rs830884 (OR 0.32, 
95%CI 0.19-0.54, p=1.74x10-6), rs843748 (OR2.43, 95%CI 1.61-3.68,p=1.01x10-5) and 
rs797519 (OR0.50, 95%CI 0.35-0.72, p=8.21x10-5) (272). A retrospective study in a 
Japanese population of 70 colorectal cancer patients treated with modified FOLFOX6 
attempted to validate the top nine hits from the Korean GWAS (94). They used the 
same criteria for defining a ‘case’ of neuropathy.  The study is clearly limited by its 
retrospective nature but measures were put in place to aim for consistency in assessing 
the phenotype of patients. In univariate analysis, they found that two of the SNPs were 
significantly related to developing neuropathy, rs843748 in ACYP2 (p=0.056) and 
rs17140129 in FARS2 (p=0.072). The FARS2 SNP remained significant in multiple logistic 
regression analysis (OR 6.5, 95%CI 1.2-35.7, p=0.034). Additionally, rs10486003 in TAC1 
was associated with time to onset of chronic neuropathy.  A replication study in an 
Italian population demonstrated only a trend towards a protective effect of the FARS2 
SNPs (OR 0.34, 95%CI 0.09-1.22, p=0.081 for rs17140129) and of rs843748 in ACYP2 
when using the TNSc (OR 0.27, 95%CI 0.10-0.75,p=0.008; significance lost on multi-test 
adjustment) (89). 
A second GWAS study looking at colorectal cancer patients aimed to examine 
associations with a range of 5-Fluorouracil or FOLFOX toxicities. With regard to 
investigating an association with oxaliplatin- induced peripheral neuropathy, there 
were 133 patients in a discovery set and 324 patients in a replication cohort. The 
strongest associated SNPs only reached significance at the <10-4 level, so none reached 
the generally accepted level for genome wide significance. These hits were not found to 
be significant when examined in the replication cohort (273). 
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Taxanes 
 
A GWAS in a Caucasian paclitaxel-treated population of 855 breast cancer patients 
identified a SNP (rs10771973) in the FGD4 gene (HR 1.57, 95%CI 1.30-1.91, p=2.6x10-6) 
(82). This was replicated in both Caucasian and African American replication cohorts. A 
second SNP, in EPHA5, a gene with biological plausibility, showed significant association 
in the discovery set only (HR1.63, 95% CI 1.34-1.98, p=9.6x10-7). 
A further GWAS in a population of 144 Caucasian patients treated with paclitaxel and 
carboplatin for a variety of primary cancers found an association with rs17348202 in 
close proximity to the EPHA4 gene (HR 4.85, 95% CI 2.57-9.13, p=1.02x10-6) with other 
top hits including rs4141404 and rs2413045 in the LIMK2 gene (HR2.41, 95% CI 1.66-
3.48, p=3.22x10-6; HR 2.36, 95%CI1.57-3.56, p=3.67x10-5, respectively) and rs3829306 in 
SLCO1B1 (HR3.10, 95% CI 1.82-5.26, p=2.84x10-5). This group performed meta-analysis 
of the two paclitaxel-based GWAS within which two SNPs crossed the genome-wide 
significance level; rs7349683 in EPHA5 (HR=1.68, 95% CI 1.42-1.99, p=1.4x10-9) and , 
rs4737264 in XKR4  (HR=1.71, 95% CI 1.41-2.06,p=3.11x10-8) (85).  
An abstract based on interim analysis of a GWAS presented at the American Society of 
Clinical Oncology (ASCO) meeting 2011 reported the most significant findings in 
relationship to neuropathy were SNPs in RWDD3 rs2296308 (HR per allele 1.5, 
p=8.5x10-8) and TECTA rs1829 (HR2.07, p=3.15x10-7) (354) There does not appear to be 
a full publication of this work to date. Attempted replication of association with these 
SNPs have either shown no association or contradictory results (323, 334). 
A further GWAS presented thus far in abstract form only was that by Hertz et al at ASCO 
2013 (271). It reported results of a GWAS in docetaxel- treated castrate- resistant 
prostate cancer patients treated within a large phase III clinical trial. They report their 
top hit rs11017056, which met the significance level for genome wide significance. 
However, neither this SNP, nor several others selected were replicated in a cohort of 
paclitaxel treated breast cancer patients. 
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Vincristine 
 
A GWAS in a paediatric acute lymphoblastic leukaemia population involved 321 and 222 
children respectively in two prospective US-based clinical trial cohorts. All children were 
treated for acute lymphoblastic leukaemia with chemotherapy regimens involving 36-
39 doses of vincristine. The investigators identified a SNP in the promoter region of 
CEP72 (rs924607) which was associated with development of grade 2-4 vincristine- 
related neuropathy with 56% of patients with the homozygous variant genotype 
developing this complication compared with 21.4% of those with the heterozygote or 
wild type genotype (p=6.3x10-9) (72). A replication study in a Spanish paediatric ALL trial 
cohort involving 142 patients however did not confirm this association (OR 0.65, 95% CI 
0.17-2.43, p=0.5), albeit they focussed on neurotoxicity developing during the induction 
phase of chemotherapy only (289).  
 
3.4 DISCUSSION 
 
There have been concerns raised in the literature regarding the methodological quality 
of pharmacogenetics studies (267, 355). This can greatly affect reproducibility of results 
and lead to false conclusions being drawn. This in turns leads to difficulty in 
interpretation and ability to apply results to clinical practice. This review identifies 
many methodological issues with the current literature regarding the pharmacogenetics 
of CIPN. 
 
Study size was generally small. Based on previous evidence regarding sample size 
needed to ensure sufficient power in pharmacogenetics studies, most studies were 
likely underpowered to detect a statistically significant relationship with a genetic 
variant (267). Power calculations were rarely undertaken and in the majority of studies 
the reader was uninformed of the likelihood of detecting a significant genetic effect, if 
indeed one exists. 
 
Many studies lacked sufficient detail upfront as to how analysis was undertaken and 
endpoints investigated leading to the risk of within-study selective reporting. In many 
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studies, the outcomes in terms of peripheral neuropathy were not pre-stated and the 
mode of inheritance assumed for analysis is not disclosed; we therefore do not know if 
several modes of inheritance and outcomes had been analysed with only the most 
significant being presented, thus inflating the type I error rate.   
For many of the studies CIPN is one of many survival, response and toxicity outcomes 
examined. Partly as a consequence there is frequently lack of detail in phenotype 
definition, which is fundamental to the accuracy of results. CIPN is a challenging 
adverse reaction to study due to its subjective nature and the fact that there is a lack of 
an ideal assessment tool or measure. Particular care is therefore needed in definition of 
‘cases’ and ‘controls’. Some studies however appear to fail to make fundamental 
considerations. In the case of oxaliplatin, many studies did not differentiate between 
acute and chronic neurotoxicity. Given the different mechanisms of the two forms, it is 
unlikely that grouping these together will yield consistent phenotypic categories and 
therefore genotyping results may be meaningless. Many studies did not exclude 
patients with pre-existing neuropathy and most failed to consider that there may be 
relevant clinical covariates such as diabetes, alcohol excess or differential neurotoxic 
potential of the various drug regimens used in their study cohort. There is a balance to 
be struck between including different regimens of the same drug in study cohorts in 
order to allow larger populations to be studied and keeping the clinical characteristics 
as uniform as possible.  
 
A more significant problem existed in a handful of studies, however, where patients 
were treated with differentially neurotoxic chemotherapy regimens including for 
example carboplatin and cisplatin in the same cohort and cohorts where some patients 
were receiving a second potentially neurotoxic agent in addition to the index drug. The 
fact that many studies do not state minimum dose criteria to be received by patients 
classed as ‘control’ subjects raises the question as to whether they are true control 
subjects if they received only a small dose of the neurotoxic agent if it was stopped 
early for other toxicity such as hypersensitivity or myelosuppression. Many studies 
were prospective and had clear plans for assessment of CIPN; however a significant 
number relied upon case-note review for assessment as to the degree of neurotoxicity. 
It has been well documented that physicians frequently underestimate the severity of 
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this side effect (140, 356, 357) and therefore there are major inaccuracies in relying on 
documented information alone for assessing presence/ absence and severity of CIPN. It 
was disappointing how few studies presented their results to allow meta-analysis. This 
limits the usefulness of the meta-analyses performed along with the heterogeneous 
nature of many of the studies.  
A solution could be formation of a consortium for investigating pharmacogenetics of 
chemotherapy related toxicity which would allow investigators to share individual data 
and undertake individual patient data meta-analysis. Formation of such expert working 
parties would also allow standardisation of phenotype definition which has been an 
invaluable process in other fields (358, 359). Increasingly cumulative dose to NCI CTC 
grade 2 neuropathy has been used as an outcome. There are pitfalls with this due to 
inconsistencies in rating between grade 1-2 neuropathy (140) and in accurately 
differentiating a case from a control patient, in particular for oxaliplatin-induced 
neuropathy where the phenomenon of coasting is common (when a patient completes 
all planned chemotherapy only to develop grade 3 neurotoxicity very shortly 
afterwards) and this phenotypic information is lost in this outcome measure. A solution 
could be a combination of a standard scale such as NCI CTC or TNSc and a patient report 
outcome, or a more descriptive explanation of the terms used in the grade definitions 
to ensure high inter-rater consistency. 
There are a small number of interesting SNPs emerging as potential factors in this 
complex, seemingly polygenic susceptibility to CIPN which require well-planned, 
methodologically robust studies to attempt to validate them. As well as complying with 
published guidelines of standards for pharmacogenetics studies, extreme care is 
needed to fully define and meticulously categorise patient phenotype prior to 
undertaking genotypic analysis. Those SNPs particularly warranting further investigation 
in association with taxane-induced neuropathy would appear to include; CYP2C8*3 due 
to positive associations seen in a number of studies (281, 301, 305); CYP3A4*22 due to 
its positivity in one large trial in both discovery and replication sets (100) and lack of any 
independent replication to date; TUBB2A SNPs as identified by one candidate gene 
approach (285) and confirmed of interest in a large replication study (274) albeit not 
confirmed in a docetaxel cohort (103); the EPHA genes, given data available from  two 
published GWAS (82, 85); and the CMT-associated genes investigated by Beutler and 
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Boora et al (321, 322); ABCC2 SNPs also warrant further investigation. For oxaliplatin-
induced neuropathy, the list is shorter. The three most statistically significant SNPs in 
the Japanese GWAS (272) partially replicated in a second Japanese population (94) 
could be investigated further, albeit one study in a Caucasian population has only 
shown one weakly positive outcome with one of the group of SNPs (89). Finally, for 
vincristine neuropathy CEP75 variants (72) and CYP3A5*3 may warrant further 
investigation (41, 71, 291). Whole exome sequencing may also lead to further rare 
variants in genes affecting drug metabolism which may prove to be significant. It is 
evident so far that any genetic variant which could confer susceptibility to CIPN is likely 
to have a relatively small effect size and that rather than finding one or two high risk 
SNPS, that eventually a panel of susceptibility variants may be identified and combined 
in a polygenic risk score. 
 
3.5 CONCLUSION 
 
Much work is needed in this area to investigate pharmacogenetic associations to aim 
towards better risk stratification of potential chronic neuropathy which may affect 
return to normal function after a course of chemotherapy. Improving quality of 
methodology, in particular, in phenotypic definition and clinical assessment is however 
essential to aim towards more meaningful, clinically applicable findings. 
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PHARMACOGENETIC STUDY:  
A CANDIDATE GENE STUDY TO 
INVESTIGATE PUTATIVE ASSOCIATIONS 
WITH CIPN  
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4.1 INTRODUCTION 
 
There is a clear need for further pharmacogenetic studies in the investigation of 
chemotherapy induced peripheral neuropathy (CIPN) to further our knowledge of this 
complex adverse effect. The systematic review presented in chapter 2 highlighted the 
methodological flaws and areas for focus based on comprehensive review of previous 
work in this area. It is important to note that the systematic review presented in 
chapter 2, whilst updated in 2016 to ensure completeness for publication and thesis 
submission, was initially evaluated 18 months prior to the final search to allow progress 
with our clinical study and decision on the array of SNPs for review in our investigation. 
 
4.1.1 Taxane study 
 
In the field of taxane-induced peripheral neuropathy, seven putative variants were 
selected based on suggestive candidate gene or genome-wide association studies; 
CYP3A4*22, CYP2C8*3, FGD4 rs10771973, EPHA4 rs17348202, EPHA5 rs7349683, 
EPHA6 rs301927, XKR4 rs4737264. 
It has been shown that paclitaxel pharmacokinetics with exposure to higher drug levels 
during the cycle is associated with an increased risk of neuropathy (29, 360, 361), and 
so it follows that variants in genes coding for enzymes involved in the metabolic 
pathways of taxanes have been studied. This has largely been without demonstration of 
any association with neurotoxicity. However, of these variants, a selected few do look 
of interest. 
 
CYP3A4*22 had been studied in a relatively large cohort of patients who had received 
paclitaxel for a variety of solid tumours (361). The variant allele is known to lead to 
lower CYP3A4 activity of which the taxanes are known substrates. In female patients, 
this SNP was shown to be significantly associated with development of NCI CTC grade 3 
neuropathy in both exploratory and replication cohorts (122 and 110 patients, 
respectively). Exploratory analysis combining the two cohorts revealed an increased risk 
of grade 3 neurotoxicity in CYP3A4*22 variant carriers (HR=22.1 95%CI 4.7-105, 
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p<0.001). Only a small number of cases were included in this cohort and so these 
results must be treated with caution;  however the biological plausibility of this finding 
warrants further investigation.   
CYP2C8*3 had been studied in fifteen TIPN studies (29, 82, 274, 281, 296, 299, 301, 318, 
330, 336, 337, 343, 344, 361, 362), although three of these included overlapping patient 
cohorts (281, 296, 330).  Four of the studies reported a significant  association with the 
development of TIPN (29, 281, 296, 301) and a fifth reported a trend in this direction 
(330).  
Of the SNPs related to taxane metabolic pathways, we elected to attempt replication of 
the association with CYP3A4*22 and CYP2C8*3 in our patient cohort. 
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Table 4.1 Summary of evidence to support SNP selection for candidate gene study 
Gene and SNP Study Findings to date Effect estimate 
(95%CI, p value) 
Biological relevance 
CYP3A4*22 Apellaniz-Ruiz 2015 
(345)* 
Trend towards need 
for treatment 
modification 
Not stated (p=0.066) 
 
The variant allele is known to 
be related to lower CYP3A4 
activity of which the taxanes 
are known substrates 
DeGraan 2013 (361) Significant association 
with development of 
NCI CTC grade 3-4 
CIPN 
OR 19.1 (3.3-110, 
p=0.001) in validation 
cohort 
 
Meta-analysis (see 
chapter 2) 
Significant association 
with development of 
NCI CTC grade 3-4 
CIPN 
OR 13.98 (3.17-61.75, 
I20%) see meta-analysis in 
chapter 2 
 
CYP2C8*3 Abraham 2014(274) No significant 
association  
HR 1.13 (0.92-1.41, 
p=0.27) 
The variant allele is known to 
be related to lower CYP2C8 
activity of which the taxanes 
are known substrates 
Baldwin 2012(82) No significant 
association  
NS  
Bergmann 
2011(336) 
No significant 
association 
NS (p= 0.98)  
Bergmann 
2012(318) 
No significant 
association 
NS (p=0.46)  
Boso 2014 (344)* No significant 
association 
NS  
DeGraan 2013 (361) 
 
No significant 
association  
NS 
 
 
Green 2008 (29) Association with 
increased risk of 
motor neuropathy  
NS (p=0.034)  
Hertz 2012 (330) 
 
Non-significant 
association for 
development of NCI 
CTC grade 3-4 
neuropathy 
OR 3.13 (0.89-11.01, 
p=0.075) 
 
 
Hertz 2013 (281) Association with 
cumulative dose at 
NCI CTC grade 2-4 
neuropathy 
European- American 
cohort: HR per allele 1.93 
(1.05-3.55, p=0.032) 
African American cohort: 
HR 3.3 (1.04-10.45, 
p=0.043) 
 
Hertz 2014 (296) 
 
Association with 
increased neuropathy 
of CYP2C8 low 
metaboliser 
phenotype 
HR 1.722 (p=0.018) 
 
 
Lamba (343) No significant 
association  
NS  
Leskela 2011 (301) Association  with 
cumulative dose of 
paclitaxel to grade 2 
neuropathy 
HR per allele 1.72 (1.05-
2.82, p=0.032) 
 
 
Marsh 2007 (363) 
 
No significant 
association 
NS  
Ofverholm 2010 
(346) 
 
No significant 
association 
NS  
Rizzo 2010 (337) 
 
No significant 
association 
NS (p=0.6664)  
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EPHA4 rs17348202  Leandro Garcia 
2013 (85) 
 
Significant association 
with cumulative dose 
at NCI CTC grade>2 
CIPN  
HR 4.85 (2.57-9.13, 
p=1.02x10-6) 
The product of EPHA4 is an 
ephrin receptor which has 
been associated with neuronal 
regeneration after injury. 
EPHA5 rs7349683 Baldwin 2012 (82) 
 
 
Association with 
cumulative dose at 
NCI CTC grade>2 CIPN 
in discovery set 
HR 1.63 (1.34-1.98, 
p=9.6x10-7) in discovery 
set. 
 
The product of EPHA5 is an 
ephrin receptor which has 
been associated with neuronal 
regeneration after injury. 
Leandro- Garcia (85) Association with 
cumulative dose at 
NCI CTC grade>2 CIPN 
 
Meta-analysis 
evidence of significant 
association with 
cumulative dose at 
NCI CTC grade>2 CIPN 
HR 1.83 (1.32-2.55, 
p=3.33x10-4) 
 
 
HR 1.68 (1.42-1.99, 
p=1.4x10-9) 
 
EPHA6 rs301927 Leandro-Garcia 
2013 (85) 
Association with 
cumulative dose at 
grade>2 CIPN 
HR 2.35 (1.57-3.53, 
p=3.44x10-5) 
The product of EPHA6 is an 
ephrin receptor which has 
been associated with neuronal 
regeneration after injury. 
FGD4 rs10771973 Baldwin 2012 (82) Association with 
cumulative dose at 
grade>2 CIPN 
HR 1.57 (1.3-1.91, 
p=2.6x10-6) in exploratory 
cohort and replicated in 
validation sets 
FGD4 polymorphisms are 
associated with effects on 
development or maintenacne 
of Schwann cell function and 
are associated with congenital 
peripheral neuropathy(364, 
365)  
XKR4 rs4737264 Baldwin 2012 (82) 
 
Association with 
cumulative dose at 
grade>2 CIPN 
HR 1.68 (1.36-2.09, 
p=1.9x10-6) in discovery 
set;  
HR1.84 (1.02-3.33, 
p=0.021 in European 
replication set.  
HR 1.23 (0.69-2.21, 
p=0.24) in the African 
American replication set 
Protein product expressed in 
the cerebellum and frontal 
lobe and associated with 
attention deficit and 
hyperactivity disorder(366) and 
sensitivity to schizophrenia 
medications (367) 
Leandro- Garcia (85) Association with 
cumulative dose at 
grade>2 CIPN 
Meta-analysis between 
two GWAS; HR 1.71 (1.41-
2.06, p=3.11x10-8) 
 
 
 *studies were published after SNP selection and so weren’t considered during the SNP selection process for the current study.    
 
Two genome wide association studies performed in patients who had received 
paclitaxel chemotherapy were published in 2012 (82) and 2013 (85) , respectively. 
Baldwin et al. studied a large cohort of paclitaxel- treated breast cancer patients (82). 
Of the top hits in the exploratory cohort, one SNP reached significance in the Caucasian 
and African American replication sets. This SNP (rs10771973) lies in the FGD4 gene, a 
gene that is associated with congenital peripheral neuropathy and in the exploratory 
cohort demonstrated a hazard ratio of 1.57 (95% CI 1.3-1.91, p=2.6 x 10-6) in the 
cumulative dose to grade 2 neuropathy analysis.  Their top hit in the exploratory 
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analysis was in the EPHA5 gene (rs7349683), the product of which has been associated 
with neuronal regeneration after injury. However, this association was not replicated in 
the validation cohorts. 
 
Leandro-Garcia et al performed their GWAS in 144 patients treated with paclitaxel 
175mg/m2 three-weekly for any solid neoplasia (85). They did not identify any SNPs 
which crossed the threshold for genome wide significance; however interestingly 
amongst their top hits (p values <10-5) it was notable, given Baldwin’s findings, that a 
SNP in EPHA4 was present (rs17348202, HR 4.85, 95%CI 2.57-9.13, p=1.02 x 10-6) and a 
SNP in EPHA6 featured amongst the top hits (rs301927, HR 2.35, 95%CI 1.57-3.53). 
Their results for rs1159057 in EPHA5, which is in high linkage equilibrium with Baldwin’s 
EPHA5 SNP, showed a HR of 2.01 (95% CI 1.43-2.84, p= 6.84 x10-5). Their group 
performed meta-analysis of their own and Baldwin’s results and both rs7349683 and 
rs4737264 in the XKR4 produced results which crossed the genome wide significance 
level (HR 1.68, 95%CI 1.42-1.99, p=1.42 x 10-9 and HR 1.71, 95% 1.41-2.06, p=3.11 x    
10-8). 
 
From the results of the systematic review, these findings were amongst the most 
interesting and appeared to warrant attempted replication. We therefore planned a 
candidate gene study to investigate an association of the SNPs listed in table 4.2 with 
the development of clinically significant sensory peripheral neuropathy in a cohort of 
taxane-treated patients. 
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Table 4.2. List of candidate SNPs to be investigated in the taxane-treated cohort 
Gene rs number Chr position (bp) Allele 
nomenclature 
Amino Acid 
Substitution 
Functional Consequence 
CYP3A4  rs35599367 7:99768693 *22  
 
n/a ↓activity (27, 368) 
CYP2C8 rs10509681 
rs11572080 
10:95038992 
10:95067273 
*3 
 
p.K399R 
p.R139K 
↓activity (369, 370) 
EPHA4 rs17348202 2:221207458 
 
 n/a Unknown effect of SNP; however 
EPHA4 is known to play an 
important role in the development 
of the nervous system including 
axonal guidance (371) and 
neuronal repair after injury (372-
375) 
EPHA5 rs7349683 4:66197804  p.G996G 
(NP_001268694.1) 
 
Not known but almost exclusively 
expressed in the nervous system 
(376) and plays a role in axon 
guidance (377). 
EPHA6 rs301927 3:97346618  intronic Not known but part of the same 
family of molecules as EphA4 and 
EphA5 
XKR4 rs4737264 8:55198762  intronic Not fully understood and protein 
not well characterised, expressed 
in the cerebellum and thus far 
associated with ADHD (366) and 
risperidone response(367) 
FGD4 rs10771973 12:32640040  intronic Specific point mutations have been 
associated with congenital 
peripheral neuropathy CMT (364, 
365) 
Tables compiled with reference to dbSNP (378) and PharmGKB (379) databases 
ADHD= Attention deficit and hyperactivity disorder 
CMT= Charcot Marie Tooth disorder 
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4.1.2 Oxaliplatin study 
 
From the systematic review, it was clear that oxaliplatin was the most studied drug in 
terms of investigating the association with CIPN. A number of candidate gene studies 
have investigated possible associations with genetic variants which may interfere with 
the metabolic pathways of platinum drugs. However, many of these have been 
contradictory. From data collected through the systematic review, meta-analysis was 
carried out where sufficient information was given in the study for inclusion. Overall, 
these analyses of many genetic associations including those of GSTP1, GSTM1, GSTT1, 
ERCC1 and 2 and XRCC1 showed no clear association. Rather than repeat these 
investigations in our study we elected to review the results of genome wide 
associations performed investigating oxaliplatin- induced peripheral neuropathy 
outcomes.  
 
Two GWA studies have been carried out in this field. Neither revealed SNPs which 
crossed the generally accepted significance level for GWAS, but one did reveal a 
number of SNPs which were significantly associated with neurotoxicity at the <10-5 level 
in their discovery cohort. This study involved 96 and 247 Korean patients in discovery 
and replication sets, respectively. They were treated with oxaliplatin and association 
was sought for those who experienced > grade 2 neuropathy or those experiencing 
grade 2 chronic neuropathy for >7 days. They identified nine significant SNPs; the most 
significant association that they observed was in TAC1 (rs10486003) with an odds ratio 
of 0.17 (95%CI 0.07-0.42, p= 2.04 x 10-5). This association was replicated in the 
validation set with a combined OR of 0.32 (95%CI 0.19- 0.52, p=4.84 x 10-7) The TAC1 
gene encodes four members of the tachykinin family, including substance P, which are 
thought to act as neurotransmitters. Four other SNPS were found to be significant in a 
multiple regression analysis (rs2338, rs830884, rs843748 and rs797519)(272). In total 9 
SNPs, significant at the <10-5 level in the discovery set, showed association in the 
replication set. 
 
 A retrospective study in a Japanese population of 70 colorectal cancer patients treated 
with modified FOLFOX6 attempted to further explore the top nine hits from the Korean 
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GWAS (94). They used the same criteria for defining a ‘case’ of neurotoxicity.  The study 
was limited by its retrospective nature but measures were put in place to aim for 
consistency in assessing the phenotype of patients. In a univariate analysis, they found 
that two of the nine GWAS-identified SNPs appeared to be significantly related to the 
development of neuropathy, rs843748 in ACYP2 and rs17140129 in FARS2. The SNP in 
FARS2 remained significant in multiple logistic regression analysis (OR 6.5, 95%CI 1.2-
35.7, p=0.034). The top SNP in the GWAS, rs10486003 in TAC1, whilst not shown to be 
related to the risk of development of neuropathy in the Japanese study, did appear to 
be significantly associated with the time to the onset of grade 1 chronic neuropathy.   
 
These results appeared of potential interest but they were yet to be investigated in a 
Caucasian population. In our population of Caucasian individuals of European ancestry, 
we planned a candidate gene study to investigate possible associations with chronic 
oxaliplatin induced peripheral neuropathy and rs843748 (ACYP2), rs17140129 (FARS2) 
and rs10486003 (TAC1).  
 
Table 4.3 Summary of details of SNPs selected for exploration in the oxaliplatin cohort 
Gene rs number Chr position (bp) Amino Acid 
Substitution 
Functional Consequence 
ACYP2 Rs843748 2:54502912 Intronic variant Uncertain. ACYP2 encodes acylphosphatase 2 
which is related to Ca2+/Mg2+-ATPase pump 
associated with skeletal muscle (380) and 
variants have also been linked to cisplatin 
ototoxicity (381)  
FARS2 Rs17140129 6:5298362 Intronic variant Uncertain. The protein product plays a role in 
mitochondrial protein translation. Mutations in 
this gene can result in encephalopathy (380) 
TAC1 Rs10486003 7:97229778 n/a This gene encodes four products of the 
tachykinin peptide hormone family which are 
thought to function as neurotransmitters 
which interact with nerve receptors and 
smooth muscle cells (380). 
Tables compiled with reference to dbSNP(378) and PharmGKB (379)databases 
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4.2 METHODS 
 
4.2.1 Patients and Methods 
 
Two studies contributed to the total population for genotyping. The first was a 
prospective cohort of patients recruited at the beginning or during chemotherapy. Both 
studies were approved by the Liverpool ethics committee and all patients signed a 
consent form after being provided with information about the study (See appendix 1 
for study protocols and ethics approval). 
 
Inclusion criteria were: 
(1) Patients over 18 years of age 
(2) Due to commence/ receiving chemotherapy with one of the following regimens: 
a. Paclitaxel 175mg/m2 three- weekly with or without concurrent three-
weekly carboplatin (at least 4 cycles planned) or equivalent  
b. Docetaxel 100mg/m2 for at least 4 planned cycles or at least 6 planned 
cycles of docetaxel 75mg/m2.  
c. Oxaliplatin 85mg/m2 or greater for at least 6 planned cycles 
 
Exclusion criteria were:  
(1) Patients with pre-existing peripheral neuropathy symptoms  
(2)  Patients receiving concurrent cisplatin or vinca alkaloid due to their known 
neurotoxic potential.  
 
Patients were monitored by their own medical team and assessed each cycle by a 
chemotherapy nurse who scored the patients neuropathy according to the NCI CTC 
scale. In addition to these routine assessments, patients were clinically assessed by a 
member of the CIPN study team, and sensory and motor neuropathy graded according 
to the NCI CTC scale on or before the first day of cycle one, cycle four, post cycle 6 and 
post completion of treatment (for those receiving more than six cycles of 
chemotherapy).  
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Prospectively recruited patients who discontinued the planned course of chemotherapy 
early without meeting case criteria, who did not reach the minimum dose criteria to be 
classed as a control, were excluded from genotyping analysis. Examples included 
patients who discontinued paclitaxel due to hypersensitivity reactions after one or two 
cycles, or those who stopped chemotherapy due to disease progression on an interval 
scan. All prospectively recruited patients were also asked to complete EORTC-QLQ C30 
and CIPN20 quality of life modules at recruitment, at cycle four, post cycle 6 and post 
completion of treatment (for those receiving more than six cycles of chemotherapy). 
They were also asked to again complete the same quality of life modules at 6 and 18 
months post-completion of treatment. 
 
The second study was a case-control study performed as part of the Molecular Genetics 
of Adverse Drug Reactions NIHR portfolio study.  Patients were recruited through two 
sites, Clatterbridge Cancer Centre NHS Foundation Trust and St Helens and Knowsley 
NHS Trust. Eligible patients were identified either on the Chemotherapy Day Units 
where they received their treatment, notified to the trials team by patients’ consultants 
or via lists of patients who had received the appropriate chemotherapy drugs 
generated by the coding department.  
 
Inclusion criteria were: 
(1)  Patients over 18 years of age 
(2)  Meeting the case or control definition 
Case definition: developed grade 3-4 CIPN during or within 6 weeks of 
completion of taxane or oxaliplatin chemotherapy OR have developed grade 2 
neuropathy resulting in dose delay, dose reduction or early cessation of their 
taxane or oxaliplatin therapy. 
Control definition: experienced no neuropathy or mild (maximum NCI CTC 
grade 1) neuropathy only. 
(3) Had completed a course of chemotherapy including 
(a) Paclitaxel 175mg/m2 three- weekly with or without concurrent 
three-weekly carboplatin  (at least 4 cycles planned) or 
equivalent  
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(b) Docetaxel 100mg/m2 for at least 4 planned cycles or at least 6 
planned cycles of docetaxel 75mg/m2.  
(c) Oxaliplatin 85mg/m2 or greater for at least 6 planned cycles 
 
 Exclusion criteria were:  
      (1) the presence of any pre-existing peripheral neuropathy symptoms, or  
      (2)  subsequent treatment with a further neurotoxic chemotherapy agent which 
could hamper      assessment of severity or persistence of CIPN caused by the 
index drug course.  
 
Medical case-notes and chemotherapy nursing records were reviewed to assess 
documentation of neuropathy during and after chemotherapy but patients were only 
recruited after a consultation with an experienced CIPN research practitioner to 
confirm NCI CTC grading of neuropathy. Case-notes alone were not relied upon due to 
the well-recognised fact that neuropathy is frequently under-recognised in routine 
practice. 
 
For cases, patients must have experienced grade 3-4 CIPN or have developed grade 2 
neuropathy resulting in dose delays, dose reductions or early cessation of their taxane 
or oxaliplatin therapy. Controls had to have completed a course of chemotherapy 
comprising at least 4 cycles of paclitaxel 175mg/m2 given three-weekly; at least 4 cycles 
of docetaxel 100mg/m2; at least 6 cycles of docetaxel 75mg/m2; or at least 6 cycles of 
oxaliplatin 85mg/m2. This was to ensure that anyone being categorised as a control had 
had a sufficiently high cumulative dose of taxane or oxaliplatin to feel confident that 
they represented an appropriate control rather than simply not having received enough 
of the drug.  They had to have experienced a maximum of grade 1 neuropathy with no 
adjustment to their taxane therapy required for neurotoxicity. Particular care was taken 
when evaluating oxaliplatin-treated patients to ensure that both acute and chronic 
neuropathy symptoms were assessed and that it was the chronic neuropathy grading 
that contributed to their eligibility criteria for the study. 
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For all patients recruited through both studies, demographic data were collected along 
with clinical history of diabetes, alcohol excess or other conditions which could 
independently pre-dispose to neuropathy. Treatment details were recorded, including 
any dose delays, reductions or early cessation with reasons for any changes to planned 
schedule and importantly, the cumulative dose of taxane/ oxaliplatin received was 
recorded. 
 
A 9ml EDTA blood sample was taken from each subject. If venepuncture was not 
possible a saliva sample was taken. 
 
4.2.2 DNA extraction and genotyping 
 
 DNA was extracted from whole blood using chemagen kits. If for any reason it wasn’t 
possible to collect a blood sample, a saliva sample was taken and DNA extracted using 
DNA Genotek Oragene DNA kits. DNA was quantified using NanodropTM. The samples 
were then normalised and plated onto 96-well plates. All selected SNPs were confirmed 
to have a minor allele frequency >5% in Caucasian populations using HapMap prior to 
proceeding.  
Taxane genotyping 
 
Primers were obtained from Metabion (Planegg, Germany). Details of forward, reverse 
and extension primers are provided in table 4.4. The samples were genotyped using 
iPLEX chemistry on the MAssArray platform according to the manufacturer’s 
instructions (Agena Bioscience GmBH, Hamburg, Germany) on mixed plates of cases 
and controls to ensure genotyping was performed blinded to clinical data. Any samples 
with a genotyping rate of <75% (6/8 SNPs) were to be excluded, as were any SNP assays 
with a call rate of <97%. 98 (50%) samples were analysed in duplicate to ensure quality 
and consistency of genotyping data.  
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Table 4.4. Details of forward, reverse and extension primers 
 Forward primer (5' -3') Reverse primer (5' -3') Extension primer (5' -3') 
rs35599367 ACGTTGGATGCTCCTTGATCTCA
GAGGTAG 
ACGTTGGATGCAGAAGGTGTTATCAGG
TGC 
CTCCATCACACCCAG 
rs11572080 ACGTTGGATGTTTCTCCCTCACA
ACCTTGC 
ACGTTGGATGCAGTGAGCTTCCTCTTGA
AC 
ACGGTCCTCAATGCTC 
rs10771973 ACGTTGGATGGATGGCGATTTTT
CTTCCCC 
ACGTTGGATGACCCAAATCAGCTAGGA
CTC 
GCTAGGACTCAGAGACA 
rs10509681 ACGTTGGATGCTTATCTAGAAAG
TGGCCAG 
ACGTTGGATGTGGCATTACTGACTTCCG
TG 
gCGTGCTACATGATGACA 
rs7349683 ACGTTGGATGATACCGGCCCATC
TTGATTG 
ACGTTGGATGATTGGCAGAACATAGCC
CAC 
CACCTACTGATCTGTAGGC 
rs17348202 ACGTTGGATGCAAAATTCTTAGG
TTCCCACG 
ACGTTGGATGCATGTGACAAGTGGCTG
TCG 
TTGGATATCAGGATCTAGAG 
rs301927 ACGTTGGATGGACAGAAAGGGA
AACATCTC 
ACGTTGGATGGAGATTTTTAAAAGGTCT
TC 
TAGCCAAATATGAGAATCATTG 
rs4737264 ACGTTGGATGTCATTACAATGTG
AATGGC 
ACGTTGGATGAAGGATTCTGGCTATCAC
CC 
ACCCACTATTACAGGGTTGTATA
T 
 
Oxaliplatin genotyping 
 
Genotyping for the three selected SNPs was carried out using pre-validated, 
commercially available TaqMan real-time PCR allelic discrimination assays 
(LifeTechnologies, Paisley, UK) on mixed plates of cases and controls to ensure 
genotyping was performed blinded to clinical data. Any samples with more than one 
SNP result missing was planned for exclusion. Any SNP assays with a call rate of <97% 
were planned for exclusion. 18 samples (15%) were analysed in duplicate to assess 
genotype concordance.  
 
4.2.3 Statistical analysis 
 
The primary outcome investigated was an association of the selected SNPs with the 
occurrence of grade 3 or 4 sensory neuropathy, or grade 2 sensory neuropathy 
associated with dose delays, dose reductions or early cessation of taxane therapy. 
Potential clinical covariates were analysed between cases and controls prior to 
proceeding to genotyping analysis using SPSS (version 22). Age and BMI were compared 
using a student t test and cumulative dose of either paclitaxel/ docetaxel or oxaliplatin 
were compared between case and control groups using Mann Whitney tests. Status 
with regard to diabetes, alcohol consumption, concurrent medication with selective 
serotonin reuptake inhibitor (SSRI) or SNRI, gabapentin or pregabalin, calcium channel 
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blocker, or amitriptyline and prior taxane exposure were compared using chi square 
and Fishers exact tests. For oxaliplatin only, 2-weekly versus 3-weekly schedule was also 
compared using the chi square test. 
 
Univariate analysis was carried out for SNP association with case or control status. Any 
clinical factors found to differ significantly (p<0.1) between case and control groups 
were then entered into the analysis (backward selection procedure). An exception to 
this was difference in cumulative dose for taxane patients. All control individuals had 
received a set minimum course of the drug as outlined above in the inclusion criteria 
and group comparisons were performed to confirm sufficient cumulative dose. Both 
docetaxel and paclitaxel-receiving patient control groups had received significantly 
more of the index drug than the case group. This can be accounted for by the fact that 
many of the case patients had had dose reductions or early cessation of their taxane 
due to their susceptibility to neurotoxicity. Cumulative dose was included in the 
oxaliplatin multivariate analysis as although minimum dose criteria were applied it was 
evident that cases had received a higher median cumulative dose of oxaliplatin. 
 
Genotyping data was analysed with PLINK software using a logistic model and assuming 
an additive mode of inheritance. A Bonferroni p-value threshold of 0.00625 was set for 
the taxane study and 0.017 for the oxaliplatin study to account for multiple testing.  For 
the patient reported outcome data (EORTC QLQ C30 and CIPN20 modules), all quality of 
life data were scored as per the EORTC guidelines. End of treatment CIPN20 sensory 
scores were compared according to case or control status using the Mann Whitney U 
test within SPSS (version22). 
 
As a number of different SNP associations were being investigated no single sample size 
or power calculation is possible as the power to detect a significant difference in risk 
conferred by an individual SNP will vary depending on the effect size and the minor 
allele frequency. The aim was to recruit as many patients as possible within the study 
time period. 
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4.3 RESULTS 
 
4.3.1 Taxane study results 
 
A total of 193 eligible Caucasian patients of European background were recruited. Six 
patients were excluded from the genotyping for quality control reasons leaving 187 
patients with valid genotyping data.  All eight SNPs had call rate >99%. Four samples 
were excluded due to <75% successful genotyping, of which one sample had a 
particularly low concentration of DNA. Two samples were excluded due to non-
concordance on duplicate genotyping (for each of these two duplicated samples, one of 
the eight SNPs was non-concordant, in each, one sample of the pair was called as a 
heterozygote and one as a homozygote wild-type for both pairs). Both of these samples 
were excluded from all SNP analysis. All SNPs were confirmed to be in Hardy Weinberg 
equilibrium (HWE) (p values all >0.2). 
 
For the 187 patients included, there were only four missing genotypes; genotyping was 
successful for all but two SNPs in two samples. Both of these samples had low DNA 
concentration (9.725ng/ul and 44.82ng/ul, respectively) and this may therefore have 
contributed to the less than complete genotyping.  
 
As a means of checking for clear genotyping errors or inconsistencies between the 
study population and the general population, where data was available, the study 
genotype frequencies were compared to those published through the HapMap-CEU 
(Utah residents with Northern/ Western ancestrory) population stated on the dbSNP 
database (378). This data is presented in table 4.5. For all except one SNP, there was no 
significant difference between our genotyping frequencies and those reported in the 
reference population. For the one SNP, the difference was due to the greater 
proportion of heterozygotes seen in the reference population compared to wildtype 
homozygotes for rs7349683, compared to our population. 
 
 
 160 
Table 4.5 Genotyping distributions compared to other Caucasian populations (using 
HapMap- CEU genotype frequencies) 
Rs number Allele 
(ref/var) 
Study population genotype data Public 
data 
(n=no. of 
patients) 
Chi square 
test p value 
Study data vs 
public data) 
A1/A1 A1/A2 A2/A2 MAF* MAF*  
rs35599367 C/T 160 25 0 0.00675 0.025 
(60) 
 
 
n/a (MAF 
available only) 
rs11572080 G/A 142 41 3 0.126 0.1083 
(60) 
p=0.66 
rs10509681 T/C 142 41 3 0.126(C) 0.1372 
(C) 
(n=113) 
p=1.00 
rs10771973 G/A 105 69 13 0.254 
(A) 
0.281 (A) 
(n=112) 
p=0.806 
rs7349683 C/T 92 75 20 0.3074 0.4027 
(n=113) 
p=0.00 
rs17348202 T/C 164 22 0 0.0591 0.0575 
(n=113) 
p=1.00 
rs301927 A/G 135 48 4 0.150 0.1637  
(n=113) 
p=0.841 
rs4737264 A/C 105 69 13 0.2540 0.2389 
(n=113) 
p=0.564 
*MAF=mean allele frequency 
 
Demographic data for the eligible recruited patients are shown in table 4.6. Median age 
was 60.3 years. There was no significant difference in concurrent diabetes or alcohol 
consumption between cases or controls, and neither was there a difference in age or 
BMI. There was a significantly greater proportion of female patients in the case group. 
This is likely because paclitaxel causes more neuropathy than docetaxel and all of the 
paclitaxel- receiving patients were female in this cohort.  
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Table 4.6. Demographic and clinical details of the taxane- treated cohort 
 Population 
N=193 
Controls 
N=124 
Cases 
N=69 
P value 
where 
appropriate 
Age (years) 60.3 59.9 61.0 P=0.486 ◊ 
Gender Female 
Male 
157 
36 
94 
30 
63 
6 
P=0.008 Ϯ  
Drug Docetaxel 
Paclitaxel 
101 
92 
74 
50 
27 
42 
P=0.006 Ϯ 
BMI  26.75 26.49 27.21 P=0.467 ◊ 
Diabetes No 
Yes 
187 
6 
122 
2 
65 
4 
p=0.188 ≠ 
Alcohol 
consumption 
<1 unit per week 
1-14 units per 
week 
15-21 units per 
week 
>21 units per 
week 
Missing 
95 
75 
 
5 
 
3 
 
15 
57 
52 
 
4 
 
2 
 
9 
38 
23 
 
1 
 
1 
 
6 
p=0.544 Ϯ 
Prior taxane 
treatment 
No 
Yes 
Missing 
181 
10 
2 
115 
8 
1 
66 
2 
1 
p=0.499 ≠ 
Concurrent 
SSRI or SNRI 
No 
Yes 
175 
18 
111 
13 
64 
5 
p=0.449 ≠ 
Concurrent 
amitriptyline 
No 
Yes 
186 
7 
122 
2 
64 
5 
p= 0.100 ≠ 
Concurrent 
gabapentin 
or pregabalin 
No 
Yes 
188 
5 
121 
3 
67 
2 
p=1.00 ≠ 
Concurrent 
calcium 
channel 
blocker 
No 
Yes 
Missing 
173 
19 
1 
113 
10 
1 
60 
9 
p=0.282 Ϯ 
Cumulative 
dose (mg/m2) 
Docetaxel 
Paclitaxel 
467.6 
888.2 
483.4 
996.2 
424.3 
759.1 
p=0.04◊ 
p=0.00 ◊ 
 Ϯ= chi square, ≠ = Fishers test, ◊= Mann- Whitney U test 
 
 
None of the seven variants were found to be associated with development of taxane 
induced peripheral neuropathy on univariate analysis or after adjustment for 
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potentially relevant clinical factors (table 4.7). Study of docetaxel and paclitaxel- treated 
groups separately also showed no clear evidence of association (table 4.8).  
   
Table 4.7. Genotyping results for taxane-treated cases and controls with effect 
estimates 
Gene SNP Taxane  
Controls Cases OR (95% CI) p value 
CYP2C8 *3 *1/*1 
*1/*3 
*3/*3 
Missing 
92 
26 
1 
0 
50 
15 
2 
1 
 
1.25 (0.67-2.34) 
 
0.484 
CYP3A4 *22 
(rs3559936
7) 
CC 
CT 
TT 
Missing 
105 
13 
0 
1 
55 
12 
0 
1 
 
1.78 (0.76-4.16) 
 
0.184 
EPHA4 rs17348202 TT 
CT 
CC 
Missing 
105 
13 
0 
1 
59 
9 
0 
0 
 
1.24 (0.50-3.08) 
 
0.638 
EPHA5 rs7349683 CC 
CT 
TT 
Missing 
58 
49 
12 
0 
34 
26 
8 
0 
 
1.00 (0.64- 
1.56) 
 
0.992 
EPHA6 rs301927 AA 
AG 
GG 
Missing 
87 
31 
1 
0 
48 
17 
3 
0 
 
1.18 (0.67-2.10) 
 
0.553 
FGD4 rs10771973 GG 
GA 
AA 
Missing 
68 
44 
7 
0 
37 
25 
6 
0 
 
1.17 (0.73-1.88) 
 
0.521 
XKR4 rs4737264 AA 
AC 
CC 
Missing 
69 
42 
8 
0 
36 
27 
5 
0 
 
1.17 (0.73-1.88) 
 
0.521 
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Table 4.8. Genotyping results for taxane-treated cases and controls stated separately 
for docetaxel- and paclitaxel treated patients, respectively 
Gene SNP Docetaxel  Paclitaxel 
  Controls Cases Controls Cases 
CYP2C8 *3 *1/*1 
*1/*3 
*3/*3 
Missing 
55 
16 
0 
0 
19 
6  
0 
1 
37 
10 
1 
0 
31 
9 
2 
0 
CYP3A4 *22 
rs35599367 
CC 
CT 
TT 
Missing 
64 
8 
0 
0 
21 
4 
0 
0 
43 
4 
0 
1 
33 
8 
0 
0 
EPHA4 rs17348202 TT 
CT 
CC 
Missing 
65 
7 
0 
0 
22 
4 
0 
0 
41 
6 
0 
1 
36 
5 
0 
0 
EPHA5 rs7349683 CC 
CT 
TT 
Missing 
32 
30 
10 
0 
11 
12 
3 
0 
26 
19 
3 
0 
23 
14 
4 
0 
EPHA6 rs301927 AA 
AG 
GG 
Missing 
52 
17 
3 
0 
16 
9 
1 
0 
35 
13 
0 
0 
31 
8 
2 
0 
FGD4 rs10771973 GG 
GA 
AA 
Missing 
38 
31 
3 
0 
13 
10 
3 
0 
32 
12 
4 
0 
24 
14 
3 
0 
XKR4 rs4737264 AA 
AC 
CC 
Missing 
45 
24 
3 
0 
17 
8 
1 
0 
26 
17 
5 
0 
19 
18 
4 
0 
 
4.3.2 Results for oxaliplatin study 
 
A total of 120 Caucasian colorectal cancer patients were eligible for genotyping 
analysis, 78 males and 42 females with a mean age of 61 years (range 27-80). The 
demographic and clinical data for the patient cohort are detailed in table 4.9.  
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Table 4.9 Demographic data for the oxaliplatin cohort 
 
 
Population Controls Cases  
Gender                             Female 
                                              Male 
42 
78 
23 
29 
19 
49 
 P=0.064 Ϯ 
Age (mean) 61.0 62.4 59.9 P=0.175 ≠ 
BMI (mean) 27.14 27.12 27.15 P=0.976≠  
Diabetes                                 Yes 
                                                  No 
13 
107 
7 
45 
6 
62 
P=0.418 Ϯ   
Previous oxaliplatin              Yes                                                                        
                                                  No 
6
114 
3 
49 
3
65 
p-1.00 ≠ 
Frequency of oxaliplatin   
                                        2 weekly 
                                        3 weekly 
83 
37 
38 
14 
45 
23 
P= 0.417 Ϯ  
Alcohol consumption         
                                <1 unit per wk 
                                 1-14 units/wk 
                                15-21 units/wk                                                                                                  
                                   >21 units/wk 
 
61 
43 
4
6 
 
23 
21 
0 
3 
 
38 
22 
4
3 
P=0.227 Ϯ  
Concurrent treatment 
with a SSRI/SNRI    
No 
Yes                                                  
112 
8
48 
4
64 
4 
P=0.726 ≠  
Concurrent treatment 
with 
gabapentin/pregabalin 
No 
Yes 
118 
2 
50 
2 
68 
0 
P=0.186 ≠  
Concurrent treatment 
with amitryptilline 
No 
Yes 
118 
2 
52 
0 
66 
2 
P=0.505 ≠  
Concurrent treatment 
with a calcium channel 
blocker 
No 
Yes 
105 
15 
43 
9 
62 
6 
P=0.164 Ϯ  
Cumulative dose oxaliplatin 
(mg/m2) (mean) 
662.2 622.7 692.4 P= 0.067 ◊ 
Ϯ= chi square, ≠ = Fishers test, ◊= Mann- Whitney U test 
 
The cumulative dose achieved was slightly lower in the control group for oxaliplatin-
treated patients although a mean dose of 622.7mg/m2 represents a satisfactory 
exposure. For a small group of patients, despite meeting the control criteria for at least 
six cycles of oxaliplatin, their total dose fell below this arbitrary threshold of 510mg/m2 
due to dose reductions for non-neurotoxicity reasons. It may also be that they were 
more palliative treatment patients in the control group who often receive fewer cycles 
per course than adjuvant patients. In our trial population, men were significantly at 
higher risk of meeting criteria for a case for CIPN. Due to the relatively small size of the 
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sample and the mixed study design, it is difficult to know how significant this is. There 
was no significant difference in the cumulative dose received between males and 
females (642.9 compared with 688.5mg/m2). There was also no difference in the 
schedules between gender groups. 
 
With regard to genotyping, call rates for all three SNPs were >99%.  For rs843748 and 
rs10486003 there was one missing genotype each. No samples had to be excluded for 
having more than one genotype missing. For one sample, the likely reason for missing 
genotype data was low DNA concentration from a saliva sample. One of the duplicated 
samples showed non-concordance in one SNP (rs10486003), one sample was called as a 
heterozygote and one as homozygote wild-type. This sample was excluded for all SNP 
analysis leaving a sample size of 119. As with the genotyped taxane- treated cohort, 
genotype frequencies were compared between our study and those published on the 
dbSNP database (378). 
 
Table 4.10 Genotyping distributions compared to other Caucasian populations (using 
HapMap- CEU genotype frequencies) 
Rs number Allele 
(A1/A2) 
Study population genotype data Public 
data 
Chi square 
test p value* 
Study data vs 
public data) 
A1/A1 A1/A2 A2/A2 MAF MAF  
rs843748 
(ACYP2) 
A/G 32 49 37 0.5212 0.5417 
 
P=0.767 
rs17140129 
(FARS2) 
A/G 87 31 1 0.1387 0.1460  
 
 
P=0.813 
rs10486003 
(TAC1) 
C/T 91 26 1 0.1186 0.1018  P=0.860 
*Exact 2 sided p value stated 
 
 
There was no association seen with any of the three SNPs selected in our Caucasian 
population on either univariate analysis or on multivariate analysis (table 4.11). 
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Table 4.11 Genotyping results for oxaliplatin- treated patient cohort with effect 
estimates 
SNP Controls Cases OR (95% CI) P value 
rs843748 
(ACYP2) 
AA 
AG 
GG 
missing 
15 
20 
16 
0 
17 
29 
21 
1 
0.93 (0.58-
1.50) 
0.778 
rs17140129 
(FARS2) 
AA 
AG 
GG 
missing 
36 
15 
0 
0 
51 
16 
1 
0 
0.87 (0.40-
1.90) 
0.734 
rs10486003 
(TAC1) 
CC 
CT 
TT 
Missing 
41 
10 
0 
0 
50 
16 
1 
1 
1.46 (0.63-
3.39) 
0.382 
 
 
Since this work was carried out, an Italian group has also attempted this same 
replication in a Causcasian population (89). They elected to investigate eight SNPs from 
the original GWAS by Won et al in a population of 150 colorectal cancer patients. They 
also could not demonstrate an association with the GWAS-identified SNPs. Given that 
data was available from three of four studies investigating these three SNPs, the 
combined results were entered into a meta-analysis. The main limitation to this is the 
slightly differing case definition. Terrazzino et al used grade 2-4 chronic neuropathy, 
Oguri et al used grade 3-4 or grade 2 lasting more than 7 days and in our study, we used 
grade 3-4 chronic neuropathy or grade 2 chronic neuropathy resulting in adjustment to 
treatment regimen. But given that differences were small in the definitions, and all 
studies have used NCI CTC, it didn’t seem unreasonable to look at the pooled data. 
Unfortunately, the genotype data per case/ control status was not published in the 
original GWAS (272), and so these data could not be entered into a RevMan meta-
analysis.  Also, the Oguri study did not state their odds ratios and so this study could not 
be entered into a QWAMA meta-analysis. Therefore, both meta-analyses were 
conducted by including three out of four studies. The forest plots from RevMan meta-
analysis are presented below in figure 4.1. The results from meta-analysis using 
QWAMA are presented in table 4.12.  
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 (a) 
 
(b) 
 
 
(c) 
 
Figure 4.1. Forest plots showing pooled data from studies investigating a) rs843748 
(ACYP2) b) rs17140129 (FARS2) and c)Rs10486003 (TAC1) 
 
Table 4.12 QWAMA meta-analysis; pooling odds ratios from eligible studies 
investigating association with GWAS- identified SNPs 
Rs number OR (95% CI) Z p-value 
Rs843748 2.21 (1.72-2.86) 6.11 1.02E-009 
Rs17140129 1.17 (0.81-1.70) 0.85 0.40 
Rs10486003 0.67 (0.46-0.99) -2.04 0.04 
 
For the ACYP2 SNP our results agree with the direction of risk of the variant allele found 
by the Asian studies albeit in a non-significant way, whereas for the FARS2 variant 
which was associated with an OR of 14.45 in the original GWAS, both studies in 
Caucasian populations do not even suggest a trend in this direction. For TAC1 the 
results in all three studies look very similar. Oguri et al demonstrated an association 
with time to onset of CIPN with this variant rather than an association with 
development of marked CIPN symptoms (94).  In the original GWAS, this variant was 
protective with an OR 0.17. The QWAMA analyses are highly skewed by the Won data 
(272). 
 
 168 
4.3.3 Patient reported outcomes 
  
Patient reported outcomes as summarised by the EORTC CIPN 20 sensory scores were 
compared between cases and controls to test confidence in phenotyping for this 
subjective adverse effect. Patient reported outcomes were only available for the 
prospectively recruited patients but provide extra information for a sample of patients. 
CIPN20 results were available for a total of 88 genotyped patients (49 controls and 39 
cases). There was no significant difference in the sensory or motor scores at baseline 
but were numerically slightly higher in the control group (p=0.57 and 0.78 for sensory 
and motor scores, respectively). At all other time points, the case group scored higher 
and p values for the difference in scores are presented in table 4.12. All are significant 
demonstrating that our phenotypic classification is supported by patient reported 
outcomes. 
 
Table 4.13. p values demonstrating significant differences in CIPN20 sensory and motor 
scores at all time points throughout assessment up to 18 months post-completion of 
chemotherapy 
 
Group N P value 
(after 6 
cycles 
sensor
y 
score) 
P value 
(after 6 
cycles 
sensor
y 
score) 
N P value 
(after 6 
cycles 
sensor
y 
score) 
P 
value 
(moto
r 
score 
after 6 
cycles) 
No of 
patient
s 
P value 
(sensor
y score 
6 
months 
post- 
chemo) 
P value 
(motor 
score 6 
month
s post-
chemo
) 
Numbe
r of 
patient
s 
P value 
(sensor
y score 
18 
months 
post- 
chemo) 
P value 
(motor 
score 
18 
month
s post-
chemo
) 
Control
s 
4
7 
0.000 0.008 4
9 
0.000 0.000 36 0.000 0.017 25 0.032 0.041 
Cases 2
5 
3
9 
22 18 
All p values are two sided and generated using the Mann Whitney U test to compare scores 
 
 
4.4 DISCUSSION 
 
In this study, designed to attempt replication of previous putative genetic associations 
with taxane and oxaliplatin induced peripheral neuropathy, we failed to demonstrate a 
significant association with any of the selected candidate SNPs. There was not even a 
suggestive trend in our data. This could be due to many reasons; Firstly, no association 
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may in fact exist. With the CYP3A4*22, the initial study that identified the association 
only found the association in female cohorts and the numbers of cases were very small 
(100). They looked at an association with NCICTC grade 3 neurotoxicity and the *22 
variant using a dominant model. However, only two patients in the exploratory cohort 
and four patients in the validation cohort experienced grade 3 neurotoxicity. Our case 
definition was slightly different, but evaluation of our female paclitaxel group alone to 
compare with their analysis as closely as possible, still leaves us with no significant 
association (p=0.21). The proportion of patients with the variant allele was similar in 
both our and De Graan’s study (15% and 14%, respectively). Whilst some studies of 
CYP2C8*3 have shown an association, others have not, and our study adds weight to 
the negative studies. The other SNPs have been identified through GWAS and may be 
false positives. The paclitaxel genome wide studies also used a different outcome 
measure, cumulative dose to grade 2 neuropathy (82, 85). This outcome has been 
increasingly used in studies investigating CIPN and genetic risk. This has the advantage 
that it takes into account the dose received.  However it does not take account those 
patients who may develop grade 2 or higher neuropathy at the end of treatment, who 
will have received the same dose as those who have not had any neuropathy 
throughout treatment. It is also not clear what happens to those patients who stop 
paclitaxel early due to other reasons. For oxaliplatin, perhaps the SNPs identified as 
potentially associated with oxaliplatin induced peripheral neuropathy are only relevant 
in an East Asian population or again perhaps they are purely false positives. In the 
original GWAS, although the SNPs looked promising particularly given their within-study 
and partial independent replication they did not meet the significance level generally 
accepted for genome wide studies, and this may offer an explanation as to why further 
studies have not been able to replicate the findings. 
 
Secondly, an association may exist but the increased risk conferred by variant 
genotypes may be small and our study was simply not large enough to detect these 
differences. The size of our study is a weakness. A larger population would ideally be 
used to investigate this likely complex susceptibility trait.  
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There are however some strengths of our study. Despite the retrospective recruitment 
of a proportion of our patient cohort, all patients were specifically interviewed to 
confirm the history and details of chemotherapy induced peripheral neuropathy rather 
than relying purely on documentation in case notes. Care was taken in defining 
phenotyping to ensure controls had had sufficient exposure to ensure that the 
individual cumulative dose had reached a clinically relevant threshold. All paclitaxel 
patients received three weekly therapy with carboplatin achieving homogeneity of 
treatment. All docetaxel patients were treated on three weekly schedules at a dose of 
60-100mg/m2. All oxaliplatin treated patients were being treated for colorectal cancer 
in combination with a fluoropyrimidine, and two weekly or three weekly schedule was 
considered as a covariate. A more homogeneous cohort may have been achieved by 
specifying just one tumour group in one setting, i.e.. adjuvant or palliative, but that 
would have impacted on the sample size.  Therefore, a balance must be achieved 
between the degree of standardisation of the studied population versus limiting the 
numbers recruited.  A further strength of our study was using patient reported 
outcomes to support and validate health professional CIPN assessment and grading. 
With such a subjective toxicity, this is particularly important. 
 
4.5 CONCLUSION 
 
This was a candidate gene study for susceptibility based on a comprehensive systematic 
review of the evidence base to date. In neither the taxane, nor the oxaliplatin-treated 
groups, were the previously reported SNPs found to have a significant association with 
clinically important CIPN. Small study size was the main limitation and phenotypic 
characterisation the biggest strength. Since undertaking the study, other studies have 
agreed with the conclusions of this study, but new SNP associations have also been 
reported which may open avenues for further investigation.   Building of a biobank of 
well-defined case and control subjects with patient reported outcome data to support 
categorisation has the potential to be an asset to continue to explore further potential 
associations. In the field of taxane-induced peripheral neuropathy, the Charcot Marie 
Tooth related genes (321, 322) warrant further investigation. For oxaliplatin, a large 
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GWAS may be necessary with well-defined phenotypic categorisation to generate new 
avenues for exploration. 
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CHAPTER 5 
 
 
 
 IMPACT OF CIPN ON QUALITY OF LIFE: 
CLINICAL COHORT STUDY 
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5.1 INTRODUCTION 
 
There has been increasing focus in recent years on survivorship issues in cancer care. As 
a report by MacMillan Cancer Support identified, there are 500,000 people living with 
poor health or disability due to cancer or its treatment (382). Some of this number is 
certainly due to effects of incurable cancer and not all will be avoidable, but a 
significant number live with long term toxicity of treatment and understanding this 
better is vital to improve patient counselling, treatment, support and hopefully in the 
end, prevention.  There are no good estimates of the prevalence of chemotherapy 
induced peripheral neuropathy. It has been shown that physicians underestimate CIPN 
symptoms (154) and there is relatively little published data documenting the impact of 
persistent CIPN.  Although incidence data are available from clinical trials, CIPN is 
frequently reported as a largely reversible adverse effect.  However, as mentioned 
previously, a small proportion of patients experience persistent symptoms and this may 
be under-estimated in clinical trials because of the nature of the follow which tends to 
be short-term.  Indeed, experience from real-life populations supports the notion that 
long-term effects are more significant than previously reported. 
 
A group exploring the experience of CIPN conducted a qualitative thematic systematic 
synthesis of the literature to understand the effect of this adverse reaction (383). They 
identified five studies which collectively evaluated 88 patients who had received 
neurotoxic chemotherapy. These studies described some of the functional impacts of 
CIPN, including effects on buttoning shirts, fastening jewellery, turning pages, walking, 
and climbing stairs. The studies also reported that patients had been unable to return 
to usual work duties and felt that socialising was inhibited. 
 
A systematic review published in 2014 found only 11 studies which actually investigated 
a direct association between CIPN and quantitative measures of quality of life (384). 
Eight studies suggested a correlation (138, 152, 385-390) whereas three studies did not 
(391-393). Other studies included in the review, whilst not directly exploring the 
correlation between quality of life measures and CIPN, looked at both changes in 
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quality of life and CIPN, separately, over time. For instance, one prospective study 
demonstrated that EORTC QLQ-C30 QoL scores did not change over time whilst CIPN 
increased (394). Similarly, a number of randomised controlled trials reported 
differential rates of neurotoxicity between treatment arms but no difference in QoL 
(395, 396). The authors concluded that further prospective studies using validated 
questionnaires were necessary.  
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Table 5.1 Table of studies to date exploring a direct association between CIPN and QoL 
Study Population Primary cancer and treatment Design CIPN assessment QoL assessment 
tool 
Conclusions 
Type of 
assessment 
Tool 
Arraras  et 
al (397) 
39 Lung cancer; platinum 
doublets 
Prospective HCP NCI CTC EORTC QLQ-C30 
EORTC QLQ-LC13 
No significant association with low global QOL 
Bayo et al 
(398) 
92 Breast cancer; docetaxel, 
epirubicin, cyclophosphamide 
Cross-
sectional 
Patient 
HCP 
Toxicity questionnaire 
NCI CTC 
Euro-QOL-5D No evidence of association between CIPN and QOL 
Calhoun et 
al (392) 
99 Ovarian cancer; carboplatin 
and paclitaxel 
Prospective Patient 
HCP 
 
NP 
FACT/GOG-NTX 
Sensory symptoms, pin prick sensation, 
power, reflexes, vibration test 
Thermal discrimination threshold test, 
vibration threshold test 
FACT-G No effect; FACT-G improved as FACT/GOG-NTX deteriorated 
Cella et al 
(152) 
230 Lung cancer; carboplatin and 
paclitaxel 
Prospective Patient FACT/GOG-NTX, FACT-taxane FACT-G Significant decrease in total FACT-G scores with 
neurotoxicity but no correlation with change in global QoL  
Driessen et 
al (390) 
131 (43 
pre-, 88 
post- 
chemo) 
Mixed tumour types treated 
with any potentially neurotoxic 
drugs 
Cross-
sectional 
Patient CINQ(399) 
FACT/GOG-NTX 
FACT-G Significant negative correlation with both FACT/GOG-NTX 
and CINQ with FACT-G scores 
Griffith et 
al (388) 
29 Mixed tumour types treated 
with taxanes or platinums 
Prospective Patient FACT/GOG-NTX, Neuropathic pain scale FACT-G Correlation between NCI CTC sensory grading and current 
perception threshold with inverse relationship between CPT 
and FACT/GOG-NTX and FACT-G total score HCP NCI CTC  
Clinical Pinprick sensation, reflexes  
NP Current perception threshold, quantative 
sensory testing, mechanical detection 
thresholds,vibration perception threshold, 
grip strength 
 
Hershman 
et al (400) 
100 Early stage breast cancer; 
adjuvant taxanes 
Mixed 
prospective 
and cross-
sectional 
Patient 
NP 
FACT-GOG-NTX 
QST; tactile threshold and vibration 
threshold 
FACT-G Severe neuropathy associated with lower scores on the 
physical well being subscale of the FACT-G. FACT/GOG-NTX 
scores inversely correlated with hand vibration QST 
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Kim et al 
(387) 
32 B-cell lymphoma; R-CHOP or R-
CVP 
Prospective Patient Neuropathy symptom score and neuropathy 
disability score(401) 
SF-36 Significant reduction in physical function, social function, 
role function, bodily pain, vitality and physical component 
summary scores of the SF-36 in patients with neurotoxicty 
HCP NCI CTC  
NP NCS  
Mols et al 
(385) 
1643 Colorectal cancer; no chemo, 
oxaliplatin- based chemo and 
chemo without oxaliplatin 
Cross-
sectional 
Patient EORTC QLQ-CIPN20 EORTC C30 Those with many neuropathy symptoms reported 
significantly worse scores on all functioning and the global 
health status scale.  
Morita et 
al (391)  
377 Lung cancer; irinotecan with or 
without cisplatin or cisplatin 
and vindesine 
Prospective  HCP WHO guidelines QOL-ACD(402) No significant effect between peripheral neuropathy and 
the four domains of the QOL scale 
Ostchega 
et al (389) 
30 Testicular or ovarian cancer; 
cisplatin 
Cross-
sectional 
Patient: 
research 
based 
symptom 
survey 
Satisfaction with life scale(403) 
QoL questionnaire 
Satisfaction with 
life scale(403) 
QoL 
questionnaire 
CIPN associated with QoL 
Padman et 
al (10) 
25 Colorectal cancer; oxaliplatin Cross-
sectional 
(>2 years 
post 
chemo) 
Patient Semi-structured interview and EORTC 
CIPN20 
WHOQOL BREF 
EQ-5D-5L 
Higher TNS score showed a trend towards poorer WHOQOL 
scores but was not significant. 
No significant correlation between self-reported 
neuropathy symptoms and functional impairment scores.  HCP NCI CTC, mTNS 
NP Modified TNS 
Song et al 
(404) 
66 Haematology malignancies; 
vincristine, thalidomide, 
lenalidomide,or bortezomib 
Cross-
sectional 
study 
Patient EORTC CIPN20 EORTC QLQ-C30 CIPN-related lower limb extremity symptoms associated 
with global health status and functional scales of the EORTC 
QLQ- C30 
Sorbe et al 
(386) 
110 Ovarian cancer; Docetaxel and 
carboplatin 
Prospective Patient 
HCP  
Clinical and 
NP 
Questionnaire 
NCI CTC 
Romberg test, patellar and Achilles reflexes, 
2-point discrimination and vibratory sense. 
EORTC QLQ-C30, 
EORTC OV28 
Significant association between development of CIPN and 
global QoL 
Tachi et al 
(405) 
48 Breast cancer; treatment not 
stated 
Prospective HCP NCI CTC EQ-5D 
QOL-ACD 
No significant association between peripheral neuropathy 
and quality of life 
Tofthagen 
et al (406) 
111 Colorectal cancer; oxaliplatin Cross-
sectional 
study 
Patient CIPNAT SF-36 No effect on the general health measure of the SF-36 but 
association with worse outcome on all other subscales and 
higher scores for CIPN 
Yoo et al 
(407) 
195 Mixed; taxanes and or 
platinum 
Cross-
sectional 
study 
Patient 
HCP 
FACT/GOG-Ntx 
Power, reflexes, pinprick perception, 
vibratory perception 
FACT-G Weak negative associations between clinical findings 
associated with CIPN and various subscales of the FACT-G 
HCP= health care professional, NP=neurophysiological. 
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There are several reasons why some studies may not have shown a correlation between 
CIPN and quality of life measures.  For example, in Calhoun et al, the majority of the 
population with ovarian cancer had advanced disease; if they responded to chemotherapy, 
it is unsurprising that their quality of life may improve despite worsening CIPN given that 
their cancer symptoms may improve and they feel that treatment is having some success 
(392).  In the Morita et al study, occurrence of peripheral neuropathy and QOL scores were 
assessed over the first four weeks of treatment only. Given that CIPN usually develops with 
higher cumulative doses over time, it is unsurprising that only a small number of patients 
experienced this side effect during the 4-week time period, and that the study showed no 
significant impact on QOL (391). In the Ramchandren study looking at 37 survivors of 
childhood acute lymphoblastic leukaemia, almost a third were found to have neuropathy on 
neurophysiological studies but most were asymptomatic, and thus no correlation was seen 
with overall quality of life (393). 
 
Since the systematic review, a number of studies have been published. Padman et al 
performed a cross- sectional study of patients at least 2 years post initiation of oxaliplatin-
based chemotherapy. They combined clinical and neurophysiological examination (nerve 
conduction studies) with the WHO quality of life scale and EQ-5D-5L health questionnaire to 
grade depression and the EORTC QLQ-CIPN20. They also interviewed all patients. Twenty-
five patients participated although only 13 went ahead with neurophysiological tests. Two 
had pre-existing diabetic neuropathy. Out of the 25, three reported always having 
symptoms of CIPN, and six often had symptoms of CIPN. The main conclusions from the 
interviews were that a number of these patients felt inadequately warned about the 
possibility of such symptoms. A small number of patients were not able to continue working 
due to symptoms of CIPN. Overall however it seemed that they felt satisfied with the 
decision to receive the treatment (10). 
 
A study relating questionnaire scores on the Functional Assessment of Cancer Therapy- 
Gynecologic Oncology Group- neurotoxicity subscale (FACT-GOG-Ntx) to a bedside 
assessment of CIPN by experienced nurses including vibration and light touch testing 
showed a weak correlation with negative quality of life scores. Patients reported that 
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‘numbness or tingling in feet’, feeling ‘weak all over’, ‘numbness or tingling in the hands’ 
and ‘trouble buttoning buttons’ had a severe, negative impact on their quality of life (407). 
 
Tofthagen et al performed a cross-sectional study of 111 colorectal cancer survivors at 1-7 
years post-initiation of chemotherapy using the Medical Outcomes Study Short Form 36 (SF-
36) to measure health-related quality of life alongside a modified version of the 
‘Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT)’ which measured 
both symptom severity and interference of symptoms with everyday activities (406). They 
demonstrated a correlation between poorer HRQOL and scores indicating increased CIPN 
symptoms and interference on the CIPNAT scales. They found no association between years 
since initiation of chemotherapy and scores on the CIPNAT suggested significant persistence 
of symptoms. However, the cross-sectional design could have introduced bias into the 
population. Patients with CIPN seven years after chemotherapy may be more motivated to 
participate and return questionnaires than those whose lives have returned to normal 
several years on.    
 
Arraras et al looked at a prospectively recruited group of 39 patients during chemotherapy 
and follow up for non-small cell lung cancer. Whilst there was an increase in neuropathy 
through treatment, it was not considered to be a significant risk factor for low quality of life 
scores with fatigue being a bigger influence (397).  Bayo et al performed a cross-sectional 
study of 92 breast cancer patients undergoing adjuvant or neoadjuvant docetaxel 
treatment. Whilst some adverse effects appeared to have a negative impact on quality of 
life, peripheral neuropathy was not significantly correlated with quality of life as measured 
by the Euro-QoL-5D (398). Tachi et al compared elements of the Euro-QoL-5D questionnaire 
before and after the first episode of chemotherapy for 48 patients with breast cancer. They 
noted a decrease in quality of life measures but this didn’t appear to be significantly 
associated with the occurrence of peripheral neuropathy (405). 
 
Only relatively few prospective studies have been performed and results have been 
contradictory. The tools used have varied widely. Quality of life and patient report tools 
were incorporated into the current project design both to support phenotypic 
characterisation for the pharmacogenetics study (Chapter 3) but also to further investigate a 
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link between occurrence and severity of CIPN and impact on quality of life measures both 
during chemotherapy but also at a set time distant to completion of chemotherapy.  
 
 
5.2 METHODS 
 
Patients aged 18 years old or over were invited to participate if they were commencing or 
were receiving chemotherapy with either at least four cycles of three-weekly taxanes 
(docetaxel or paclitaxel) or at least six cycles of oxaliplatin. All patients being treated 
through Clatterbridge Cancer Centre undergo a nurse-led pre-assessment appointment 
prior to commencing a course of chemotherapy. Pre-assessment appointments were 
screened on a weekly basis to identify patients attending who may be eligible. 
Chemotherapy clinic diaries were also screened regularly to check for eligible patients. 
 
Patients were excluded if they had a history of peripheral neuropathy prior to starting the 
index course of chemotherapy. They were also excluded if they were receiving more than 
one drug with a high risk of neurotoxicity, for example, concurrent treatment with cisplatin 
was not allowed. All included patients completed a written consent form. 
 
Patients were assessed at each cycle by a chemotherapy nurse. A toxicity proforma is 
routinely completed for all patients including an assessment of CIPN according to the NCI 
CTC criteria. CIPN was independently assessed by a member of the study team on cycle 4, 
after cycle 6 and after the final cycle (if patients were receiving >6 cycles of treatment). 
 
Patients were asked to complete EORTC C30 and CIPN 20 forms at the start of their 
treatment, at cycle 4, after cycle 6 and after the final cycle (for patients receiving >6 cycles 
of chemotherapy). They were also sent the same questionnaires to be completed at six and 
at eighteen months after the completion of chemotherapy. Patients completed their 
questionnaires independently unless they specifically asked for help with either reading the 
questions or documenting their responses. 
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5.2.1. EORTC CIPN20 module  
 
The CIPN20 scale was developed by the European Organisation for Research and Treatment 
of Cancer (EORTC) (155) and is used in conjunction with their main 30-item health-related 
quality of life module, the EORTC-QLQ C30. The 20 patient self-report questions relate 
specifically to symptoms of sensory, motor and autonomic neuropathy (table 5.2).  
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Table 5.2. EORTC CIPN-20 module 
During the past week: 
 Not at all A little Quite a bit Very much 
Did you have tingling fingers or hands?a 1 2 3 4 
Did you have tingling toes or feet?a 1 2 3 4 
Did you have numbness in your fingers or hands?a 1 2 3 4 
Did you have numbness in your toes or feet?a 1 2 3 4 
Did you have shooting or burning pain in your fingers or hands?a 1 2 3 4 
Did you have shooting or burning pain in your toes or feet?a 1 2 3 4 
Did you have cramps in your hands?b 1 2 3 4 
Did you have cramps in your feet?b 1 2 3 4 
Did you have problems standing or walking because of difficulty 
feeling the ground under your feet?a 
1 2 3 4 
Did you have difficulty distinguishing between hot and cold 
water?a 
1 2 3 4 
Did you have a problem holding a pen, which made writing 
difficult?b 
1 2 3 4 
Did you have difficulty manipulating small objects with your 
fingers (for example, fastening small buttons)?b 
1 2 3 4 
Did you have difficulty opening a jar or bottle because of 
weakness in your hands?b 
1 2 3 4 
Did you have difficulty walking because your feet dropped 
downwards?b 
1 2 3 4 
Did you have difficulty climbing stairs or getting up out of a chair 
because of weakness in your legs?b 
1 2 3 4 
Were you dizzy when standing up from a sitting or lying 
position?c 
1 2 3 4 
Did you have blurred vision?c 1 2 3 4 
Did you have difficulty hearing?a 1 2 3 4 
Please answer the following question only if you drive a car 
Did you have difficulty using the pedals?b 1 2 3 4 
Please answer this question only if you are a man 
Did you have difficulty getting or maintaining an erection?c 1 2 3 4 
a sensory scale, b motor scale, c autonomic scale 
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Patients rate the degree of effect of specified symptoms on a Likert scale scored 1-4 where 
a score of one equates to ‘not at all’ and a score of 4 equates to ‘very much’. As can be seen 
from the analysis plan below, autonomic scores were not utilised for this study as 
autonomic neuropathy is not commonly expected with the drugs involved in this cohort of 
patients. 
 
5.2.2 Statistics 
 
The primary aims of this study were two-fold; To investigate for an association between 
CIPN20 (sensory and motor neuropathy) score and global quality of life and functional score 
and to investigate the impact of persistence of changes following treatment.   
 
Descriptive statistics were used to summarize sample characteristics and the patient 
reported outcomes measured by the EORTC QLQ C30 and the EORTC CIPN-20. It is 
important to note that for functional and global of quality of life measures a higher score 
indicates better outcomes and for the neuropathy elements and the symptom scores a 
higher score indicates greater symptom burden. For measures using the prospective data 
only, patients receiving three or more cycles were included rather than using an intention to 
treat population. This is because the primary outcome of interest is toxicity related rather 
than an efficacy outcome. For purposes of prospective, longitudinal analysis it was planned 
to explore the data based on two separate groups, paclitaxel and oxaliplatin, rather than as 
a whole due to the marked heterogeneity.  For the whole group analysis, there were 
planned analyses of sensory and motor scores with functional and global quality of life 
scores using Spearman’s rank test. Similar analysis was planned for exploration of 
correlation in the prospective paclitaxel and oxaliplatin groups, respectively. 
 
 For exploration of persistent neuropathy, those with scores ten points above mean baseline 
levels at 18 months post chemotherapy were categorised as having persistent neuropathy 
and these patients were compared with respect to functional scores to those whose 
neuropathy had resolved to mean baseline levels plus ten points or below at 18 months 
post chemotherapy completion.  The cut-off of ten points above baseline was selected as 
this is there is evidence that a ten point difference in many symptom based scores in 
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cancer-related QOL scales is considered the lower estimate of a clinical meaningful medium 
effect (408, 409).  
 
To explore correlation between NCI CTC grade and sensory score, mean sensory score was 
calculated at each time point and the means compared between groups using ANOVA. 
 
5.3 RESULTS 
 
5.3.1 Patients 
 
In total, 162 patients were recruited to the quality of life study. After exclusions in the 
prospectively recruited cohort (see figure 5.1), 133 patients were left. The clinical 
characteristics of the total and prospective populations are detailed in table 5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Flow diagram to show recruited patients and reasons for exclusion 
 
 
 
 
 
162 patients 
Oxaliplatin: 4 exclusions 
Early cessation of chemotherapy for 
unrelated reasons (before midpoint): 
     Renal failure: 1 
     Acute limb ischaemia (AKA):1 
General deterioration before midpoint: 1 
Lost to follow up (baseline only):1 
No QoL questionnaires completed:1 
Paclitaxel: 19 exclusions 
Deteriorated before midpoint: 5 
Early cessation of therapy due to 
hypersensitivity reaction/ anaphylaxis: 6 
Early cessation due to other toxicity: 
arthralgia: 1 
Death before midpoint: 2 
No QoL questionnaires completed:2  
Baseline questionnaire only:2 
Patient withdrawal: 1 
 
Docetaxel: 5 exclusions 
Toxicity : 3 
Death before midpoint: 1 
Early cessation due to unrelated toxicity: 1 
 
133 patients 
94 prospectively recruited 
patients (baseline plus at least 
one other timepoint completed) 
39 recruited at end of 
chemotherapy (one assessment 
post chemotherapy) 
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Table 5.3. Characteristics of the study population as a whole and for the prospectively 
recruited patient cohorts 
 Whole population 
(n=133) 
Prospective 
cohort  
(n=94)* 
Paclitaxel 
prospective 
cohort (n=48) 
Oxaliplatin 
prospective 
cohort (n=34) 
Median age (range) 62 (43-80) 62.5 (43-80) 60 (43-80) 63 (48-77) 
Males/ females 47M/ 86F 31M/ 63F 48 F 19 M/ 15 F 
Primary cancer 
Colorectal cancer 
Ovarian cancer 
Primary peritoneal cancer or 
other gynae**  
Prostate 
 
49 
47 
22 
 
15 
 
34 
36 
13 
 
12 
 
0 
35 
13 
 
0 
 
34 
0 
0 
 
0 
Regimens  
Carboplatin/ paclitaxel 
Carboplatin/ paclitaxel/Bev 
Ox/MdG 
Ox/MdG/ Bev 
Ox/cape  
Ox/cape/ Bev 
XELOX 
Docetaxel 
 
66 
2 
17 
1 
24 
2 
6 
15 
 
47 
1 
12 
0 
16 
0 
6 
12 
 
47 
1 
0 
0 
0 
0 
0 
0 
 
0 
0 
12 
0 
16 
0 
6 
0 
Alcohol excess (>15 units per 
weeks) 
15 11 1 7 
Diabetes 6 4 2 2 
*This number includes 48 paclitaxel treated patients, 34 oxaliplatin treated patients and 12 docetaxel treated patients 
**uterus, cervix, fallopian tube 
Ox: oxaliplatin, MdG:Modified de Gramont, Bev: Bevacizumab, Cape: capecitabine, XELOX: capecitabine and oxaliplatin 
 
In the oxaliplatin prospective cohort, 34 patients completed a baseline questionnaire. 
Twenty-four patients completed questionnaires (71%) after 3 cycles and 24 (71%) after 6 
cycles. Twenty patients received greater than six treatment cycles, 16 of whom completed 
questionnaires. Twenty-two patients (65%) completed 6 month follow up questionnaires, 
and 15 (44%) completed 18 month questionnaires. Reasons for not completing subsequent 
questionnaires included: lost to follow up; non-return of questionnaires, progressive disease 
or early cessation of treatment due to other reasons and death during the follow-up period.  
 
For the paclitaxel prospective cohort, 58 patients were recruited, 48 of whom were included 
in the study. This was due to five patients discontinuing treatment after one or two cycles 
due to hypersensitivity reactions to paclitaxel, three patients stopped prior to midpoint 
assessment, two due to grade 3 fatigue and one due a general deterioration in condition. 
Two patients sadly died before cycle 3. 48 patients therefore had a baseline quality of life 
assessment and at least one further assessment. Forty-one patients completed the 
questionnaires after three cycles (midpoint; 85%) and forty at the post cycle six-time point 
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(83%). In the paclitaxel cohort, only one patient received >6 cycles and completed a further 
set of questionnaires at the end of treatment. Thirty patients completed questionnaires at 
six-month follow up (63%) and twenty-two at the 18-month post chemotherapy time point 
(46%). An additional 19 patients had data available for cross sectional study. Twelve 
docetaxel-treated patients were recruited prospectively and a further three were suitable 
for cross-sectional analysis.  
 
At the six month time point, five patients in the oxaliplatin prospective cohort had 
commenced second line chemotherapy and three of the docetaxel patients had started 
second line therapy with abiraterone. At the 18-month follow up point, a further two of the 
oxaliplatin group had commenced second line therapy and a further two docetaxel patients 
were receiving further systemic anti-cancer therapy. At the six-month time point, none of 
the paclitaxel patients who returned their questionnaires were on subsequent lines of 
therapy but at the 18-month time point, three of the patients who returned questionnaires 
were on subsequent lines of therapy for progression of their cancer.  
 
5.3.2 Analysis of the total study population 
 
Figures 5.2 and 5.3 show scatter plots showing sensory and motor scores, respectively, 
plotted against both functional score and global quality of life scores at each time point 
post-baseline.  
From visual inspection of these scatter plots it is evident that there is perhaps weak 
correlation between sensory scores and functional score, but it is far less clear that there is 
link with global QoL scores. The same is true for motor scores. Table 5.3 details Spearman 
Rank correlation testing to further explore these relationships. 
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Figure 5.2. Scatter plots of sensory scores against functional scores and global quality of life 
scores at each time point post-baseline 
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Figure 5.3. Scatter plots of motor score against functional scores and global quality of life 
scores 
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Table 5.4. Results of investigation of correlation between sensory and motor scores, 
respectively and both functional score and global QOL score for the whole cohort 
 
Spearman rank 
correlation 
Baseline After 3 cycles/ 
midpoint 
After 6 cycles EOT (if >6 
cycles) 
6 months 18 
months 
Correlation 
between sensory 
score and 
functional score 
-0.307 
p=0.002 
(n=98) 
-0.320 
p=0.002 
(n=88) 
-0.284 
p=0.004 
(n=102) 
-0.317 
p=0.087 
(n=30) 
-0.396 
p= 0.001 
(n=69) 
-0.165 
p=0.264 
(n=48) 
Correlation 
between sensory 
score and global 
QOL 
-0.226 
p=0.025 
(n=98) 
-0.361 
p=0.001 
(n=89) 
-0.258 
p=0.009 
(n=102) 
-0.254 
p=0.175 
(n=30) 
-0.335 
p=0.005 
(n=69) 
-0.057 
p=0.701 
(n=48) 
Correlation 
between motor 
score and 
functional score 
-0.437 
p=0.000 
(n=98) 
-0.607 
p=0.000 
(n=88) 
-0.568 
p=0.000 
(n=102) 
-0.598 
p=0.000 
(n=30) 
-0.682 
p=0.000 
(n=69) 
-0.486 
P=0.000 
(n=49) 
Correlation 
between motor 
score and quality 
of life 
-0.422 
p=0.000 
(n=98) 
-0.582 
p=0.000 
(n=89) 
-0.465 
p=0.000 
(n=102) 
-0.504 
p=0.005 
(n=30) 
-0.580 
p=0.000 
(n=69) 
-0.447 
p=0.001 
(n=49) 
 
It can be seen from the results of Spearman rank correlation analysis that at many time 
points there was a statistically significant inverse correlation between both sensory scores 
and motor scores but the correlation was fairly weak. The correlation was actually stronger 
with motor scores than sensory scores. Reasons for the weak correlation may lie with other 
factors affecting functional and global QOL scores including a cancer diagnosis, other 
toxicities from chemotherapy, post-operative recovery in some patients and symptoms 
related to the underlying cancer which are also likely to have an impact on both of these 
scores. Sensory scores were correlated with both functional and global QoL scores during 
chemotherapy and also at 6 months post-chemotherapy. Sensory scores at 18 months 
follow-up did not correlate with functional and global QOL scores. The numbers are smaller 
here thereby reducing the power of the study to detect a correlation. Some patients may 
have then had progressive cancer at this stage and this may impact more strongly on QOL 
measures than ongoing sensory symptoms or it may be that in the vast majority of patients, 
sensory symptoms are not predominant enough to cause any impact.  Motor neuropathy 
scores however continue to appear to influence functional and global QOL scores at 18 
months post chemotherapy. It may be that those that experience a significant motor 
element to their neuropathy are those with severe CIPN generally.    
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5.3.3 Analysis of the prospective cohorts 
 
For further analysis, the cohort was divided into paclitaxel and oxaliplatin cohorts to identify 
two groups which were relatively homogeneous with regard to treatment and primary 
cancer.  The paclitaxel prospective group is an all-female population being treated with 
three weekly schedules of paclitaxel with carboplatin AUC 5 or 6 for ovarian, primary 
peritoneal or other gynaecological primary.  
 
The oxaliplatin prospective cohort is a group being treated with oxaliplatin with a 
fluoropyridimine (either intravenous infusion of 5-fluorouracil or oral capecitabine) for 
colorectal cancer. Of this group, 21 of the 34 patients were being treated adjuvantly post- 
resection of their primary cancer and 13 were being treated for advanced disease. As seven 
of the 13 patients being treated for advanced disease were on second or subsequent lines 
of systemic anti-cancer therapies by completion of the post-chemotherapy follow up time 
points, exploratory analysis of the adjuvant cohort was also undertaken again to reduce 
confounding factors. 
 
The tables and graphs below summarise the mean scores for each main category measured 
on the EORTC-QLQ C30 and for the sensory and motor components of the EORTC CIPN-20.  
 
 
 
Figure 5.4 shows the sensory scores over time. It can clearly be seen that the mean scores 
increase rapidly after the start of chemotherapy and continue to increase until the 
completion of treatment after which time they start to improve. However they remain 
elevated at a mean of 19.5 at 18 months post-chemotherapy compared with 7.4 at baseline 
(p<0.001, Wilcoxon test). The sensory score remains at the highest level for those who had 
adjuvant oxaliplatin, presumably due to the higher cumulative dose that these patients 
would be expected to receive.  
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Sensory scores 
Paclitaxel Oxaliplatin Oxaliplatin (adjuvant)  
Time point n Mean  SD N Mean SD n Mean SD 
Baseline 48 4.3 9.1 34 3.0 5.1 21 3.3 5.8 
Mid-point 40 14.3 16.0 25 19.4 17.7 16 23.1 19.4 
After 6 cycles 41 25.1 21.6 24 18.5 14.7 14 18.2 14.4 
EOT (>6 cycles)    16 43.0 27.3 14 48.1 25.1 
6 months  30 20.8 17.6 23 28.0 24.0 16 41.0 27.4 
18 months  21 17.3 19.5 18 19.3 19.1 13 25.9 21.7 
 
Figure 5.4 Summary of mean sensory scores for the prospective cohorts 
 
A similar pattern was seen with motor scores (figure 5.5); however whilst the peak motor 
score was not as high as the sensory scores, as would be expected from these drugs which 
cause a predominantly sensory neuropathy, the recovery appears less obvious, especially 
for paclitaxel- treated patients. Motor scores remained an average of 10.2 points higher at 
18 months of follow up compared to baseline (9.7 to 19.9, p <0.001, Wilcoxon test). 
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Motor score Paclitaxel Oxaliplatin (all) Oxaliplatin (adjuvant) 
Time point n Mean  SD n Mean SD n Mean SD 
Baseline 48 5.9 10.6 34 4.8 9.2 21 5.8 10.4 
Mid-point 41 10.1 14.6 25 14.3 14.7 16 18.2 15.8 
After 6 cycles 41 15.9 18.0 24 16.7 16.4 14 14.9 12.3 
EOT (>6 cycles)    16 28.5 28.9 14 32.5 28.6 
6 months  30 17.2 17.3 23 28.0 24.0 16 30.1 27.4 
18 months  21 15.1 22.7 18 19.3 19.1 13 22.4 20.6 
 
Figure 5.5. Summary of mean motor scores for the prospective cohort 
 
 
 
 
 
 
 
 
 
Figure 5.6 summarises the functional scores over time. Functional scores were moderately 
high throughout with the main dip being towards the end of the course of chemotherapy, 
particularly in the oxaliplatin- treated patients. Functional scores did not change particularly 
noticeably for the paclitaxel- treated patients during treatment which may represent 
symptomatic improvement from their cancer balancing out any chemotherapy toxicity. 
There was however an increase once chemotherapy was completed. The mean difference 
between baseline and 18-month scores was not significant (6.3 points, p 0.383).  
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Functional 
score 
Paclitaxel Oxaliplatin (all) Oxaliplatin (adjuvant) 
Time point n Mean  SD n Mean SD n Mean SD 
Baseline 48 77.2 18.4 34 77.0 24.0 21 79.0 23.8 
Mid-point 41 77.1 18.3 25 75.6 15.9 16 74.8 17.1 
After 6 cycles 40 76.3 19.3 23 68.4 21.6 14 72.9 23.0 
EOT (>6 cycles)    15 73.9 23.0 13 71.6 23.5 
6 months  30 80.5 19.8 22 72.9 21.4 16 75.7 21.0 
18 months 22 79.1 21.7 16 69.4 34.0 11 77.6 27.0 
 
 
Figure 5.6 Summary of mean functional scores over time for the prospective group 
 
 
 
 
Global quality of life scores are graphically illustrated in figure 5.7. It can be seen that only 
relatively subtle changes are seen in global quality of life scores over the time course. There 
is a dip towards the end of chemotherapy but this was only a very small change (mean 
difference 2.4 between baseline and after 6 cycles of chemotherapy). 
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Global quality 
of life 
Paclitaxel Oxaliplatin (all) Oxaliplatin (adjuvant) 
Time point n Mean  SD N Mean SD N Mean  SD 
Baseline 48 70.8 20.3 34 68.4 24.6 21 67.5 26.6 
Mid-point 41 72.6 18.2 25 66.0 17.5 16 65.1 19.5 
After 6 cycles 40 67.1 18.4 23 57.3 20.5 14 63.7 21.1 
EOT (>6 cycles)    15 66.7 25.8 13 62.8 25.4 
6 months 30 74.2 19.1 22 66.3 21.1 16 69.8 19.2 
18 months  22 73.5 23.0 16 64.7 32.4 11 72.0 26.2 
 
Figure 5.7 Summary of global quality of life scores for the prospective cohort 
 
 
 
 
Finally, overall symptom scores are summarised in figure 5.8. Again, the peak score was 
towards the end of chemotherapy but this improved during follow-up, there being no 
significant difference between baseline scores and 18-month follow up scores (p=0.6). 
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Symptom score Paclitaxel Oxaliplatin (all) Oxaliplatin (adjuvant) 
Time point n Mean  SD N Mean SD n Mean SD 
Baseline 48 22.2 16.2 34 20.8 18.5 21 19.7 20.2 
Mid-point 41 20.7 15.4 25 25.2 13.8 16 24.7 12.4 
After 6 cycles 41 24.6 17.9 24 31.9 18.3 14 28.4 18.9 
EOT (>6 cycles)    16 27.1 20.0 14 29.4 20.2 
6 months 30 17.7 15.3 22 24.1 18.8 16 21.0 18.0 
18 months  22 17.0 15.6 16 23.1 28.0 11 19.6 22.2 
 
Figure 5.8. Summary of overall symptom score over time for the prospective cohort 
Correlation between sensory and motor score and functional and global QoL score 
 
The Spearman rank test was used to investigate the correlation between functional and 
global QoL scores, and each of the sensory and motor scores. Due to the multiple testing, p 
values of <0.01 were considered significant. 
Table 5.5. Results of investigation of correlation between sensory and motor scores, 
respectively and both functional score and global QOL score for the prospective paclitaxel-
treated cohort 
Spearman 
rank 
correlation 
Baseline After 3 
cycles 
After 6 
cycles 
6 months-post 
chemotherapy 
18 months- 
post 
chemotherapy 
Sensory 
and 
functional 
-0.304 
p=0.036 
(n=48) 
-0.291 
p=0.068 
n=40 
-0.043 
p=0.793 
(n=40) 
-0.533 
p=0.002 
(n=30) 
-0.359 
p=0.110 
(n=21) 
Sensory 
and QOL 
-0.242 
p=0.097 
(n=48) 
-0.349 
p=0.027 
(n=40) 
-0.136 
p=0.403 
(n=40) 
-0.460 
p=0.011 
(n=30) 
-0.212 
p= 0356 
(n=21) 
Motor and 
functional 
-0.508 
p=0.000 
(n=48) 
-0.546 
p=0.000 
(n=41) 
-0.447 
p=0.004 
(n=40) 
-0.831 
p=0.000 
(n=30) 
-0.562 
p=0.008 
(n=21) 
Motor and 
QoL 
-0.469 
p=0.001 
(n=48) 
-0.496 
p=0.001 
(n=41) 
-0.417 
p=0.007 
(n=40) 
-0.772 
p=0.000 
(n=30) 
-0.481 
p=0.027 
(n=21) 
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The main finding of note was the significant correlation seen at all time points between 
motor score and functional score, and at most time points with global QoL in the 
prospective, paclitaxel-treated cohort. Interestingly, the correlation looked stronger at six 
and eighteen months post-chemotherapy, which may be due to less confounding factors 
from other toxicities at these points. 
In this smaller cohort, we did not see a statistically significant correlation with sensory 
scores apart from at the six months post- chemotherapy time point which again suggests 
that sensory neuropathy is a factor in function post chemotherapy and reaches statistical 
significance in the absence of other function-influencing toxicities that are likely to be 
present during the chemotherapy treatment itself. 
Table 5.6. Results of investigation of correlation between sensory and motor scores, 
respectively and both functional score and global QOL score for the prospective oxaliplatin-
treated cohort 
 
Spearman rank 
correlation 
Baseline After 3 
cycles 
After 6 
cycles 
End of 
treatment 
(if >6 
cycles) 
6 
months-
post 
chemo 
18 months- 
post 
chemo 
Sensory score 
and functional 
score 
-0.482 
p=0.004 
(n=34) 
-0.368 
p=0.071 
(n=25) 
-0.509 
p=0.013 
(n=23) 
-0.733 
p=0.002 
(n=15) 
-0.11 
p=0.622 
(n=22) 
-0.234 
p=0.383 
(n=16) 
Sensory score 
and global QOL 
-0.314 
p=0.071 
(n=34) 
-0.451 
p=0.024 
(n=25) 
-0.331 
p=0.123 
(n=23) 
-0.729 
p=0.002 
(n=15) 
-0.086 
p=0.704 
(n=22) 
-0.207 
p=0.442 
(n=16) 
Motor score 
and functional 
score 
0.516 
p=0.002 
(n=34) 
-0.649 
p=0.000 
(n=25) 
-0.733 
p=0.000 
(n=23) 
-0.748 
p=0.001 
(n=15) 
-0.483 
p=0.023 
(n=22) 
-0.447 
p=0.082 
(n=16) 
Motor score 
and global QoL 
-0.385 
p=0.025 
(n=34) 
-0.567 
p=0.003 
(n=25) 
-0.392 
p=0.065 
(n=23) 
-0.730 
p=0.002 
(n=15) 
-0.334 
p=0.128 
(n=22) 
-0.444 
p=0.085 
(n=16) 
 
In the oxaliplatin-treated prospective cohort, once again, the strongest correlation was 
between motor score and functional score, although in this group, it did not quite meet 
statistical significance at the post-chemotherapy time points. Crucially the number of 
patients in this cohort was smaller and therefore the power to detect such differences was 
smaller. From the graph of motor score over time, there appeared to be greater 
improvement in motor scores in the oxaliplatin group than in the paclitaxel group which 
may also have contributed to the lack of significance. There was also more confounding in 
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this group due to the fact that more patients in the oxaliplatin cohort as compared with the 
paclitaxel cohort had started second line chemotherapy at the 6 and 18 month time points 
which is likely to have its own impact on both functional score and QoL. In terms of the 
sensory score, the only time point at which there was correlation between functional score 
or global QoL score was at the end of the treatment point for those patients who received 
more than six cycles of chemotherapy.  
 
5.3.4 Persistent CIPN, functional score and quality of life 
Sub-group analysis restricted to those patients with persistent neuropathy at 18 months 
post chemotherapy was as an exploratory analysis because of the limited sample size.  The 
mean baseline sensory score was 7.4. As stated above, using evidence that a ten point 
difference in many symptom based scores in cancer-related QOL scales is often considered 
the lower estimate of a clinically meaningful effect (408, 409), a cut-off of 17.4 was used to 
arbitrarily define those with persistent sensory neuropathy and those without. Similarly, 
recognising that 9.7 was the mean baseline motor score, a cut-off of 19.7 was used to define 
persistent motor neuropathy. By these definitions, 15 patients had persistent sensory 
neuropathy (8 paclitaxel-treated patients and 7 oxaliplatin- treated patients) and 8 had 
persistent motor neuropathy (3 paclitaxel-treated patients and 5 oxaliplatin-treated 
individuals).  There was no statistically significant difference between global QOL and 
functional scores for those either with or without persistent sensory neuropathy within the 
prospective cohort. However, again motor neuropathy seemed to be more problematic with 
a statistically significant difference in the functional score (p=0.002) and global QOL score 
(p=0.026) at the 18 month time point.   
 
5.3.5 Analysis of CIPN-20 scores and NCI CTC grading of CIPN 
 
Figure 5.9 shows the mean sensory scores illustrated over the time period of the study 
based on groups of patients defined by the maximum recorded NCI CTC grade (0-3) during 
chemotherapy. There was a significant difference in mean sensory scores at the post- 3 
cycles, post- 6 cycles, end of treatment (where >6 cycles) and 6 month post-chemotherapy 
time points. This was not statistically significant at the 18 month time point but the 
difference in mean scores for those assessed as experiencing grade 3 neuropathy during 
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chemotherapy appeared to be notably higher than those with grade 0-2 sensory neuropathy 
during treatment. This would appear to support the clinician grading within this study group 
and replicate the correlation that has been previously noted between NCI CTC grading and 
the CIPN-20 sensory score.  
 
 
Figure 5.9. A graph to show sensory score over time according to NCI CTC grade. 
 
Figures 5.10 and 5.11 show functional and global QoL scores over the time points for the 
four different maximum NCI CTC grading categories, respectively. There was no clear 
relationship with quality of life and a significant relationship with functional score was 
demonstrated only at the post- cycle 6 time point (p=0.001). 
Contrasting this with the results seen with the CIPN20 scores, this suggests, as may be 
expected, that the CIPN20 is far more responsive to differences in severity of symptoms 
within the broad grade categories of the NCI CTC grading scale. 
Max grade  
(NCI CTC) 
Mean sensory score 
Baseline Midpoint After 6 cycles EOT (<6 cycles) 6 months 18 months 
0 3.006 5.876 8.3 59.3 (1)* 6.0 11.8 
1 5.3 12.1 18.4 21.9 23.4 12.1 
2 3.9 17.7 25.1 42.4 33.4 17.0 
3 0.7 26.3 41.7 56.2 49.2 29.4 
Anova test 
p value 
p=0.344 p=0.001 p=0.000 p=0.007 p=0.000 p=0.084 
*Spurious result, omitted for purposes of graphing but not analysis. 
Table 5.7 Table detailing mean sensory scores per maximum NCI CTC grading category and 
ANOVA test results  
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Figure 5.10. A graph showing mean functional score over time categorised according to 
maximum NCI CTC sensory neuropathy grading 
 
 
 
Figure 5.11 A graph showing mean global QoL score over time categorised according to 
maximum NCI CTC sensory neuropathy grading 
 
 
 
5.4 DISCUSSION 
 
This study demonstrates a significant inverse correlation between sensory and motor scores 
on the CIPN20 with functional and global QoL scores on the EORTC-QLQ-C30 at most 
timepoints for the cohort as a whole. The correlation is not strong but it is clearly present. It 
is perhaps unsurprising that there is not a stronger correlation due to the multiple other 
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symptomatic, social, psychological and cancer-related factors that may be also impacting on 
function and overall QoL during and in the months following chemotherapy. In the separate 
paclitaxel- and oxaliplatin- treated prospective cohorts, there was some correlation but it 
was only statistically significant at a small number of time points. In the paclitaxel cohort, 
the sensory score was negatively correlated with functional score at 6 months post-
chemotherapy, probably because other chemotherapy-related side effects had subsided 
and neuropathy potentially had a greater influence on function. Motor scores, however, 
were negatively correlated with functional and global QoL scores at all except one time 
point. The 18 month post-chemotherapy time point showed a trend probably because of 
limited sample size. In the oxaliplatin cohort, at the end of treatment time point for those 
patients receiving >6 cycles, there was a significant negative correlation between the 
sensory score and both functional and global QoL scores.  
The general trend for all results was a more significant correlation with motor score as 
compared with the sensory score. This is perhaps surprising in a predominantly sensory 
neuropathy. There may be a number of reasons for this: it may simply be that when motor 
neuropathy occurs it results in more significant impact on normal functioning. It could also 
be argued that those with motor symptoms have more severe levels of neuropathy. It could 
also be related to the questionnaire and how motor and sensory score were separated and 
the questionnaire items used to build each score. 
 Whilst the EORTC CIPN-20 is clearly a well-validated and meaningful tool to collect patient-
reported data regarding CIPN, like many patient report modules, it does have its potential 
problems and the categorisation of items in the module into ‘sensory’ and ‘motor’ is not 
completely clear cut, particularly for certain questions. For example, the question regarding 
presence of difficulty standing up due to weakness in your legs could answered ‘very much’ 
difficulty when the predominant symptom is fatigue. ‘Motor’ items such as difficulty holding 
a pen or manipulating small objects in your fingers could equally indicate sensory 
neuropathy impairing the ability to appreciate the objects between your fingers rather than 
a motor neuropathy being responsible. It may be that high scores on certain ‘motor’ items 
are not purely assessing motor neuropathy, but are inadvertently representing marked 
sensory impairment. The question regarding hearing as a sensory item could be argued as 
being unhelpful unless being used for potentially ototoxic drugs such as cisplatin.  
 
 200 
Confounding is the main limitation of this study. Whilst prospective drug-specific, tumour-
specific groups were examined separately as well as together, other confounding factors 
such as stage of cancer, surgical management and other co-morbidities were not taken into 
consideration in this study leading to heterogeneity within the study population. Similarly, 
there was no control for other chemotherapy-related toxicities which may also cause 
functional effects particularly during the chemotherapy period.   
A further limitation of the study is that because the time points for quality of life assessment 
were driven by cycle numbers, those that stopped chemotherapy early due to neuropathy 
were missing from the end of treatment assessments as their ‘end of treatment’ may have 
been, after for example, only 6 cycles, whereas they may have been planned to have 8 or 12 
cycles. There are also a number of patients who were receiving second line chemotherapy 
regimens at the post-treatment, follow up time points which may have affected scores. 
Sample size in the later time points was small which reduced the power of the study; 
however the starting sample sizes were comparable, and in some cases, better than 
previous CIPN-related quality of life studies. 
Missing data is frequently an issue in longitudinal quality of life studies in cancer (410). 
Some of this is unavoidable due to the nature of the disease causing deterioration in health, 
death or a wish of patients to put their cancer behind them and not be reminded of it by 
completing forms related to chemotherapy after the treatment course is finished. However, 
the amount of missing data could have perhaps been improved with more study support 
and using the limited support available more effectively. I was relying largely on seeing the 
patients personally at the designated time points during chemotherapy. However, with 
hindsight and in different circumstances I would have utilised the small amount of data 
support I had to help chase these up and perhaps given the patients the assessment forms 
upfront and used telephone prompts to remind patients to return them in pre-paid 
envelopes in case I was not able to review the patients in person on the correct day.  
 
One of the most important findings of this study is the finding that those with persistent 
‘motor’ neuropathy symptoms as assessed by the CIPN-20 module have persistently 
significantly lower functional scores. This is notwithstanding the small sample sizes at this 
point. This reinforces the importance of this side effect and the need to continue to build 
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our understanding of the factors that predispose an individual, and understand mechanism, 
so that this may eventually lead to preventative strategies. 
 
5.5 CONCLUSION 
This chapter has highlighted the effects of CIPN on quality of life. The study demonstrates 
that there can be persistence of significantly elevated levels of CIPN20 sensory and motor 
scores 18 months after completion of taxane and oxaliplatin-based chemotherapy. The main 
finding of note is that whilst CIPN is generally recognised as a predominantly sensory 
neuropathy, it is the motor score on the CIPN20 which seems to produce more functional 
and quality of life impairment, and this is shown to be persistent even 18-months after 
completion of chemotherapy.   
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CHAPTER 6 
 
 
 
 
DISCUSSION AND FUTURE DIRECTIONS 
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This collection of work has systematically assessed the clinical and genetic risk factors that 
may lead to the development of CIPN. I have described how drug, cumulative dose, duration 
of infusion and possibly scheduling may have an impact on the risk of neuropathy. Body 
mass index warrants further investigation as a risk factor for the development of this 
adverse effect and the racial differences observed in toxicity, particularly with regard to 
vincristine need to be further explored. Beyond this, there is currently little to define the at-
risk individual for CIPN. 
 
Chapter 2 described the multiple studies previously performed with the aim of identifying 
genetic risk factors. It highlighted the need to be robust with respect to phenotypic 
definition and echoes others working in CIPN research in calling for consensus on outcome 
measures (138).  
 
The candidate gene study was not able to confirm associations in the selected putative 
SNPs.  The small study size was the main limitation and phenotypic characterisation the 
biggest strength. This was the first study to attempt replication of association of taxane 
induced peripheral neuropathy and CYP3A4*22, and in fact showed no association within 
this cohort with a greater number of ‘cases’ and may therefore be argued to be more likely 
to be a true reflection of the influence or otherwise of this variant in development of CIPN. 
The GWAS-identified variants selected for investigation in relation to taxane induced 
neuropathy again were not replicated in this cohort and this is in agreement with a recent 
study also looking to replicate these findings in a UK population (274). For oxaliplatin 
induced peripheral neuropathy, variants identified in Asian GWAS and candidate studies 
(94, 272) as possibly being associated with development of cumulative oxaliplatin induced 
neuropathy were similarly not replicated in this project.  
The SNPs were chosen at a time point dictated by the point in progress through the project. 
Since then, other studies (89, 274, 344) have agreed with conclusions of this study in 
relation to the SNPs genotyped, while other studies have identified other variants (321, 
322). Building of a biobank of well-defined case and control subjects with patient reported 
outcome data to support categorisation has the potential to be an asset to continue to 
explore further potential associations. In the field of taxane induced peripheral neuropathy 
the Charcot Marie Tooth related genes, in particular ARGEF10, (321, 322) warrant further 
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investigation, as do variants in TUBB2A (274). In the case of oxaliplatin induced peripheral 
neuropathy, GWAS in a large Causcasian population with well-defined phenotypic 
categorisation is warranted as it is difficult to identify SNPs from the current literature that 
warrant further investigation.   
 
A strength of the study was to use both patient reported outcomes alongside a standard 
grading tool such as the NCI CTC grading score. Although the optimal study outcome 
measures with regard to CIPN are yet to be agreed, it could be argued that clinical 
assessment of CIPN could have been improved upon by using the Total Neuropathy Score 
(clinical) rather than using NCI CTC grading. This was considered but was not believed to be 
feasible due to practical constraints within the study. Due to the limited funding there was 
always going to be a very limited number of trial professionals involved in the assessment of 
patients and a more involved assessment of neuropathy would have created barriers of 
both time and space for such examinations and may have impacted on recruitment. There 
was also a training issue as the study was rolled out to multiple centres. Research 
practitioners would have to be trained in testing of deep tendon reflexes and vibration 
testing as inaccuracies in performing this test can result in greater inconsistency between 
grading. For a more complete assessment of CIPN however a visual analogue scale could 
have been added for neuropathic pain which was not well accounted for in assessment of 
the patients in this study. It was recorded wherever possible in the quality of life study 
cohort but I suspect this was an underestimate of the true incidence in this population.  
From the quality of life investigation, it was demonstrated that both sensory and motor 
scores remained clinically and statistically significantly elevated at 18 months post 
chemotherapy completion.  Relatively weak negative correlation was seen between sensory 
score and motor score and quality of life and functional scores, respectively at most time 
points.  The weak correlation could be due to the many other confounding factors that may 
exist for each individual going through a course of chemotherapy for cancer including other 
toxicities and cancer symptoms, and emotional wellbeing. The correlation was stronger for 
motor neuropathy and indeed persistent motor neuropathy was significantly associated 
with poorer functional and global QOL status than those without persistent motor 
neuropathy, whereas this was not the case for sensory neuropathy. This indicates that 
motor neuropathy symptoms are more detrimental to normal activity; however it may also 
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be a function of the CIPN20 since some of the items on the motor score may also be 
attributed to marked sensory neuropathy or fatigue. As always, experience in research is a 
learning curve. If I were to repeat the project I would aim to develop more robust methods 
of collecting follow up quality of life assessments. Missing forms is frequently an issue in 
longitudinal quality of life studies in cancer (410) due to a multitude of reasons previously 
mentioned; however providing patients with the questionnaires upfront at recruitment with 
return envelopes and using telephone prompts may have improved return rates.   
For both the pharmacogenetics and quality of life studies, ideally greater numbers should 
have been included. Within the time constraints of the project and limited research staff to 
support recruitment and follow up, this was the maximum that could be achieved. 
Recruitment continues however through the NIHR portfolio Molecular Genetics of Adverse 
Drug Reactions study and future analyses will therefore have greater power to detect 
potentially small but significant effects, particularly when looking at the complex genetic 
variants which may be hypothesized to contribute to an ‘at-risk’ genotype.  
 
This thesis has comprehensively explored clinical and genetic risk factors for development of 
CIPN. It has added to the evidence regarding pharmacogenetics risk factors and supports 
evidence of a statistically significant link to reduced quality of life with CIPN both during, but 
more importantly after chemotherapy.  
Oncological management of malignancy frequently involves weighing up potential benefits 
of toxic treatments against their potential adverse effects. The adverse reactions and size of 
benefit varies between different treatment schedules in different cancers. The ideal 
scenario would be one where instead of weighing up general median benefits and side 
effects, it was possible to personalise these discussions to individual patients. This would be 
particularly important in situations where the benefit of a specific treatment is modest but 
the risk of long term adverse reactions is significant. Whilst countless studies are performed 
for assessing the efficacy of new drugs with translational aspects focusing on biomarkers of 
response, very few studies focus on toxicity, and impact on survivorship.  This situation 
needs to be improved, as it is only through studies that are specifically set up and designed 
to investigate and characterise the ‘at risk’ phenotype and genotypes, that we will truly 
achieve individualised care that takes into account cancer survivorship and long term quality 
of life. 
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